{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:16:49Z","timestamp":1793888209034,"version":"4.8.0"},"reference-count":1194,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001459","name":"Ministry of Education - Singapore","doi-asserted-by":"publisher","award":["MOE-T2EP30120-0016"],"award-info":[{"award-number":["MOE-T2EP30120-0016"]}],"id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011744","name":"National University Health System","doi-asserted-by":"publisher","award":["NUHSRO\/2023\/039\/RO5+6\/Seed-Mar\/04"],"award-info":[{"award-number":["NUHSRO\/2023\/039\/RO5+6\/Seed-Mar\/04"]}],"id":[{"id":"10.13039\/501100011744","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-024-01634-6","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T16:22:14Z","timestamp":1736785334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":162,"title":["Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition"],"prefix":"10.1186","volume":"18","author":[{"given":"Antonino","family":"Glaviano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Si-Hui","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas M.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Hui Clarissa","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiu Yan","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Okina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donavan Jia Jie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wency","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Li","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Yi-Hui","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthu K.","family":"Shanmugam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Zi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan Zea","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina H. K.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby Yun-Ju","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Ungefroren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Giovannetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean G.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tullia C.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads Hald","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin-Zhi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek C.","family":"Radisky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salem","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Diana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt A.","family":"Schalper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Merghoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali P.","family":"Kusumbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan Prem","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"issue":"10352","key":"1634_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0140-6736(22)01438-6","volume":"400","author":"GCRF Collaborators","year":"2022","unstructured":"Collaborators GCRF. The global burden of cancer attributable to risk factors, 2010\u201319: a systematic analysis for the global burden of disease study 2019. Lancet. 2022;400(10352):563\u201391.","journal-title":"Lancet"},{"issue":"7","key":"1634_CR2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1056\/NEJMcibr2213497","volume":"388","author":"K Ganesh","year":"2023","unstructured":"Ganesh K. Uncoupling Metastasis from Tumorigenesis. N Engl J Med. 2023;388(7):657\u20139.","journal-title":"N Engl J Med"},{"issue":"3","key":"1634_CR3","first-page":"470","volume":"73","author":"R Li","year":"2024","unstructured":"Li R, Liu X, Huang X, Zhang D, Chen Z, Zhang J, et al. Single-cell transcriptomic analysis deciphers heterogenous cancer stem-like cells in colorectal cancer and their organ-specific metastasis. Gut. 2024;73(3):470\u201384.","journal-title":"Gut"},{"issue":"26","key":"1634_CR4","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1056\/NEJMra0805239","volume":"359","author":"AC Chiang","year":"2008","unstructured":"Chiang AC, Massagu\u00e9 J. Molecular basis of metastasis. N Engl J Med. 2008;359(26):2814\u201323.","journal-title":"N Engl J Med"},{"key":"1634_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217022","volume":"596","author":"Y Yu","year":"2024","unstructured":"Yu Y, Lyu C, Li X, Yang L, Wang J, Li H, et al. Remodeling of tumor microenvironment by extracellular matrix protein 1a differentially regulates ovarian cancer metastasis. Cancer Lett. 2024;596: 217022.","journal-title":"Cancer Lett"},{"issue":"4","key":"1634_CR6","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41556-022-00877-0","volume":"24","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Donaher JL, Das S, Li X, Reinhardt F, Krall JA, et al. Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis. Nat Cell Biol. 2022;24(4):554\u201364.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"1634_CR7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10555-023-10162-7","volume":"43","author":"N Ebrahimi","year":"2024","unstructured":"Ebrahimi N, Manavi MS, Faghihkhorasani F, Fakhr SS, Baei FJ, Khorasani FF, et al. Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response. Cancer Metastasis Rev. 2024;43(1):457\u201379.","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"1634_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","volume":"20","author":"A Dongre","year":"2019","unstructured":"Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69\u201384.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1634_CR9","doi-asserted-by":"crossref","unstructured":"Yang S, Zhang D, Sun Q, Nie H, Zhang Y, Wang X, et al. Single-Cell and Spatial Transcriptome Profiling Identifies the Transcription Factor BHLHE40 as a Driver of EMT in Metastatic Colorectal Cancer. Cancer Res. 2024.","DOI":"10.1158\/0008-5472.c.7311389.v1"},{"issue":"5","key":"1634_CR10","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871\u201390.","journal-title":"Cell"},{"issue":"2","key":"1634_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","volume":"20","author":"A Dongre","year":"2019","unstructured":"Dongre A, Weinberg RA. New insights into the mechanisms of epithelial\u2013mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69\u201384.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"1634_CR12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","volume":"29","author":"I Pastushenko","year":"2019","unstructured":"Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212\u201326.","journal-title":"Trends Cell Biol"},{"issue":"2","key":"1634_CR13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ccell.2023.01.007","volume":"41","author":"MB Nilsson","year":"2023","unstructured":"Nilsson MB, Yang Y, Heeke S, Patel SA, Poteete A, Udagawa H, et al. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell. 2023;41(2):340-55.e6.","journal-title":"Cancer Cell"},{"issue":"1","key":"1634_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12943-024-01954-8","volume":"23","author":"F Broghammer","year":"2024","unstructured":"Broghammer F, Korovina I, Gouda M, Celotti M, van Es J, Lange I, et al. Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome. Mol Cancer. 2024;23(1):39.","journal-title":"Mol Cancer"},{"key":"1634_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41420-020-0286-z","volume":"6","author":"MM Faheem","year":"2020","unstructured":"Faheem MM, Seligson ND, Ahmad SM, Rasool RU, Gandhi SG, Bhagat M, et al. Convergence of therapy-induced senescence (TIS) and EMT in multistep carcinogenesis: current opinions and emerging perspectives. Cell Death Discov. 2020;6:51.","journal-title":"Cell Death Discov"},{"issue":"1","key":"1634_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41416-020-01177-w","volume":"124","author":"L Peyre","year":"2021","unstructured":"Peyre L, Meyer M, Hofman P, Roux J. TRAIL receptor-induced features of epithelial-to-mesenchymal transition increase tumour phenotypic heterogeneity: potential cell survival mechanisms. Br J Cancer. 2021;124(1):91\u2013101.","journal-title":"Br J Cancer"},{"issue":"3","key":"1634_CR17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1634_CR18","doi-asserted-by":"publisher","first-page":"5285892","DOI":"10.1155\/2016\/5285892","volume":"2016","author":"M Mladinich","year":"2016","unstructured":"Mladinich M, Ruan D, Chan CH. Tackling cancer stem cells via inhibition of EMT transcription factors. Stem Cells Int. 2016;2016:5285892.","journal-title":"Stem Cells Int"},{"issue":"34","key":"1634_CR19","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/onc.2010.215","volume":"29","author":"A Singh","year":"2010","unstructured":"Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29(34):4741\u201351.","journal-title":"Oncogene"},{"key":"1634_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2024.03.002","volume":"100","author":"AQ Khan","year":"2024","unstructured":"Khan AQ, Hasan A, Mir SS, Rashid K, Uddin S, Steinhoff M. Exploiting transcription factors to target EMT and cancer stem cells for tumor modulation and therapy. Semin Cancer Biol. 2024;100:1\u201316.","journal-title":"Semin Cancer Biol"},{"key":"1634_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40169-015-0048-3","volume":"4","author":"S Heerboth","year":"2015","unstructured":"Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lapinska K, et al. EMT and tumor metastasis. Clin Transl Med. 2015;4:6.","journal-title":"Clin Transl Med"},{"issue":"1","key":"1634_CR22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.canlet.2015.12.033","volume":"380","author":"M Pietil\u00e4","year":"2016","unstructured":"Pietil\u00e4 M, Ivaska J, Mani SA. Whom to blame for metastasis, the epithelial\u2013mesenchymal transition or the tumor microenvironment? Cancer Lett. 2016;380(1):359\u201368.","journal-title":"Cancer Lett"},{"issue":"6","key":"1634_CR23","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ccr.2012.09.022","volume":"22","author":"JH Tsai","year":"2012","unstructured":"Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell. 2012;22(6):725\u201336.","journal-title":"Cancer Cell"},{"issue":"6","key":"1634_CR24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ccr.2012.10.012","volume":"22","author":"OH Oca\u00f1a","year":"2012","unstructured":"Oca\u00f1a OH, C\u00f3rcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S, et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell. 2012;22(6):709\u201324.","journal-title":"Cancer Cell"},{"issue":"1","key":"1634_CR25","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41598-023-50710-3","volume":"14","author":"M Terragno","year":"2024","unstructured":"Terragno M, Vetrova A, Semenov O, Sayan AE, Kriajevska M, Tulchinsky E. Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate. Sci Rep. 2024;14(1):425.","journal-title":"Sci Rep"},{"issue":"1","key":"1634_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12967-023-04102-w","volume":"21","author":"K Horny","year":"2023","unstructured":"Horny K, Sproll C, Peiffer L, Furtmann F, Gerhardt P, Gravemeyer J, et al. Mesenchymal-epithelial transition in lymph node metastases of oral squamous cell carcinoma is accompanied by ZEB1 expression. J Transl Med. 2023;21(1):267.","journal-title":"J Transl Med"},{"issue":"3","key":"1634_CR27","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.3390\/ijms24032555","volume":"24","author":"L Liang","year":"2023","unstructured":"Liang L, Kaufmann AM. The significance of cancer stem cells and epithelial-mesenchymal transition in metastasis and anti-cancer therapy. Int J Mol Sci. 2023;24(3):2555.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1634_CR28","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1084\/jem.20181827","volume":"216","author":"NM Aiello","year":"2019","unstructured":"Aiello NM, Kang Y. Context-dependent EMT programs in cancer metastasis. J Exp Med. 2019;216(5):1016\u201326.","journal-title":"J Exp Med"},{"issue":"23","key":"1634_CR29","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1016\/j.devcel.2021.11.006","volume":"56","author":"F L\u00fc\u00f6nd","year":"2021","unstructured":"L\u00fc\u00f6nd F, Sugiyama N, Bill R, Bornes L, Hager C, Tang F, et al. Distinct contributions of partial and full EMT to breast cancer malignancy. Dev Cell. 2021;56(23):3203-21.e11.","journal-title":"Dev Cell"},{"issue":"6","key":"1634_CR30","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.devcel.2018.05.027","volume":"45","author":"NM Aiello","year":"2018","unstructured":"Aiello NM, Maddipati R, Norgard RJ, Balli D, Li J, Yuan S, et al. EMT subtype influences epithelial plasticity and mode of cell migration. Dev Cell. 2018;45(6):681-95.e4.","journal-title":"Dev Cell"},{"issue":"8","key":"1634_CR31","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3390\/ph14080740","volume":"14","author":"J Dardare","year":"2021","unstructured":"Dardare J, Witz A, Merlin JL, Bochnakian A, Toussaint P, Gilson P, et al. Epithelial to mesenchymal transition in patients with pancreatic ductal adenocarcinoma: state-of-the-art and therapeutic opportunities. Pharmaceuticals (Basel). 2021;14(8):740.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1634_CR32","doi-asserted-by":"publisher","first-page":"1070383","DOI":"10.3389\/fmolb.2022.1070383","volume":"9","author":"C Martins-Lima","year":"2022","unstructured":"Martins-Lima C, Chianese U, Benedetti R, Altucci L, Jer\u00f3nimo C, Correia MP. Tumor microenvironment and epithelial-mesenchymal transition in bladder cancer: cytokines in the game? Front Mol Biosci. 2022;9:1070383.","journal-title":"Front Mol Biosci"},{"key":"1634_CR33","doi-asserted-by":"publisher","first-page":"6114976","DOI":"10.1155\/2023\/6114976","volume":"2023","author":"Y Huang","year":"2023","unstructured":"Huang Y, Li SR, Gao YJ, Zhu YH, Zhang XF. Novel gene signatures promote epithelial-mesenchymal transition (EMT) in glucose deprivation-based microenvironment to predict recurrence-free survival in hepatocellular carcinoma. J Oncol. 2023;2023:6114976.","journal-title":"J Oncol"},{"issue":"2","key":"1634_CR34","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/biomedicines12020418","volume":"12","author":"AP Goncharov","year":"2024","unstructured":"Goncharov AP, Vashakidze N, Kharaishvili G. Epithelial-mesenchymal transition: a fundamental cellular and microenvironmental process in benign and malignant prostate pathologies. Biomedicines. 2024;12(2):418.","journal-title":"Biomedicines."},{"issue":"3","key":"1634_CR35","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403.","journal-title":"Cancer Cell"},{"issue":"8","key":"1634_CR36","doi-asserted-by":"publisher","first-page":"7240","DOI":"10.3390\/ijms24087240","volume":"24","author":"R Bei","year":"2023","unstructured":"Bei R, Masuelli L. Novel therapeutic targets for tumor microenvironment in cancer. Int J Mol Sci. 2023;24(8):7240.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1634_CR37","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ccell.2024.03.011","volume":"42","author":"G Lei","year":"2024","unstructured":"Lei G, Zhuang L, Gan B. The roles of ferroptosis in cancer: Tumor suppression, tumor microenvironment, and therapeutic interventions. Cancer Cell. 2024;42(4):513\u201334.","journal-title":"Cancer Cell"},{"issue":"11","key":"1634_CR38","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423\u201337.","journal-title":"Nat Med"},{"issue":"1","key":"1634_CR39","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-024-01765-9","volume":"9","author":"A Hu","year":"2024","unstructured":"Hu A, Sun L, Lin H, Liao Y, Yang H, Mao Y. Harnessing innate immune pathways for therapeutic advancement in cancer. Signal Transduct Target Ther. 2024;9(1):68.","journal-title":"Signal Transduct Target Ther"},{"key":"1634_CR40","doi-asserted-by":"publisher","first-page":"1368687","DOI":"10.3389\/fimmu.2024.1368687","volume":"15","author":"T Dou","year":"2024","unstructured":"Dou T, Li J, Zhang Y, Pei W, Zhang B, Wang B, et al. The cellular composition of the tumor microenvironment is an important marker for predicting therapeutic efficacy in breast cancer. Front Immunol. 2024;15:1368687.","journal-title":"Front Immunol"},{"issue":"4","key":"1634_CR41","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3390\/biom14040438","volume":"14","author":"X Zhang","year":"2024","unstructured":"Zhang X, Ma H, Gao Y, Liang Y, Du Y, Hao S, et al. The tumor microenvironment: signal transduction. Biomolecules. 2024;14(4):438.","journal-title":"Biomolecules"},{"issue":"4","key":"1634_CR42","first-page":"215","volume":"19","author":"H Salmon","year":"2019","unstructured":"Salmon H, Remark R, Gnjatic S, Merad M. Host tissue determinants of tumour immunity. Nat Rev Cancer. 2019;19(4):215\u201327.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1634_CR43","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174\u201386.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"1634_CR44","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.trecan.2022.03.001","volume":"8","author":"PE Saw","year":"2022","unstructured":"Saw PE, Chen J, Song E. Targeting CAFs to overcome anticancer therapeutic resistance. Trends Cancer. 2022;8(7):527\u201355.","journal-title":"Trends Cancer"},{"issue":"4","key":"1634_CR45","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41568-023-00549-7","volume":"23","author":"M Tsoumakidou","year":"2023","unstructured":"Tsoumakidou M. The advent of immune stimulating CAFs in cancer. Nat Rev Cancer. 2023;23(4):258\u201369.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1634_CR46","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3390\/cells12030509","volume":"12","author":"G Eissner","year":"2023","unstructured":"Eissner G. Mesenchymal stromal cells \u201cthink\u201d globally, but act locally. Cells. 2023;12(3):509.","journal-title":"Cells"},{"issue":"17","key":"1634_CR47","doi-asserted-by":"publisher","first-page":"10023","DOI":"10.3390\/ijms231710023","volume":"23","author":"Y Huang","year":"2022","unstructured":"Huang Y, Wu Q, Tam PKH. Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications. Int J Mol Sci. 2022;23(17):10023.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1634_CR48","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3390\/cells10030548","volume":"10","author":"H Su","year":"2021","unstructured":"Su H, Cantrell AC, Zeng H, Zhu SH, Chen JX. Emerging role of pericytes and their secretome in the heart. Cells. 2021;10(3):548.","journal-title":"Cells"},{"key":"1634_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216074","volume":"556","author":"Z Jiang","year":"2023","unstructured":"Jiang Z, Zhou J, Li L, Liao S, He J, Zhou S, et al. Pericytes in the tumor microenvironment. Cancer Lett. 2023;556: 216074.","journal-title":"Cancer Lett"},{"issue":"4","key":"1634_CR50","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jord\u0101o MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11(4):933\u201359.","journal-title":"Cancer Discov"},{"issue":"1","key":"1634_CR51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41590-022-01385-x","volume":"24","author":"A Christofides","year":"2023","unstructured":"Christofides A, Katopodi XL, Cao C, Karagkouni D, Aliazis K, Yenyuwadee S, et al. SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses. Nat Immunol. 2023;24(1):55\u201368.","journal-title":"Nat Immunol"},{"issue":"4","key":"1634_CR52","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41568-022-00547-1","volume":"23","author":"L Cassetta","year":"2023","unstructured":"Cassetta L, Pollard JW. A timeline of tumour-associated macrophage biology. Nat Rev Cancer. 2023;23(4):238\u201357.","journal-title":"Nat Rev Cancer"},{"key":"1634_CR53","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-061020-053702","volume":"39","author":"C Dong","year":"2021","unstructured":"Dong C. Cytokine regulation and function in T cells. Annu Rev Immunol. 2021;39:51\u201376.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"1634_CR54","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.immuni.2022.12.001","volume":"56","author":"A Chow","year":"2023","unstructured":"Chow A, Uddin FZ, Liu M, Dobrin A, Nabet BY, Mangarin L, et al. The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity. 2023;56(1):93-106.e6.","journal-title":"Immunity"},{"issue":"2","key":"1634_CR55","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.immuni.2023.01.004","volume":"56","author":"S Dikiy","year":"2023","unstructured":"Dikiy S, Rudensky AY. Principles of regulatory T cell function. Immunity. 2023;56(2):240\u201355.","journal-title":"Immunity"},{"issue":"7945","key":"1634_CR56","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41586-022-05593-1","volume":"613","author":"NL de Vries","year":"2023","unstructured":"de Vries NL, van de Haar J, Veninga V, Chalabi M, Ijsselsteijn ME, van der Ploeg M, et al. \u03b3\u03b4 T cells are effectors of immunotherapy in cancers with HLA class I defects. Nature. 2023;613(7945):743\u201350.","journal-title":"Nature"},{"issue":"7","key":"1634_CR57","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41568-022-00466-1","volume":"22","author":"CM Laumont","year":"2022","unstructured":"Laumont CM, Banville AC, Gilardi M, Hollern DP, Nelson BH. Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nat Rev Cancer. 2022;22(7):414\u201330.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1634_CR58","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/imm.13568","volume":"168","author":"J Xia","year":"2023","unstructured":"Xia J, Xie Z, Niu G, Lu Z, Wang Z, Xing Y, et al. Single-cell landscape and clinical outcomes of infiltrating B cells in colorectal cancer. Immunology. 2023;168(1):135\u201351.","journal-title":"Immunology"},{"issue":"8","key":"1634_CR59","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","volume":"21","author":"T Bald","year":"2020","unstructured":"Bald T, Krummel MF, Smyth MJ, Barry KC. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat Immunol. 2020;21(8):835\u201347.","journal-title":"Nat Immunol"},{"issue":"1","key":"1634_CR60","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12943-023-01737-7","volume":"22","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Cheng L, Liu L, Li X. NK cells are never alone: crosstalk and communication in tumour microenvironments. Mol Cancer. 2023;22(1):34.","journal-title":"Mol Cancer"},{"issue":"1","key":"1634_CR61","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","volume":"21","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer. 2022;21(1):184.","journal-title":"Mol Cancer"},{"issue":"1","key":"1634_CR62","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41392-023-01337-3","volume":"8","author":"R Zhang","year":"2023","unstructured":"Zhang R, Dong M, Tu J, Li F, Deng Q, Xu J, et al. PMN-MDSCs modulated by CCL20 from cancer cells promoted breast cancer cell stemness through CXCL2-CXCR2 pathway. Signal Transduct Target Ther. 2023;8(1):97.","journal-title":"Signal Transduct Target Ther"},{"key":"1634_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.938289","volume":"10","author":"M Yan","year":"2022","unstructured":"Yan M, Zheng M, Niu R, Yang X, Tian S, Fan L, et al. Roles of tumor-associated neutrophils in tumor metastasis and its clinical applications. Front Cell Dev Biol. 2022;10: 938289.","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"1634_CR64","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1136\/gutjnl-2021-325137","volume":"71","author":"S Tian","year":"2022","unstructured":"Tian S, Chu Y, Hu J, Ding X, Liu Z, Fu D, et al. Tumour-associated neutrophils secrete AGR2 to promote colorectal cancer metastasis via its receptor CD98hc-xCT. Gut. 2022;71(12):2489\u2013501.","journal-title":"Gut"},{"issue":"1","key":"1634_CR65","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41467-022-35615-5","volume":"14","author":"X Lei","year":"2023","unstructured":"Lei X, Khatri I, de Wit T, de Rink I, Nieuwland M, Kerkhoven R, et al. CD4+ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment. Nat Commun. 2023;14(1):217.","journal-title":"Nat Commun"},{"key":"1634_CR66","doi-asserted-by":"publisher","first-page":"1105244","DOI":"10.3389\/fimmu.2023.1105244","volume":"14","author":"B Subtil","year":"2023","unstructured":"Subtil B, Iyer KK, Poel D, Bakkerus L, Gorris MAJ, Escalona JC, et al. Dendritic cell phenotype and function in a 3D co-culture model of patient-derived metastatic colorectal cancer organoids. Front Immunol. 2023;14:1105244.","journal-title":"Front Immunol"},{"issue":"1","key":"1634_CR67","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","volume":"6","author":"J Huang","year":"2021","unstructured":"Huang J, Zhang L, Wan D, Zhou L, Zheng S, Lin S, et al. Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct Target Ther. 2021;6(1):153.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1634_CR68","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s13046-022-02484-1","volume":"41","author":"A Jurj","year":"2022","unstructured":"Jurj A, Ionescu C, Berindan-Neagoe I, Braicu C. The extracellular matrix alteration, implication in modulation of drug resistance mechanism: friends or foes? J Exp Clin Cancer Res. 2022;41(1):276.","journal-title":"J Exp Clin Cancer Res"},{"key":"1634_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.216036","volume":"555","author":"Y Lee","year":"2023","unstructured":"Lee Y, Graham P, Li Y. Extracellular vesicles as a novel approach for breast cancer therapeutics. Cancer Lett. 2023;555: 216036.","journal-title":"Cancer Lett"},{"key":"1634_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215979","volume":"552","author":"QY Chen","year":"2023","unstructured":"Chen QY, Gao B, Tong D, Huang C. Crosstalk between extracellular vesicles and tumor-associated macrophage in the tumor microenvironment. Cancer Lett. 2023;552: 215979.","journal-title":"Cancer Lett"},{"issue":"3","key":"1634_CR71","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3390\/cancers14030539","volume":"14","author":"R Lappano","year":"2022","unstructured":"Lappano R, Todd LA, Stanic M, Cai Q, Maggiolini M, Marincola F, et al. Multifaceted interplay between hormones, growth factors and hypoxia in the tumor microenvironment. Cancers (Basel). 2022;14(3):539.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1634_CR72","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2741\/3612","volume":"15","author":"X Zhang","year":"2010","unstructured":"Zhang X, Nie D, Chakrabarty S. Growth factors in tumor microenvironment. Front Biosci (Landmark Ed). 2010;15(1):151\u201365.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"1634_CR73","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fonc.2020.00137","volume":"10","author":"T Smida","year":"2020","unstructured":"Smida T, Bruno TC, Stabile LP. Influence of estrogen on the NSCLC Microenvironment: a comprehensive picture and clinical implications. Front Oncol. 2020;10:137.","journal-title":"Front Oncol"},{"issue":"Pt 3","key":"1634_CR74","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.semcancer.2022.02.017","volume":"86","author":"M Mughees","year":"2022","unstructured":"Mughees M, Kaushal JB, Sharma G, Wajid S, Batra SK, Siddiqui JA. Chemokines and cytokines: axis and allies in prostate cancer pathogenesis. Semin Cancer Biol. 2022;86(Pt 3):497\u2013512.","journal-title":"Semin Cancer Biol"},{"issue":"Pt 2","key":"1634_CR75","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.semcancer.2022.03.028","volume":"86","author":"S Bose","year":"2022","unstructured":"Bose S, Saha P, Chatterjee B, Srivastava AK. Chemokines driven ovarian cancer progression, metastasis and chemoresistance: Potential pharmacological targets for cancer therapy. Semin Cancer Biol. 2022;86(Pt 2):568\u201379.","journal-title":"Semin Cancer Biol"},{"issue":"7467","key":"1634_CR76","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. \n2013;501(7467):346\u201354.","journal-title":"Nature"},{"issue":"11","key":"1634_CR77","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3390\/biom13111604","volume":"13","author":"HI Atiya","year":"2023","unstructured":"Atiya HI, Gorecki G, Garcia GL, Frisbie LG, Baruwal R, Coffman L. Stromal-modulated epithelial-to-mesenchymal transition in cancer cells. Biomolecules. 2023;13(11):1604.","journal-title":"Biomolecules"},{"key":"1634_CR78","doi-asserted-by":"publisher","first-page":"28587","DOI":"10.1038\/srep28587","volume":"6","author":"S Imani","year":"2016","unstructured":"Imani S, Hosseinifard H, Cheng J, Wei C, Fu J. Prognostic value of EMT-inducing transcription factors (EMT-TFs) in metastatic breast cancer: a systematic review and meta-analysis. Sci Rep. 2016;6:28587.","journal-title":"Sci Rep"},{"issue":"8","key":"1634_CR79","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.3390\/cancers12082154","volume":"12","author":"Y Tang","year":"2020","unstructured":"Tang Y, Durand S, Dalle S, Caramel J. EMT-Inducing transcription factors, drivers of melanoma phenotype switching, and resistance to treatment. Cancers (Basel). 2020;12(8):2154.","journal-title":"Cancers (Basel)."},{"issue":"20","key":"1634_CR80","doi-asserted-by":"publisher","first-page":"5135","DOI":"10.3390\/cancers13205135","volume":"13","author":"AR Subbalakshmi","year":"2021","unstructured":"Subbalakshmi AR, Sahoo S, McMullen I, Saxena AN, Venugopal SK, Somarelli JA, et al. KLF4 induces mesenchymal-epithelial transition (MET) by suppressing multiple EMT-inducing transcription factors. Cancers (Basel). 2021;13(20):5135.","journal-title":"Cancers (Basel)."},{"key":"1634_CR81","doi-asserted-by":"publisher","first-page":"1362247","DOI":"10.3389\/fonc.2024.1362247","volume":"14","author":"RR Tindall","year":"2024","unstructured":"Tindall RR, Bailey-Lundberg JM, Cao Y, Ko TC. The TGF-\u03b2 superfamily as potential therapeutic targets in pancreatic cancer. Front Oncol. 2024;14:1362247.","journal-title":"Front Oncol"},{"issue":"23","key":"1634_CR82","doi-asserted-by":"publisher","first-page":"21113","DOI":"10.1074\/jbc.M211304200","volume":"278","author":"H Peinado","year":"2003","unstructured":"Peinado H, Quintanilla M, Cano A. Transforming growth factor \u03b2-1 induces snail transcription factor in epithelial cell lines mechanisms for epithelial mesenchymal transitions. J Biol Chem. 2003;278(23):21113\u201323.","journal-title":"J Biol Chem"},{"issue":"12","key":"1634_CR83","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1158\/1541-7786.MCR-12-0155-T","volume":"10","author":"Y Wu","year":"2012","unstructured":"Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, et al. Expression of Wnt3 activates Wnt\/\u03b2-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res. 2012;10(12):1597\u2013606.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"1634_CR84","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00018-023-05099-7","volume":"81","author":"W Xue","year":"2024","unstructured":"Xue W, Yang L, Chen C, Ashrafizadeh M, Tian Y, Sun R. Wnt\/\u03b2-catenin-driven EMT regulation in human cancers. Cell Mol Life Sci. 2024;81(1):79.","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"1634_CR85","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1158\/1078-0432.CCR-17-1366","volume":"24","author":"T Fukusumi","year":"2018","unstructured":"Fukusumi T, Guo TW, Sakai A, Ando M, Ren S, Haft S, et al. The NOTCH4\u2013HEY1 pathway induces epithelial\u2013mesenchymal transition in head and neck squamous cell carcinoma. Clin Cancer Res. 2018;24(3):619\u201333.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1634_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep20209","volume":"6","author":"S Fukuda","year":"2016","unstructured":"Fukuda S, Nishida-Fukuda H, Nanba D, Nakashiro K-i, Nakayama H, Kubota H, et al. Reversible interconversion and maintenance of mammary epithelial cell characteristics by the ligand-regulated EGFR system. Sci Rep. 2016;6(1):1\u201316.","journal-title":"Sci Rep"},{"issue":"7","key":"1634_CR87","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1158\/0008-5472.CAN-07-2559","volume":"68","author":"TR Graham","year":"2008","unstructured":"Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, et al. Insulin-like growth factor-I\u2013dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Can Res. 2008;68(7):2479\u201388.","journal-title":"Can Res"},{"key":"1634_CR88","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/mto.2016.18","volume":"3","author":"D Jiao","year":"2016","unstructured":"Jiao D, Wang J, Lu W, Tang X, Chen J, Mou H, et al. Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met dependent PI3K\/Akt\/mTOR signaling pathways in lung cancer. Mol Therapy-Oncolytics. 2016;3:16018.","journal-title":"Mol Therapy-Oncolytics"},{"issue":"1","key":"1634_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-15139-5","volume":"7","author":"B-J Choi","year":"2017","unstructured":"Choi B-J, Park S-A, Lee S-Y, Cha YN, Surh Y-J. Hypoxia induces epithelial-mesenchymal transition in colorectal cancer cells through ubiquitin-specific protease 47-mediated stabilization of Snail: A potential role of Sox9. Sci Rep. 2017;7(1):1\u201315.","journal-title":"Sci Rep"},{"issue":"1","key":"1634_CR90","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","volume":"18","author":"X Jing","year":"2019","unstructured":"Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18(1):157.","journal-title":"Mol Cancer"},{"issue":"12","key":"1634_CR91","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41571-021-00539-4","volume":"18","author":"DC Singleton","year":"2021","unstructured":"Singleton DC, Macann A, Wilson WR. Therapeutic targeting of the hypoxic tumour microenvironment. Nat Rev Clin Oncol. 2021;18(12):751\u201372.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"1634_CR92","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-023-00848-6","volume":"23","author":"X Yuan","year":"2024","unstructured":"Yuan X, Ruan W, Bobrow B, Carmeliet P, Eltzschig HK. Targeting hypoxia-inducible factors: therapeutic opportunities and challenges. Nat Rev Drug Discov. 2024;23(3):175\u2013200.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"1634_CR93","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00109-007-0281-3","volume":"85","author":"MC Brahimi-Horn","year":"2007","unstructured":"Brahimi-Horn MC, Chiche J, Pouyss\u00e9gur J. Hypoxia and cancer. J Mol Med. 2007;85(12):1301\u20137.","journal-title":"J Mol Med"},{"key":"1634_CR94","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3389\/fonc.2020.00486","volume":"10","author":"SY Tam","year":"2020","unstructured":"Tam SY, Wu VWC, Law HKW. Hypoxia-induced epithelial-mesenchymal transition in cancers: HIF-1\u03b1 and beyond. Front Oncol. 2020;10:486.","journal-title":"Front Oncol"},{"issue":"3","key":"1634_CR95","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ncb1691","volume":"10","author":"M-H Yang","year":"2008","unstructured":"Yang M-H, Wu M-Z, Chiou S-H, Chen P-M, Chang S-Y, Liu C-J, et al. Direct regulation of TWIST by HIF-1\u03b1 promotes metastasis. Nat Cell Biol. 2008;10(3):295\u2013305.","journal-title":"Nat Cell Biol"},{"issue":"6","key":"1634_CR96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129603","volume":"10","author":"W Zhang","year":"2015","unstructured":"Zhang W, Shi X, Peng Y, Wu M, Zhang P, Xie R, et al. HIF-1\u03b1 promotes epithelial-mesenchymal transition and metastasis through direct regulation of ZEB1 in colorectal cancer. PLoS ONE. 2015;10(6): e0129603.","journal-title":"PLoS ONE"},{"issue":"3","key":"1634_CR97","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.18632\/oncotarget.23225","volume":"9","author":"X Mingyuan","year":"2018","unstructured":"Mingyuan X, Qianqian P, Shengquan X, Chenyi Y, Rui L, Yichen S, et al. Hypoxia-inducible factor-1\u03b1 activates transforming growth factor-\u03b21\/Smad signaling and increases collagen deposition in dermal fibroblasts. Oncotarget. 2018;9(3):3188.","journal-title":"Oncotarget"},{"issue":"6","key":"1634_CR98","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1182\/blood-2002-02-0629","volume":"101","author":"H Zhang","year":"2003","unstructured":"Zhang H, Akman HO, Smith EL, Zhao J, Murphy-Ullrich JE, Batuman OA. Cellular response to hypoxia involves signaling via Smad proteins. Blood. 2003;101(6):2253\u201360.","journal-title":"Blood"},{"issue":"5","key":"1634_CR99","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1478-3231.2010.02205.x","volume":"30","author":"BL Copple","year":"2010","unstructured":"Copple BL. Hypoxia stimulates hepatocyte epithelial to mesenchymal transition by hypoxia-inducible factor and transforming growth factor-beta-dependent mechanisms. Liver Int. 2010;30(5):669\u201382.","journal-title":"Liver Int"},{"issue":"34","key":"1634_CR100","doi-asserted-by":"publisher","first-page":"24171","DOI":"10.1074\/jbc.M604507200","volume":"281","author":"S McMahon","year":"2006","unstructured":"McMahon S, Charbonneau M, Grandmont S, Richard DE, Dubois CM. Transforming growth factor \u03b21 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. J Biol Chem. 2006;281(34):24171\u201381.","journal-title":"J Biol Chem"},{"issue":"2","key":"1634_CR101","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/sj.bjc.6605486","volume":"102","author":"J Chen","year":"2010","unstructured":"Chen J, Imanaka N, Griffin J. Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer. 2010;102(2):351\u201360.","journal-title":"Br J Cancer"},{"issue":"1","key":"1634_CR102","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13046-020-1535-y","volume":"39","author":"X Peng","year":"2020","unstructured":"Peng X, Gao H, Xu R, Wang H, Mei J, Liu C. The interplay between HIF-1\u03b1 and noncoding RNAs in cancer. J Exp Clin Cancer Res. 2020;39(1):27.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1634_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-017-0714-8","volume":"16","author":"M Xue","year":"2017","unstructured":"Xue M, Chen W, Xiang A, Wang R, Chen H, Pan J, et al. Hypoxic exosomes facilitate bladder tumor growth and development through transferring long non-coding RNA-UCA1. Mol Cancer. 2017;16(1):1\u201313.","journal-title":"Mol Cancer"},{"issue":"5\u20136","key":"1634_CR104","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/10799893.2019.1683863","volume":"39","author":"J Ni","year":"2019","unstructured":"Ni J, Zhou S, Yuan W, Cen F, Yan Q. Mechanism of miR-210 involved in epithelial\u2013mesenchymal transition of pancreatic cancer cells under hypoxia. J Recept Signal Transduct. 2019;39(5\u20136):399\u2013406.","journal-title":"J Recept Signal Transduct"},{"issue":"1","key":"1634_CR105","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12943-023-01731-z","volume":"22","author":"L Pei","year":"2023","unstructured":"Pei L, Liu Y, Liu L, Gao S, Gao X, Feng Y, et al. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22(1):29.","journal-title":"Mol Cancer"},{"issue":"7","key":"1634_CR106","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.3390\/ijms25074031","volume":"25","author":"DA Bogdanova","year":"2024","unstructured":"Bogdanova DA, Kolosova ED, Pukhalskaia TV, Levchuk KA, Demidov ON, Belotserkovskaya EV. The differential effect of senolytics on sasp cytokine secretion and regulation of EMT by CAFs. Int J Mol Sci. 2024;25(7):4031.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1634_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0770-1","volume":"12","author":"T Liu","year":"2019","unstructured":"Liu T, Han C, Wang S, Fang P, Ma Z, Xu L, et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol. 2019;12(1):1\u201315.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"1634_CR108","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/2326-6066.CIR-19-0507","volume":"8","author":"H Xiang","year":"2020","unstructured":"Xiang H, Ramil CP, Hai J, Zhang C, Wang H, Watkins AA, et al. Cancer-associated fibroblasts promote immunosuppression by inducing ROS-generating monocytic MDSCs in lung squamous cell carcinoma. Cancer Immunol Res. 2020;8(4):436\u201350.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"1634_CR109","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3390\/cells12040628","volume":"12","author":"D Mishra","year":"2023","unstructured":"Mishra D, Banerjee D. Secretome of stromal cancer-associated fibroblasts (CAFs): relevance in cancer. Cells. 2023;12(4):628.","journal-title":"Cells"},{"issue":"3","key":"1634_CR110","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41388-023-02884-3","volume":"43","author":"FA Akinjiyan","year":"2024","unstructured":"Akinjiyan FA, Ibitoye Z, Zhao P, Shriver LP, Patti GJ, Longmore GD, et al. DDR2-regulated arginase activity in ovarian cancer-associated fibroblasts promotes collagen production and tumor progression. Oncogene. 2024;43(3):189\u2013201.","journal-title":"Oncogene"},{"issue":"1","key":"1634_CR111","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12943-019-0994-2","volume":"18","author":"ME Fiori","year":"2019","unstructured":"Fiori ME, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer. 2019;18(1):70.","journal-title":"Mol Cancer"},{"issue":"1","key":"1634_CR112","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1186\/s12885-023-11011-0","volume":"23","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, Zhu Y. FAP, CD10, and GPR77-labeled CAFs cause neoadjuvant chemotherapy resistance by inducing EMT and CSC in gastric cancer. BMC Cancer. 2023;23(1):507.","journal-title":"BMC Cancer"},{"issue":"1","key":"1634_CR113","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12935-023-02911-z","volume":"23","author":"L Yang","year":"2023","unstructured":"Yang L, Gong S, Qiao P, Zhao R, Huang S, Zhou J, et al. CAFs-derived rho-associated kinase1 mediated EMT to promote laryngeal squamous cell carcinoma metastasis. Cancer Cell Int. 2023;23(1):70.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"1634_CR114","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1038\/s41598-023-28480-9","volume":"13","author":"PM Szabo","year":"2023","unstructured":"Szabo PM, Vajdi A, Kumar N, Tolstorukov MY, Chen BJ, Edwards R, et al. Cancer-associated fibroblasts are the main contributors to epithelial-to-mesenchymal signatures in the tumor microenvironment. Sci Rep. 2023;13(1):3051.","journal-title":"Sci Rep"},{"issue":"1","key":"1634_CR115","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, Yue X, Chen Z, Liu C, Wu W, Zhang N, et al. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer. 2023;22(1):159.","journal-title":"Mol Cancer"},{"key":"1634_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2024.04.001","volume":"101","author":"YE Zhang","year":"2024","unstructured":"Zhang YE, Stuelten CH. Alternative splicing in EMT and TGF-\u03b2 signaling during cancer progression. Semin Cancer Biol. 2024;101:1\u201311.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"1634_CR117","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/bjc.2013.768","volume":"110","author":"Y Yu","year":"2014","unstructured":"Yu Y, Xiao C, Tan L, Wang Q, Li X, Feng Y. Cancer-associated fibroblasts induce epithelial\u2013mesenchymal transition of breast cancer cells through paracrine TGF-\u03b2 signalling. Br J Cancer. 2014;110(3):724\u201332.","journal-title":"Br J Cancer"},{"issue":"1","key":"1634_CR118","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-018-0758-4","volume":"17","author":"Y Ren","year":"2018","unstructured":"Ren Y, Jia HH, Xu YQ, Zhou X, Zhao XH, Wang YF, et al. Paracrine and epigenetic control of CAF-induced metastasis: the role of HOTAIR stimulated by TGF-\u00df1 secretion. Mol Cancer. 2018;17(1):5.","journal-title":"Mol Cancer"},{"issue":"3","key":"1634_CR119","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s11033-019-04719-5","volume":"46","author":"X-l Wang","year":"2019","unstructured":"Wang X-l, Huang C. Difference of TGF-\u03b2\/Smads signaling pathway in epithelial-mesenchymal transition of normal colonic epithelial cells induced by tumor-associated fibroblasts and colon cancer cells. Mol Biol Rep. 2019;46(3):2749\u201359.","journal-title":"Mol Biol Rep"},{"key":"1634_CR120","doi-asserted-by":"publisher","first-page":"11924","DOI":"10.1038\/srep11924","volume":"5","author":"J Zhuang","year":"2015","unstructured":"Zhuang J, Lu Q, Shen B, Huang X, Shen L, Zheng X, et al. TGF\u03b21 secreted by cancer-associated fibroblasts induces epithelial-mesenchymal transition of bladder cancer cells through lncRNA-ZEB2NAT. Sci Rep. 2015;5:11924.","journal-title":"Sci Rep"},{"issue":"44","key":"1634_CR121","doi-asserted-by":"publisher","first-page":"76116","DOI":"10.18632\/oncotarget.18814","volume":"8","author":"L Wang","year":"2017","unstructured":"Wang L, Cao L, Wang H, Liu B, Zhang Q, Meng Z, et al. Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6\/STAT3 signaling pathway. Oncotarget. 2017;8(44):76116.","journal-title":"Oncotarget"},{"issue":"46","key":"1634_CR122","doi-asserted-by":"publisher","first-page":"80666","DOI":"10.18632\/oncotarget.20881","volume":"8","author":"Z Qu","year":"2017","unstructured":"Qu Z, Wu J, Ji A, Qiang G, Jiang Y, Jiang C, et al. Exosomal miR-665 as a novel minimally invasive biomarker for hepatocellular carcinoma diagnosis and prognosis. Oncotarget. 2017;8(46):80666\u201378.","journal-title":"Oncotarget"},{"issue":"1","key":"1634_CR123","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12885-019-5353-6","volume":"19","author":"CR Goulet","year":"2019","unstructured":"Goulet CR, Champagne A, Bernard G, Vandal D, Chabaud S, Pouliot F, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling. BMC Cancer. 2019;19(1):137.","journal-title":"BMC Cancer"},{"issue":"2","key":"1634_CR124","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.lungcan.2013.08.008","volume":"82","author":"A Abulaiti","year":"2013","unstructured":"Abulaiti A, Shintani Y, Funaki S, Nakagiri T, Inoue M, Sawabata N, et al. Interaction between non-small-cell lung cancer cells and fibroblasts via enhancement of TGF-\u03b2 signaling by IL-6. Lung Cancer. 2013;82(2):204\u201313.","journal-title":"Lung Cancer"},{"issue":"9","key":"1634_CR125","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.jtho.2016.05.025","volume":"11","author":"Y Shintani","year":"2016","unstructured":"Shintani Y, Fujiwara A, \nKimura T, Kawamura T, Funaki S, Minami M, et al. IL-6 secreted from cancer-associated fibroblasts mediates chemoresistance in NSCLC by increasing epithelial-mesenchymal transition signaling. J Thorac Oncol. 2016;11(9):1482\u201392.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"1634_CR126","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/emboj\/cdg226","volume":"22","author":"AA Postigo","year":"2003","unstructured":"Postigo AA, Depp JL, Taylor JJ, Kroll KL. Regulation of Smad signaling through a differential recruitment of coactivators and corepressors by ZEB proteins. EMBO J. 2003;22(10):2453\u201362.","journal-title":"EMBO J"},{"issue":"8","key":"1634_CR127","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/ncb1905","volume":"11","author":"T Vincent","year":"2009","unstructured":"Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J, et al. A SNAIL1-SMAD3\/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol. 2009;11(8):943\u201350.","journal-title":"Nat Cell Biol"},{"issue":"8","key":"1634_CR128","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1080\/21645515.2017.1327107","volume":"13","author":"S Haque","year":"2017","unstructured":"Haque S, Morris JC. Transforming growth factor-\u03b2: A therapeutic target for cancer. Hum Vaccin Immunother. 2017;13(8):1741\u201350.","journal-title":"Hum Vaccin Immunother"},{"issue":"58","key":"1634_CR129","doi-asserted-by":"publisher","first-page":"97703","DOI":"10.18632\/oncotarget.20097","volume":"8","author":"SK Gudey","year":"2017","unstructured":"Gudey SK, Sundar R, Heldin CH, Bergh A, Landstr\u00f6m M. Pro-invasive properties of Snail1 are regulated by sumoylation in response to TGF\u03b2 stimulation in cancer. Oncotarget. 2017;8(58):97703\u201326.","journal-title":"Oncotarget"},{"issue":"4","key":"1634_CR130","first-page":"5694","volume":"15","author":"X Wang","year":"2018","unstructured":"Wang X, Zhang W, Sun X, Lin Y, Chen W. Cancer-associated fibroblasts induce epithelial-mesenchymal transition through secreted cytokines in endometrial cancer cells. Oncol Lett. 2018;15(4):5694\u2013702.","journal-title":"Oncol Lett"},{"issue":"9","key":"1634_CR131","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41419-018-0922-1","volume":"9","author":"X Ding","year":"2018","unstructured":"Ding X, Ji J, Jiang J, Cai Q, Wang C, Shi M, et al. HGF-mediated crosstalk between cancer-associated fibroblasts and MET-unamplified gastric cancer cells activates coordinated tumorigenesis and metastasis. Cell Death Dis. 2018;9(9):867.","journal-title":"Cell Death Dis"},{"issue":"7","key":"1634_CR132","doi-asserted-by":"publisher","first-page":"101042831771259","DOI":"10.1177\/1010428317712592","volume":"39","author":"Y Sun","year":"2017","unstructured":"Sun Y, Fan X, Zhang Q, Shi X, Xu G, Zou C. Cancer-associated fibroblasts secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1\/FGFR4 signaling. Tumor Biology. 2017;39(7):1010428317712592.","journal-title":"Tumor Biology"},{"issue":"12","key":"1634_CR133","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00109-023-02384-7","volume":"101","author":"F Takatsu","year":"2023","unstructured":"Takatsu F, Suzawa K, Tomida S, Thu YM, Sakaguchi M, Toji T, et al. Periostin secreted by cancer-associated fibroblasts promotes cancer progression and drug resistance in non-small cell lung cancer. J Mol Med (Berl). 2023;101(12):1603\u201314.","journal-title":"J Mol Med (Berl)"},{"issue":"1","key":"1634_CR134","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3892\/ijo.2016.3779","volume":"50","author":"T Shan","year":"2017","unstructured":"Shan T, Chen S, Chen X, Lin WR, Li W, Ma J, et al. Prometastatic mechanisms of CAF-mediated EMT regulation in pancreatic cancer cells. Int J Oncol. 2017;50(1):121\u20138.","journal-title":"Int J Oncol"},{"key":"1634_CR135","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3389\/fcell.2019.00060","volume":"7","author":"T Liu","year":"2019","unstructured":"Liu T, Zhou L, Li D, Andl T, Zhang Y. Cancer-associated fibroblasts build and secure the tumor microenvironment. Front Cell Dev Biol. 2019;7:60. https:\/\/doi.org\/10.3389\/fcell.2019.00060.","journal-title":"Front Cell Dev Biol."},{"issue":"1","key":"1634_CR136","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131.","journal-title":"Mol Cancer"},{"issue":"2","key":"1634_CR137","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1158\/0008-5472.CAN-23-1418","volume":"84","author":"Y Du","year":"2024","unstructured":"Du Y, Shi J, Wang J, Xun Z, Yu Z, Sun H, et al. Integration of pan-cancer single-cell and spatial transcriptomics reveals stromal cell features and therapeutic targets in tumor microenvironment. Cancer Res. 2024;84(2):192\u2013210.","journal-title":"Cancer Res"},{"key":"1634_CR138","doi-asserted-by":"publisher","first-page":"1374742","DOI":"10.3389\/fonc.2024.1374742","volume":"14","author":"L Cao","year":"2024","unstructured":"Cao L, Ouyang H. Intercellular crosstalk between cancer cells and cancer-associated fibroblasts via exosomes in gastrointestinal tumors. Front Oncol. 2024;14:1374742.","journal-title":"Front Oncol"},{"issue":"6","key":"1634_CR139","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.3390\/cancers15061899","volume":"15","author":"K Wright","year":"2023","unstructured":"Wright K, Ly T, Kriet M, Czirok A, Thomas SM. Cancer-associated fibroblasts: master tumor microenvironment modifiers. Cancers (Basel). 2023;15(6):1899.","journal-title":"Cancers (Basel)."},{"issue":"5","key":"1634_CR140","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1158\/1078-0432.CCR-13-3173","volume":"21","author":"HY Jung","year":"2015","unstructured":"Jung HY, Fattet L, Yang J. Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis. Clin Cancer Res. 2015;21(5):962\u20138.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1634_CR141","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/ncb3157","volume":"17","author":"SC Wei","year":"2015","unstructured":"Wei SC, Fattet L, Tsai JH, Guo Y, Pai VH, Majeski HE, et al. Matrix stiffness drives epithelial-mesenchymal transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction pathway. Nat Cell Biol. 2015;17(5):678\u201388.","journal-title":"Nat Cell Biol"},{"issue":"7","key":"1634_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.54","volume":"6","author":"AJ Rice","year":"2017","unstructured":"Rice AJ, Cortes E, Lachowski D, Cheung BCH, Karim SA, Morton JP, et al. Matrix stiffness induces epithelial-mesenchymal transition and promotes chemoresistance in pancreatic cancer cells. Oncogenesis. 2017;6(7): e352.","journal-title":"Oncogenesis"},{"issue":"10","key":"1634_CR143","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1242\/jcs.180539","volume":"129","author":"K Zhang","year":"2016","unstructured":"Zhang K, Grither WR, Van Hove S, Biswas H, Ponik SM, Eliceiri KW, et al. Mechanical signals regulate and activate SNAIL1 protein to control the fibrogenic response of cancer-associated fibroblasts. J Cell Sci. 2016;129(10):1989\u20132002.","journal-title":"J Cell Sci"},{"issue":"5","key":"1634_CR144","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1053\/j.gastro.2023.11.302","volume":"166","author":"M Lewinska","year":"2024","unstructured":"Lewinska M, Zhuravleva E, Satriano L, Martinez MB, Bhatt DK, Oliveira DVNP, et al. Fibroblast-derived lysyl oxidase increases oxidative phosphorylation and stemness in cholangiocarcinoma. Gastroenterology. 2024;166(5):886-901.e7.","journal-title":"Gastroenterology"},{"key":"1634_CR145","doi-asserted-by":"publisher","first-page":"956270","DOI":"10.3389\/fonc.2022.956270","volume":"12","author":"Y Makutani","year":"2022","unstructured":"Makutani Y, Kawakami H, Tsujikawa T, Yoshimura K, Chiba Y, Ito A, et al. Contribution of MMP14-expressing cancer-associated fibroblasts in the tumor immune microenvironment to progression of colorectal cancer. Front Oncol. 2022;12:956270.","journal-title":"Front Oncol"},{"issue":"14","key":"1634_CR146","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.3390\/cancers13143466","volume":"13","author":"I Belhabib","year":"2021","unstructured":"Belhabib I, Zaghdoudi S, Lac C, Bousquet C, Jean C. Extracellular matrices and cancer-associated fibroblasts: targets for cancer diagnosis and therapy? Cancers (Basel). 2021;13(14):3466.","journal-title":"Cancers (Basel)."},{"issue":"3","key":"1634_CR147","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41419-019-1397-4","volume":"10","author":"P Peixoto","year":"2019","unstructured":"Peixoto P, Etcheverry A, Aubry M, Missey A, Lachat C, Perrard J, et al. EMT is associated with an epigenetic signature of ECM remodeling genes. Cell Death Dis. 2019;10(3):205.","journal-title":"Cell Death Dis"},{"issue":"6","key":"1634_CR148","doi-asserted-by":"publisher","first-page":"2100094","DOI":"10.1002\/gch2.202100094","volume":"6","author":"H Tian","year":"2022","unstructured":"Tian H, Shi H, Yu J, Ge S, Ruan J. Biophysics role and biomimetic culture systems of ECM stiffness in cancer EMT. Glob Chall. 2022;6(6):2100094.","journal-title":"Glob Chall"},{"issue":"3","key":"1634_CR149","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D \u00d6hlund","year":"2017","unstructured":"\u00d6hlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579\u201396.","journal-title":"J Exp Med"},{"issue":"7","key":"1634_CR150","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1158\/1078-0432.CCR-18-1955","volume":"25","author":"V Bernard","year":"2019","unstructured":"Bernard V, Semaan A, Huang J, San Lucas FA, Mulu FC, Stephens BM, et al. Single-cell transcriptomics of pancreatic cancer precursors demonstrates epithelial and microenvironmental heterogeneity as an early event in neoplastic progression. Clin Cancer Res. 2019;25(7):2194\u2013205.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1634_CR151","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.ccell.2021.05.010","volume":"39","author":"S Affo","year":"2021","unstructured":"Affo S, Nair A, Brundu F, Ravichandra A, Bhattacharjee S, Matsuda M, et al. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell. 2021;39(6):883.","journal-title":"Cancer Cell"},{"key":"1634_CR152","doi-asserted-by":"publisher","DOI":"10.1172\/JCI146987","author":"S Bhattacharjee","year":"2021","unstructured":"Bhattacharjee S, Hamberger F, Ravichandra A, Miller M, Nair A, Affo S, et al. Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. J Clin Invest. 2021. https:\/\/doi.org\/10.1172\/JCI146987.","journal-title":"J Clin Invest"},{"issue":"16","key":"1634_CR153","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1038\/s41388-022-02253-6","volume":"41","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zheng S, Hu C, Li G, Lin H, Xia R, et al. Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair. Oncogene. 2022;41(16):2372\u201389.","journal-title":"Oncogene"},{"issue":"3","key":"1634_CR154","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","volume":"33","author":"A Costa","year":"2018","unstructured":"Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell. 2018;33(3):463-79.e10.","journal-title":"Cancer Cell"},{"issue":"6","key":"1634_CR155","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ccell.2022.04.011","volume":"40","author":"H Huang","year":"2022","unstructured":"Huang H, Wang Z, Zhang Y, Pradhan RN, Ganguly D, Chandra R, et al. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell. 2022;40(6):656-73.e7.","journal-title":"Cancer Cell"},{"issue":"2","key":"1634_CR156","doi-asserted-by":"publisher","first-page":"e20210815","DOI":"10.1084\/jem.20210815","volume":"219","author":"D Kerdidani","year":"2022","unstructured":"Kerdidani D, Aerakis E, Verrou KM, Angelidis I, Douka K, Maniou MA, et al. Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts. J Exp Med. 2022;219(2):e20210815.","journal-title":"J Exp Med"},{"issue":"8","key":"1634_CR157","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 2019;9(8):1102\u201323.","journal-title":"Cancer Discov"},{"key":"1634_CR158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ctdb.2018.02.002","volume":"130","author":"JM Muncie","year":"2018","unstructured":"Muncie JM, Weaver VM. The physical and biochemical properties of the extracellular matrix regulate cell fate. Curr Top Dev Biol. 2018;130:1\u201337.","journal-title":"Curr Top Dev Biol"},{"issue":"1","key":"1634_CR159","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X, et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023;22(1):48.","journal-title":"Mol Cancer"},{"issue":"1","key":"1634_CR160","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-022-01252-0","volume":"15","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Zhang H, Wang J, Liu Y, Luo T, Hua H. Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. J Hematol Oncol. 2022;15(1):34.","journal-title":"J Hematol Oncol"},{"key":"1634_CR161","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fcell.2019.00135","volume":"7","author":"LE Scott","year":"2019","unstructured":"Scott LE, Weinberg SH, Lemmon CA. Mechanochemical signaling of the extracellular matrix in epithelial-mesenchymal transition. Front Cell Dev Biol. 2019;7:135.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1634_CR162","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12935-024-03385-3","volume":"24","author":"MR Pickett","year":"2024","unstructured":"Pickett MR, Chen YI, Kamra M, Kumar S, Kalkunte N, Sugerman GP, et al. Assessing the impact of extracellular matrix fiber orientation on breast cancer cellular metabolism. Cancer Cell Int. 2024;24(1):199.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"1634_CR163","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3390\/cancers14041049","volume":"14","author":"S Ishihara","year":"2022","unstructured":"Ishihara S, Haga H. Matrix stiffness contributes to cancer progression by regulating transcription factors. Cancers. 2022;14(4):1049.","journal-title":"Cancers"},{"key":"1634_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2023.102245","volume":"85","author":"CA Horta","year":"2023","unstructured":"Horta CA, Doan K, Yang J. Mechanotransduction pathways in regulating epithelial-mesenchymal plasticity. Curr Opin Cell Biol. 2023;85: 102245.","journal-title":"Curr Opin Cell Biol"},{"issue":"7350","key":"1634_CR165","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10137","volume":"474","author":"S Dupont","year":"2011","unstructured":"Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, et al. Role of YAP\/TAZ in mechanotransduction. Nature. 2011;474(7350):179\u201383.","journal-title":"Nature"},{"key":"1634_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110462","volume":"129","author":"D Cao","year":"2020","unstructured":"Cao D, Zhu GY, Lu Y, Yang A, Chen D, Huang HJ, et al. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP\/TAZ activity. Biomed Pharmacother. 2020;129: 110462.","journal-title":"Biomed Pharmacother"},{"key":"1634_CR167","doi-asserted-by":"publisher","first-page":"10498","DOI":"10.1038\/ncomms10498","volume":"7","author":"W Lehmann","year":"2016","unstructured":"Lehmann W, Mossmann D, Kleemann J, Mock K, Meisinger C, Brummer T, et al. ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nat Commun. 2016;7:10498.","journal-title":"Nat Commun"},{"issue":"9","key":"1634_CR168","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/ncb3394","volume":"18","author":"Y Tang","year":"2016","unstructured":"Tang Y, Feinberg T, Keller ET, Li XY, Weiss SJ. Snail\/Slug binding interactions with YAP\/TAZ control skeletal stem cell self-renewal and differentiation. Nat Cell Biol. 2016;18(9):917\u201329.","journal-title":"Nat Cell Biol"},{"issue":"5","key":"1634_CR169","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1091\/mbc.e11-06-0537","volume":"23","author":"JL Leight","year":"2012","unstructured":"Leight JL, Wozniak MA, Chen S, Lynch ML, Chen CS. Matrix rigidity regulates a switch between TGF-\u03b21-induced apoptosis and epithelial-mesenchymal transition. Mol Biol Cell. 2012;23(5):781\u201391.","journal-title":"Mol Biol Cell"},{"issue":"5","key":"1634_CR170","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1091\/mbc.E20-02-0092","volume":"32","author":"AN Kilinc","year":"2021","unstructured":"Kilinc AN, Han S, Barrett LA, Anandasivam N, Nelson CM. Integrin-linked kinase tunes cell-cell and cell-matrix adhesions to regulate the switch between apoptosis and EMT downstream of TGF\u03b21. Mol Biol Cell. 2021;32(5):402\u201312.","journal-title":"Mol Biol Cell"},{"issue":"Pt 9","key":"1634_CR171","first-page":"1875","volume":"127","author":"H Yamashita","year":"2014","unstructured":"Yamashita H, Ichikawa T, Matsuyama D, Kimura Y, Ueda K, Craig SW, et al. The role of the interaction of the vinculin proline-rich linker region with vinexin \u03b1 in sensing the stiffness of the extracellular matrix. J Cell Sci. 2014;127(Pt 9):1875\u201386.","journal-title":"J Cell Sci"},{"issue":"1","key":"1634_CR172","doi-asserted-by":"publisher","first-page":"7228","DOI":"10.1038\/s41598-018-25589-0","volume":"8","author":"AJ McKenzie","year":"2018","unstructured":"McKenzie AJ, Hicks SR, Svec KV, Naughton H, Edmunds ZL, Howe AK. The mechanical microenvironment regulates ovarian cancer cell morphology, migration, and spheroid disaggregation. Sci Rep. 2018;8(1):7228.","journal-title":"Sci Rep"},{"issue":"3","key":"1634_CR173","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1002\/jcp.27078","volume":"234","author":"J Gao","year":"2019","unstructured":"Gao J, Rong Y, Huang Y, Shi P, Wang X, Meng X, et al. Cirrhotic stiffness affects the migration of hepatocellular carcinoma cells and induces sorafenib resistance through YAP. J Cell Physiol. 2019;234(3):2639\u201348.","journal-title":"J Cell Physiol"},{"key":"1634_CR174","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.matbio.2019.07.006","volume":"85\u201386","author":"AJ Berger","year":"2020","unstructured":"Berger AJ, Renner CM, Hale I, Yang X, Ponik SM, Weisman PS, et al. Scaffold stiffness influences breast cancer cell invasion via EGFR-linked Mena upregulation and matrix remodeling. Matrix Biol. 2020;85\u201386:80\u201393.","journal-title":"Matrix Biol"},{"issue":"12","key":"1634_CR175","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1039\/c7ib00128b","volume":"9","author":"AD Schwartz","year":"2017","unstructured":"Schwartz AD, Barney LE, Jansen LE, Nguyen TV, Hall CL, Meyer AS, et al. A biomaterial screening approach reveals microenvironmental mechanisms of drug resistance. Integr Biol (Camb). 2017;9(12):912\u201324.","journal-title":"Integr Biol (Camb)"},{"issue":"1","key":"1634_CR176","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/cancers14010238","volume":"14","author":"NV Popova","year":"2022","unstructured":"Popova NV, J\u00fccker M. The functional role of extracellular matrix proteins in cancer. Cancers (Basel). 2022;14(1):238.","journal-title":"Cancers (Basel)."},{"issue":"8","key":"1634_CR177","first-page":"3508","volume":"61","author":"A Menke","year":"2001","unstructured":"Menke A, Philippi C, Vogelmann R, Seidel B, Lutz MP, Adler G, et al. Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Res. 2001;61(8):3508\u201317.","journal-title":"Cancer Res"},{"issue":"9","key":"1634_CR178","doi-asserted-by":"publisher","first-page":"4662","DOI":"10.1158\/0008-5472.CAN-05-2804","volume":"66","author":"A Koenig","year":"2006","unstructured":"Koenig A, Mueller C, Hasel C, Adler G, Menke A. Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. Cancer Res. 2006;66(9):4662\u201371.","journal-title":"Cancer Res"},{"issue":"1","key":"1634_CR179","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1165\/rcmb.2007-0071OC","volume":"38","author":"Y Shintani","year":"2008","unstructured":"Shintani Y, Maeda M, Chaika N, Johnson KR, Wheelock MJ. Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-beta signaling. Am J Respir Cell Mol Biol. 2008;38(1):95\u2013104.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2","key":"1634_CR180","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2011.02.008","volume":"304","author":"JC Cheng","year":"2011","unstructured":"Cheng JC, Leung PC. Type I collagen down-regulates E-cadherin expression by increasing PI3KCA in cancer cells. Cancer Lett. 2011;304(2):107\u201316.","journal-title":"Cancer Lett"},{"issue":"3","key":"1634_CR181","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.matbio.2009.12.003","volume":"29","author":"D Medici","year":"2010","unstructured":"Medici D, Nawshad A. Type I collagen promotes epithelial-mesenchymal transition through ILK-dependent activation of NF-kappaB and LEF-1. Matrix Biol. 2010;29(3):161\u20135.","journal-title":"Matrix Biol"},{"issue":"6","key":"1634_CR182","doi-asserted-by":"publisher","first-page":"R207","DOI":"10.1016\/j.cub.2017.02.006","volume":"27","author":"R Jayadev","year":"2017","unstructured":"Jayadev R, Sherwood DR. Basement membranes. Curr Biol. 2017;27(6):R207\u201311.","journal-title":"Curr Biol"},{"issue":"5","key":"1634_CR183","first-page":"781","volume":"39","author":"E Engvall","year":"1995","unstructured":"Engvall E. Structure and function of basement membranes. Int J Dev Biol. 1995;39(5):781\u20137.","journal-title":"Int J Dev Biol"},{"issue":"3","key":"1634_CR184","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10517-019-04354-x","volume":"166","author":"DV Mal'tseva","year":"2019","unstructured":"Mal\u2019tseva DV, Makarova YA, Raigorodskaya MP, Rodin SA. Effects of laminins 332 and 411 on the epithelial-mesenchymal status of colorectal cancer cells. Bull Exp Biol Med. 2019;166(3):377\u201382.","journal-title":"Bull Exp Biol Med"},{"issue":"1","key":"1634_CR185","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2004.08.030","volume":"223","author":"V Givant-Horwitz","year":"2005","unstructured":"Givant-Horwitz V, Davidson B, Reich R. Laminin-induced signaling in tumor cells. Cancer Lett. 2005;223(1):1\u201310.","journal-title":"Cancer Lett"},{"issue":"8","key":"1634_CR186","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/cdd.2014.228","volume":"22","author":"YW Moon","year":"2015","unstructured":"Moon YW, Rao G, Kim JJ, Shim HS, Park KS, An SS, et al. LAMC2 enhances the metastatic potential of lung adenocarcinoma. Cell Death Differ. 2015;22(8):1341\u201352.","journal-title":"Cell Death Differ"},{"issue":"5","key":"1634_CR187","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1053\/j.gastro.2005.09.055","volume":"129","author":"G Giannelli","year":"2005","unstructured":"Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology. 2005;129(5):1375\u201383.","journal-title":"Gastroenterology"},{"issue":"2","key":"1634_CR188","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.18632\/oncotarget.11208","volume":"9","author":"CC Liu","year":"2018","unstructured":"Liu CC, Lin JH, Hsu TW, Hsu JW, Chang JW, Su K, et al. Collagen XVII\/laminin-5 activates epithelial-to-mesenchymal transition and is associated with poor prognosis in lung cancer. Oncotarget. 2018;9(2):1656\u201372.","journal-title":"Oncotarget"},{"issue":"3","key":"1634_CR189","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00418-008-0443-6","volume":"130","author":"M Takkunen","year":"2008","unstructured":"Takkunen M, Ainola M, Vainionp\u00e4\u00e4 N, Grenman R, Patarroyo M, Garc\u00eda de Herreros A, et al. Epithelial-mesenchymal transition downregulates laminin alpha5 chain and upregulates laminin alpha4 chain in oral squamous carcinoma cells. Histochem Cell Biol. 2008;130(3):509\u201325.","journal-title":"Histochem Cell Biol"},{"issue":"2","key":"1634_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2022.151220","volume":"101","author":"S Banerjee","year":"2022","unstructured":"Banerjee S, Lo WC, Majumder P, Roy D, Ghorai M, Shaikh NK, et al. Multiple roles for basement membrane proteins in cancer progression and EMT. Eur J Cell Biol. 2022;101(2): 151220.","journal-title":"Eur J Cell Biol"},{"key":"1634_CR191","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-3-030-40146-7_4","volume":"1245","author":"P Qiao","year":"2020","unstructured":"Qiao P, Lu ZR. Fibronectin in the tumor microenvironment. Adv Exp Med Biol. 2020;1245:85\u201396.","journal-title":"Adv Exp Med Biol"},{"key":"1634_CR192","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3389\/fonc.2020.00641","volume":"10","author":"G Efthymiou","year":"2020","unstructured":"Efthymiou G, Saint A, Ruff M, Rekad Z, Ciais D, Van Obberghen-Schilling E. Shaping up the tumor microenvironment with cellular fibronectin. Front Oncol. 2020;10:641.","journal-title":"Front Oncol"},{"issue":"1","key":"1634_CR193","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40164-023-00419-w","volume":"12","author":"F Zhou","year":"2023","unstructured":"Zhou F, Sun J, Ye L, Jiang T, Li W, Su C, et al. Fibronectin promotes tumor angiogenesis and progression of non-small-cell lung cancer by elevating WISP3 expression via FAK\/MAPK\/ HIF-1\u03b1 axis and activating wnt signaling pathway. Exp Hematol Oncol. \n2023;12(1):61.","journal-title":"Exp Hematol Oncol"},{"issue":"13","key":"1634_CR194","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/onc.2013.118","volume":"33","author":"J Park","year":"2014","unstructured":"Park J, Schwarzbauer JE. Mammary epithelial cell interactions with fibronectin stimulate epithelial-mesenchymal transition. Oncogene. 2014;33(13):1649\u201357.","journal-title":"Oncogene"},{"issue":"20","key":"1634_CR195","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1158\/0008-5472.CAN-13-0602","volume":"73","author":"LM Knowles","year":"2013","unstructured":"Knowles LM, Gurski LA, Engel C, Gnarra JR, Maranchie JK, Pilch J. Integrin alphavbeta3 and fibronectin upregulate Slug in cancer cells to promote clot invasion and metastasis. Cancer Res. 2013;73(20):6175\u201384.","journal-title":"Cancer Res"},{"issue":"5","key":"1634_CR196","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.3892\/ol.2017.5896","volume":"13","author":"CL Li","year":"2017","unstructured":"Li CL, Yang D, Cao X, Wang F, Hong DY, Wang J, et al. Fibronectin induces epithelial-mesenchymal transition in human breast cancer MCF-7 cells via activation of calpain. Oncol Lett. 2017;13(5):3889\u201395.","journal-title":"Oncol Lett"},{"issue":"10","key":"1634_CR197","doi-asserted-by":"publisher","first-page":"722","DOI":"10.2174\/187152010794728657","volume":"10","author":"K Bullard Dunn","year":"2010","unstructured":"Bullard Dunn K, Heffler M, Golubovskaya M, V. Evolving therapies and FAK inhibitors for the treatment of cancer. Anti-Cancer Agents Med. 2010;10(10):722\u201334.","journal-title":"Anti-Cancer Agents Med"},{"issue":"13","key":"1634_CR198","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1200\/JCO.2011.38.9346","volume":"30","author":"JR Infante","year":"2012","unstructured":"Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, et al. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol. 2012;30(13):1527\u201333.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1634_CR199","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/cas.13256","volume":"108","author":"C Hu","year":"2017","unstructured":"Hu C, Chen X, Wen J, Gong L, Liu Z, Wang J, et al. Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo. Cancer Sci. 2017;108(7):1347\u201356.","journal-title":"Cancer Sci"},{"issue":"46","key":"1634_CR200","doi-asserted-by":"publisher","first-page":"45801","DOI":"10.1074\/jbc.M308168200","volume":"278","author":"A Zoltan-Jones","year":"2003","unstructured":"Zoltan-Jones A, Huang L, Ghatak S, Toole BP. Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J Biol Chem. 2003;278(46):45801\u201310.","journal-title":"J Biol Chem"},{"issue":"1","key":"1634_CR201","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12964-017-0204-z","volume":"15","author":"N Nguyen","year":"2017","unstructured":"Nguyen N, Kumar A, Chacko S, Ouellette RJ, Ghosh A. Human hyaluronic acid synthase-1 promotes malignant transformation via epithelial-to-mesenchymal transition, micronucleation and centrosome abnormalities. Cell Commun Signal. 2017;15(1):48.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"1634_CR202","doi-asserted-by":"publisher","first-page":"10626","DOI":"10.1038\/s41598-024-61426-3","volume":"14","author":"O Jokelainen","year":"2024","unstructured":"Jokelainen O, Rintala TJ, Fortino V, Pasonen-Sepp\u00e4nen S, Sironen R, Nykopp TK. Differential expression analysis identifies a prognostically significant extracellular matrix-enriched gene signature in hyaluronan-positive clear cell renal cell carcinoma. Sci Rep. 2024;14(1):10626.","journal-title":"Sci Rep"},{"key":"1634_CR203","first-page":"485468","volume":"1","author":"G Chow","year":"2010","unstructured":"Chow G, Tauler J, Mulshine JL. 2010 Cytokines and growth factors stimulate hyaluronan production: role of hyaluronan in epithelial to mesenchymal-like transition in non-small cell lung cancer. J Biomed Biotechnol. 2010;1:485468.","journal-title":"J Biomed Biotechnol"},{"issue":"43","key":"1634_CR204","doi-asserted-by":"publisher","first-page":"17460","DOI":"10.1073\/pnas.1206653109","volume":"109","author":"CP El-Haibi","year":"2012","unstructured":"El-Haibi CP, Bell GW, Zhang J, Collmann AY, Wood D, Scherber CM, et al. Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci. 2012;109(43):17460\u20135.","journal-title":"Proc Natl Acad Sci"},{"issue":"37","key":"1634_CR205","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1038\/onc.2012.475","volume":"32","author":"H Porsch","year":"2013","unstructured":"Porsch H, Bernert B, Mehi\u0107 M, Theocharis A, Heldin C-H, Heldin P. Efficient TGF\u03b2-induced epithelial\u2013mesenchymal transition depends on hyaluronan synthase HAS2. Oncogene. 2013;32(37):4355\u201365.","journal-title":"Oncogene"},{"issue":"2","key":"1634_CR206","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.apsb.2016.01.002","volume":"6","author":"N Sato","year":"2016","unstructured":"Sato N, Cheng X-B, Kohi S, Koga A, Hirata K. Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma. Acta Pharmaceutica Sinica B. 2016;6(2):101\u20135.","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"5","key":"1634_CR207","first-page":"6297","volume":"15","author":"XB Cheng","year":"2018","unstructured":"Cheng XB, Sato N, Kohi S, Koga A, Hirata K. 4-Methylumbelliferone inhibits enhanced hyaluronan synthesis and cell migration in pancreatic cancer cells in response to tumor-stromal interactions. Oncol Lett. 2018;15(5):6297\u2013301.","journal-title":"Oncol Lett"},{"key":"1634_CR208","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ijbiomac.2022.02.095","volume":"206","author":"ML Essa","year":"2022","unstructured":"Essa ML, Elashkar AA, Hanafy NAN, Saied EM, El-Kemary M. Dual targeting nanoparticles based on hyaluronic and folic acids as a promising delivery system of the encapsulated 4-Methylumbelliferone (4-MU) against invasiveness of lung cancer in vivo and in vitro. Int J Biol Macromol. 2022;206:467\u201380.","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"1634_CR209","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.biocel.2004.01.007","volume":"36","author":"R Chiquet-Ehrismann","year":"2004","unstructured":"Chiquet-Ehrismann R, Tucker RP. Connective tissues: signalling by tenascins. Int J Biochem Cell Biol. 2004;36(6):1085\u20139.","journal-title":"Int J Biochem Cell Biol"},{"key":"1634_CR210","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.613438","volume":"12","author":"A Aubert","year":"2021","unstructured":"Aubert A, Mercier-Gouy P, Aguero S, Berthier L, Liot S, Prigent L, et al. Latent TGF-\u03b2 activation is a hallmark of the tenascin family. Front Immunol. 2021;12: 613438.","journal-title":"Front Immunol"},{"key":"1634_CR211","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.908247","volume":"12","author":"RP Tucker","year":"2022","unstructured":"Tucker RP, Degen M. Revisiting the tenascins: exploitable as cancer targets? Front Oncol. 2022;12: 908247.","journal-title":"Front Oncol"},{"issue":"2","key":"1634_CR212","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH752>3.0.CO;2-V","volume":"193","author":"N Dandachi","year":"2001","unstructured":"Dandachi N, Hauser-Kronberger C, Mor\u00e9 E, Wiesener B, Hacker GW, Dietze O, et al. Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins. J Pathol. 2001;193(2):181\u20139.","journal-title":"J Pathol"},{"issue":"2","key":"1634_CR213","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.ajpath.2010.10.015","volume":"178","author":"K Nagaharu","year":"2011","unstructured":"Nagaharu K, Zhang X, Yoshida T, Katoh D, Hanamura N, Kozuka Y, et al. Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells. Am J Pathol. 2011;178(2):754\u201363.","journal-title":"Am J Pathol"},{"issue":"5","key":"1634_CR214","first-page":"1927","volume":"33","author":"Y Takahashi","year":"2013","unstructured":"Takahashi Y, Sawada G, Kurashige J, Matsumura T, Uchi R, Ueo H, et al. Tumor-derived tenascin-C promotes the epithelial-mesenchymal transition in colorectal cancer cells. Anticancer Res. 2013;33(5):1927\u201334.","journal-title":"Anticancer Res"},{"issue":"1","key":"1634_CR215","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3892\/ol.2021.12831","volume":"22","author":"X Cheng","year":"2021","unstructured":"Cheng X, Li F, Tao Z. Tenascin-C promotes epithelial-to-mesenchymal transition and the mTOR signaling pathway in nasopharyngeal carcinoma. Oncol Lett. 2021;22(1):570.","journal-title":"Oncol Lett"},{"issue":"18","key":"1634_CR216","doi-asserted-by":"publisher","first-page":"jcs260244","DOI":"10.1242\/jcs.260244","volume":"135","author":"A Yilmaz","year":"2022","unstructured":"Yilmaz A, Loustau T, Salom\u00e9 N, Poilil Surendran S, Li C, Tucker RP, et al. Advances on the roles of tenascin-C in cancer. J Cell Sci. 2022;135(18):jcs260244.","journal-title":"J Cell Sci"},{"key":"1634_CR217","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.896099","volume":"9","author":"S Mustafa","year":"2022","unstructured":"Mustafa S, Koran S, AlOmair L. Insights into the role of matrix metalloproteinases in cancer and its various therapeutic aspects: a review. Front Mol Biosci. 2022;9: 896099.","journal-title":"Front Mol Biosci"},{"issue":"14","key":"1634_CR218","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.3390\/molecules28145567","volume":"28","author":"S Almutairi","year":"2023","unstructured":"Almutairi S, Kalloush HM, Manoon NA, Bardaweel SK. Matrix metalloproteinases inhibitors in cancer treatment: an updated review (2013\u20132023). Molecules. 2023;28(14):5567.","journal-title":"Molecules"},{"issue":"4","key":"1634_CR219","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3390\/biomedicines12040794","volume":"12","author":"MT Islam","year":"2024","unstructured":"Islam MT, Jang NH, Lee HJ. Natural products as regulators against matrix metalloproteinases for the treatment of cancer. Biomedicines. 2024;12(4):794.","journal-title":"Biomedicines."},{"key":"1634_CR220","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-3-030-40146-7_5","volume":"1245","author":"G Gonzalez-Avila","year":"2020","unstructured":"Gonzalez-Avila G, Sommer B, Garcia-Hernandez AA, Ramos C. Matrix metalloproteinases\u2019 role in tumor microenvironment. Adv Exp Med Biol. 2020;1245:97\u2013131.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"1634_CR221","doi-asserted-by":"publisher","first-page":"198","DOI":"10.4161\/cbt.10.2.12193","volume":"10","author":"L Blavier","year":"2010","unstructured":"Blavier L, Lazaryev A, Shi XH, Dorey FJ, Shackleford GM, DeClerck YA. Stromelysin-1 (MMP-3) is a target and a regulator of Wnt1-induced epithelial-mesenchymal transition (EMT). Cancer Biol Ther. 2010;10(2):198\u2013208.","journal-title":"Cancer Biol Ther"},{"issue":"10","key":"1634_CR222","doi-asserted-by":"publisher","first-page":"6232","DOI":"10.1074\/jbc.M705759200","volume":"283","author":"J Cao","year":"2008","unstructured":"Cao J, Chiarelli C, Richman O, Zarrabi K, Kozarekar P, Zucker S. Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer. J Biol Chem. 2008;283(10):6232\u201340.","journal-title":"J Biol Chem"},{"issue":"3","key":"1634_CR223","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/j.1365-2443.2011.01487.x","volume":"16","author":"D Ren","year":"2011","unstructured":"Ren D, Minami Y, Nishita M. Critical role of Wnt5a-Ror2 signaling in motility and invasiveness of carcinoma cells following Snail-mediated epithelial-mesenchymal transition. Genes Cells. 2011;16(3):304\u201315.","journal-title":"Genes Cells"},{"issue":"4","key":"1634_CR224","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1349-7006.2011.01861.x","volume":"102","author":"CY Lin","year":"2011","unstructured":"Lin CY, Tsai PH, Kandaswami CC, Lee PP, Huang CJ, Hwang JJ, et al. Matrix metalloproteinase-9 cooperates with transcription factor Snail to induce epithelial-mesenchymal transition. Cancer Sci. 2011;102(4):815\u201327.","journal-title":"Cancer Sci"},{"issue":"7047","key":"1634_CR225","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature03688","volume":"436","author":"DC Radisky","year":"2005","unstructured":"Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. 2005;436(7047):123\u20137.","journal-title":"Nature"},{"issue":"1","key":"1634_CR226","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.gendis.2014.12.002","volume":"2","author":"J Cathcart","year":"2015","unstructured":"Cathcart J, Pulkoski-Gross A, Cao J. Targeting matrix metalloproteinases in cancer: bringing new life to old ideas. Genes & diseases. 2015;2(1):26\u201334.","journal-title":"Genes & diseases"},{"issue":"10","key":"1634_CR227","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1080\/13543776.2023.2284935","volume":"33","author":"S Banerjee","year":"2023","unstructured":"Banerjee S, Baidya SK, Adhikari N, Jha T. An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present). Expert Opin Ther Pat. 2023;33(10):631\u201349.","journal-title":"Expert Opin Ther Pat"},{"issue":"3","key":"1634_CR228","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","volume":"41","author":"EN Arner","year":"2023","unstructured":"Arner EN, Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell. 2023;41(3):421\u201333.","journal-title":"Cancer Cell"},{"key":"1634_CR229","doi-asserted-by":"publisher","first-page":"1238698","DOI":"10.3389\/fimmu.2023.1238698","volume":"14","author":"M Ganjalikhani Hakemi","year":"2023","unstructured":"Ganjalikhani Hakemi M, Yanikkaya Demirel G, Li Y, Jayakumar N. Editorial: the immunosuppressive tumor microenvironment and strategies to revert its immune regulatory milieu for cancer immunotherapy. Front Immunol. 2023;14:1238698.","journal-title":"Front Immunol"},{"issue":"6","key":"1634_CR230","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.CD-23-1380","volume":"14","author":"KSS Enfield","year":"2024","unstructured":"Enfield KSS, Colliver E, Lee C, Magness A, Moore DA, Sivakumar M, et al. Spatial architecture of myeloid and T cells orchestrates immune evasion and clinical outcome in lung cancer. Cancer Discov. 2024;14(6):1018\u201347.","journal-title":"Cancer Discov"},{"issue":"11","key":"1634_CR231","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1016\/j.celrep.2017.11.052","volume":"21","author":"J Faget","year":"2017","unstructured":"Faget J, Groeneveld S, Boivin G, Sankar M, Zangger N, Garcia M, et al. Neutrophils and snail orchestrate the establishment of a pro-tumor microenvironment in lung cancer. Cell Rep. 2017;21(11):3190\u2013204.","journal-title":"Cell Rep"},{"issue":"4","key":"1634_CR232","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ccell.2014.09.002","volume":"26","author":"DS Hsu","year":"2014","unstructured":"Hsu DS, Wang HJ, Tai SK, Chou CH, Hsieh CH, Chiu PH, et al. Acetylation of snail modulates the cytokinome of cancer cells to enhance the recruitment of macrophages. Cancer Cell. 2014;26(4):534\u201348.","journal-title":"Cancer Cell"},{"key":"1634_CR233","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.722916","volume":"11","author":"J Jin","year":"2021","unstructured":"Jin J, Lin J, Xu A, Lou J, Qian C, Li X, et al. CCL2: an important mediator between tumor cells and host cells in tumor microenvironment. Front Oncol. 2021;11: 722916.","journal-title":"Front Oncol"},{"issue":"2","key":"1634_CR234","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1158\/0008-5472.CAN-12-0653","volume":"73","author":"JM Low-Marchelli","year":"2013","unstructured":"Low-Marchelli JM, Ardi VC, Vizcarra EA, van Rooijen N, Quigley JP, Yang J. Twist1 induces CCL2 and recruits macrophages to promote angiogenesis. Cancer Res. 2013;73(2):662\u201371.","journal-title":"Cancer Res"},{"key":"1634_CR235","doi-asserted-by":"publisher","first-page":"1081762","DOI":"10.3389\/fmolb.2023.1081762","volume":"10","author":"C Zhou","year":"2023","unstructured":"Zhou C, Guo L, Cai Q, Xi W, Yuan F, Zhang H, et al. Circulating neutrophils activated by cancer cells and M2 macrophages promote gastric cancer progression during PD-1 antibody-based immunotherapy. Front Mol Biosci. 2023;10:1081762.","journal-title":"Front Mol Biosci"},{"issue":"4","key":"1634_CR236","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1158\/0008-5472.CAN-23-1542","volume":"84","author":"T Luckett","year":"2024","unstructured":"Luckett T, Abudula M, Ireland L, Glenn M, Bellomo G, Stafferton R, et al. Mesothelin secretion by pancreatic cancer cells co-opts macrophages and promotes metastasis. Cancer Res. 2024;84(4):527\u201344.","journal-title":"Cancer Res"},{"issue":"8","key":"1634_CR237","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938\u201345.","journal-title":"Nat Med"},{"issue":"10","key":"1634_CR238","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41571-019-0222-4","volume":"16","author":"ME Shaul","year":"2019","unstructured":"Shaul ME, Fridlender ZG. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 2019;16(10):601\u201320.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"1634_CR239","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.3390\/cancers16091626","volume":"16","author":"TC Dakal","year":"2024","unstructured":"Dakal TC, George N, Xu C, Suravajhala P, Kumar A. Predictive and prognostic relevance of tumor-infiltrating immune cells: tailoring personalized treatments against different cancer types. Cancers (Basel). 2024;16(9):1626.","journal-title":"Cancers (Basel)."},{"key":"1634_CR240","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/983698","volume":"2015","author":"E Uribe-Querol","year":"2015","unstructured":"Uribe-Querol E, Rosales C. Neutrophils in cancer: two sides of the same coin. J Immunol Res. 2015;2015: 983698.","journal-title":"J Immunol Res"},{"issue":"5","key":"1634_CR241","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.immuni.2020.03.001","volume":"52","author":"\u00c1 Teijeira","year":"2020","unstructured":"Teijeira \u00c1, Garasa S, Gato M, Alfaro C, Migueliz I, Cirella A, et al. CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity. Immunity. 2020;52(5):856-71.e8.","journal-title":"Immunity"},{"issue":"5","key":"1634_CR242","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","volume":"26","author":"KA Schalper","year":"2020","unstructured":"Schalper KA, Carleton M, Zhou M, Chen T, Feng Y, Huang SP, et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of \nimmune-checkpoint inhibitors. Nat Med. 2020;26(5):688\u201392.","journal-title":"Nat Med"},{"issue":"2","key":"1634_CR243","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/path.5753","volume":"255","author":"CE de Andrea","year":"2021","unstructured":"de Andrea CE, Ochoa MC, Villalba-Esparza M, Teijeira \u00c1, Schalper KA, Abengozar-Muela M, et al. Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL-8. J Pathol. 2021;255(2):190\u2013201.","journal-title":"J Pathol"},{"issue":"8","key":"1634_CR244","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1158\/2159-8290.CD-12-0527","volume":"3","author":"Y Pang","year":"2013","unstructured":"Pang Y, Gara SK, Achyut BR, Li Z, Yan HH, Day CP, et al. TGF-\u03b2 signaling in myeloid cells is required for tumor metastasis. Cancer Discov. 2013;3(8):936\u201351.","journal-title":"Cancer Discov"},{"issue":"11","key":"1634_CR245","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1356965","volume":"6","author":"J Michaeli","year":"2017","unstructured":"Michaeli J, Shaul ME, Mishalian I, Hovav AH, Levy L, Zolotriov L, et al. Tumor-associated neutrophils induce apoptosis of non-activated CD8 T-cells in a TNF\u03b1 and NO-dependent mechanism, promoting a tumor-supportive environment. Oncoimmunology. 2017;6(11): e1356965.","journal-title":"Oncoimmunology"},{"key":"1634_CR246","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3389\/fonc.2019.01146","volume":"9","author":"MT Masucci","year":"2019","unstructured":"Masucci MT, Minopoli M, Carriero MV. Tumor associated neutrophils their role in tumorigenesis metastasis prognosis and therapy. Front Oncol. 2019;9:1146.","journal-title":"Front Oncol"},{"key":"1634_CR247","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-35723-8_1","volume":"1224","author":"L Wu","year":"2020","unstructured":"Wu L, Saxena S, Singh RK. Neutrophils in the tumor microenvironment. Adv Exp Med Biol. 2020;1224:1\u201320.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"1634_CR248","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13046-018-1003-0","volume":"38","author":"S Li","year":"2019","unstructured":"Li S, Cong X, Gao H, Lan X, Li Z, Wang W, et al. Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells. J Exp Clin Cancer Res. 2019;38(1):6.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"1634_CR249","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1158\/1078-0432.CCR-18-2544","volume":"25","author":"Y Wang","year":"2019","unstructured":"Wang Y, Chen J, Yang L, Li J, Wu W, Huang M, et al. Tumor-contacted neutrophils promote metastasis by a CD90-TIMP-1 juxtacrine-paracrine loop. Clin Cancer Res. 2019;25(6):1957\u201369.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1634_CR250","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1158\/1078-0432.CCR-20-1319","volume":"27","author":"A Teijeira","year":"2021","unstructured":"Teijeira A, Garasa S, Ochoa MC, Villalba M, Olivera I, Cirella A, et al. IL8, neutrophils, and NETs in a collusion against cancer immunity and immunotherapy. Clin Cancer Res. 2021;27(9):2383\u201393.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1634_CR251","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1599","volume":"14","author":"S Yang","year":"2024","unstructured":"Yang S, Jia J, Wang F, Wang Y, Fang Y, Yang Y, et al. Targeting neutrophils: Mechanism and advances in cancer therapy. Clin Transl Med. 2024;14(3): e1599.","journal-title":"Clin Transl Med"},{"issue":"19","key":"1634_CR252","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202310318","volume":"36","author":"J Zhang","year":"2024","unstructured":"Zhang J, Gu J, Wang X, Ji C, Yu D, Wang M, et al. Engineering and targeting neutrophils for cancer therapy. Adv Mater. 2024;36(19): e2310318.","journal-title":"Adv Mater"},{"key":"1634_CR253","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.901277","volume":"13","author":"A Kumar","year":"2022","unstructured":"Kumar A, Taghi Khani A, Sanchez Ortiz A, Swaminathan S. GM-CSF: a double-edged sword in cancer immunotherapy. Front Immunol. 2022;13: 901277.","journal-title":"Front Immunol"},{"issue":"6","key":"1634_CR254","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19(6):369\u201382.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1634_CR255","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"BZ Qian","year":"2010","unstructured":"Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39\u201351.","journal-title":"Cell"},{"issue":"5","key":"1634_CR256","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","volume":"174","author":"E Azizi","year":"2018","unstructured":"Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell. 2018;174(5):1293-308.e36.","journal-title":"Cell"},{"issue":"9","key":"1634_CR257","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41422-020-0355-0","volume":"30","author":"J Qian","year":"2020","unstructured":"Qian J, Olbrecht S, Boeckx B, Vos H, Laoui D, Etlioglu E, et al. A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. Cell Res. 2020;30(9):745\u201362.","journal-title":"Cell Res"},{"issue":"5","key":"1634_CR258","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/0008-5472.CAN-20-2990","volume":"81","author":"NR Anderson","year":"2021","unstructured":"Anderson NR, Minutolo NG, Gill S, Klichinsky M. Macrophage-based approaches for cancer immunotherapy. Cancer Res. 2021;81(5):1201\u20138.","journal-title":"Cancer Res"},{"issue":"1","key":"1634_CR259","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S, Saeed AFUH, Liu Q, Jiang Q, Xu H, Xiao GG, et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8(1):207.","journal-title":"Signal Transduct Target Ther"},{"key":"1634_CR260","doi-asserted-by":"publisher","first-page":"1337129","DOI":"10.3389\/fimmu.2024.1337129","volume":"15","author":"C Lin","year":"2024","unstructured":"Lin C, Chu Y, Zheng Y, Gu S, Hu Y, He J, et al. Macrophages: plastic participants in the diagnosis and treatment of head and neck squamous cell carcinoma. Front Immunol. 2024;15:1337129.","journal-title":"Front Immunol"},{"issue":"1","key":"1634_CR261","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12929-019-0568-z","volume":"26","author":"Y Chen","year":"2019","unstructured":"Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019;26(1):78.","journal-title":"J Biomed Sci"},{"issue":"12","key":"1634_CR262","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","volume":"17","author":"L Cassetta","year":"2018","unstructured":"Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17(12):887\u2013904.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1634_CR263","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","volume":"12","author":"Y Lin","year":"2019","unstructured":"Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol. 2019;12(1):76.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"1634_CR264","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.it.2022.04.008","volume":"43","author":"RY Ma","year":"2022","unstructured":"Ma RY, Black A, Qian BZ. Macrophage diversity in cancer revisited in the era of single-cell omics. Trends Immunol. 2022;43(7):546\u201363.","journal-title":"Trends Immunol"},{"key":"1634_CR265","doi-asserted-by":"publisher","first-page":"1157291","DOI":"10.3389\/fimmu.2023.1157291","volume":"14","author":"L Xiao","year":"2023","unstructured":"Xiao L, Wang Q, Peng H. Tumor-associated macrophages: new insights on their metabolic regulation and their influence in cancer immunotherapy. Front Immunol. 2023;14:1157291.","journal-title":"Front Immunol"},{"issue":"7","key":"1634_CR266","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399\u2013416.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1634_CR267","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1038\/s41467-024-46735-5","volume":"15","author":"M Cheng","year":"2024","unstructured":"Cheng M, Chen S, Li K, Wang G, Xiong G, Ling R, et al. CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer. Nat Commun. 2024;15(1):2818.","journal-title":"Nat Commun"},{"issue":"1","key":"1634_CR268","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12967-023-04688-1","volume":"22","author":"Y Du","year":"2024","unstructured":"Du Y, Lin Y, Gan L, Wang S, Chen S, Li C, et al. Potential crosstalk between SPP1 + TAMs and CD8 + exhausted T cells promotes an immunosuppressive environment in gastric metastatic cancer. J Transl Med. 2024;22(1):158.","journal-title":"J Transl Med"},{"issue":"9","key":"1634_CR269","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.3390\/cancers16091772","volume":"16","author":"V Quaranta","year":"2024","unstructured":"Quaranta V, Ballar\u00f2 C, Giannelli G. Macrophages orchestrate the liver tumor microenvironment. Cancers (Basel). 2024;16(9):1772.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1634_CR270","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41467-022-29388-0","volume":"13","author":"Z Li","year":"2022","unstructured":"Li Z, Ding Y, Liu J, Wang J, Mo F, Wang Y, et al. Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment. Nat Commun. 2022;13(1):1845.","journal-title":"Nat Commun"},{"issue":"9","key":"1634_CR271","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1158\/0008-5472.CAN-12-3981","volume":"73","author":"J Xu","year":"2013","unstructured":"Xu J, Escamilla J, Mok S, David J, Priceman S, West B, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 2013;73(9):2782\u201394.","journal-title":"Cancer Res"},{"issue":"11","key":"1634_CR272","doi-asserted-by":"publisher","first-page":"e20191820","DOI":"10.1084\/jem.20191820","volume":"217","author":"RY Ma","year":"2020","unstructured":"Ma RY, Zhang H, Li XF, Zhang CB, Selli C, Tagliavini G, et al. Monocyte-derived macrophages promote breast cancer bone metastasis outgrowth. J Exp Med. 2020;217(11):e20191820.","journal-title":"J Exp Med"},{"issue":"1","key":"1634_CR273","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13000-019-0834-0","volume":"14","author":"J Liu","year":"2019","unstructured":"Liu J, Li C, Zhang L, Liu K, Jiang X, Wang X, et al. Association of tumour-associated macrophages with cancer cell EMT, invasion, and metastasis of Kazakh oesophageal squamous cell cancer. Diagn Pathol. 2019;14(1):55.","journal-title":"Diagn Pathol"},{"issue":"5","key":"1634_CR274","first-page":"2558","volume":"40","author":"L Gao","year":"2018","unstructured":"Gao L, Zhang W, Zhong WQ, Liu ZJ, Li HM, Yu ZL, et al. Tumor associated macrophages induce epithelial to mesenchymal transition via the EGFR\/ERK1\/2 pathway in head and neck squamous cell carcinoma. Oncol Rep. 2018;40(5):2558\u201372.","journal-title":"Oncol Rep"},{"issue":"36","key":"1634_CR275","doi-asserted-by":"publisher","first-page":"24272","DOI":"10.18632\/oncotarget.24917","volume":"9","author":"RB Bednarczyk","year":"2018","unstructured":"Bednarczyk RB, Tuli NY, Hanly EK, Rahoma GB, Maniyar R, Mittelman A, et al. Macrophage inflammatory factors promote epithelial-mesenchymal transition in breast cancer. Oncotarget. 2018;9(36):24272\u201382.","journal-title":"Oncotarget"},{"issue":"12","key":"1634_CR276","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s41419-019-2131-y","volume":"10","author":"W Li","year":"2019","unstructured":"Li W, Zhang X, Wu F, Zhou Y, Bao Z, Li H, et al. Gastric cancer-derived mesenchymal stromal cells trigger M2 macrophage polarization that promotes metastasis and EMT in gastric cancer. Cell Death Dis. 2019;10(12):918.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1634_CR277","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12943-019-0976-4","volume":"18","author":"C Wei","year":"2019","unstructured":"Wei C, Yang C, Wang S, Shi D, Zhang C, Lin X, et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer. 2019;18(1):64.","journal-title":"Mol Cancer"},{"key":"1634_CR278","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.molimm.2017.06.018","volume":"90","author":"D Che","year":"2017","unstructured":"Che D, Zhang S, Jing Z, Shang L, Jin S, Liu F, et al. Macrophages induce EMT to promote invasion of lung cancer cells through the IL-6-mediated COX-2\/PGE. Mol Immunol. 2017;90:197\u2013210.","journal-title":"Mol Immunol"},{"issue":"1","key":"1634_CR279","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s13046-018-0981-2","volume":"37","author":"K Kuwada","year":"2018","unstructured":"Kuwada K, Kagawa S, Yoshida R, Sakamoto S, Ito A, Watanabe M, et al. The epithelial-to-mesenchymal transition induced by tumor-associated macrophages confers chemoresistance in peritoneally disseminated pancreatic cancer. J Exp Clin Cancer Res. 2018;37(1):307.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"1634_CR280","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41419-020-2435-y","volume":"11","author":"R Huang","year":"2020","unstructured":"Huang R, Wang S, Wang N, Zheng Y, Zhou J, Yang B, et al. CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating \u03b2-catenin\/STAT3 signaling. Cell Death Dis. 2020;11(4):234.","journal-title":"Cell Death Dis"},{"issue":"2","key":"1634_CR281","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","volume":"19","author":"F Veglia","year":"2018","unstructured":"Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19(2):108\u201319.","journal-title":"Nat Immunol"},{"key":"1634_CR282","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3389\/fimmu.2019.01401","volume":"10","author":"P Ma","year":"2019","unstructured":"Ma P, Beatty PL, McKolanis J, Brand R, Schoen RE, Finn OJ. Circulating myeloid derived suppressor cells (MDSC) that accumulate in premalignancy share phenotypic and functional characteristics with MDSC in cancer. Front Immunol. 2019;10:1401.","journal-title":"Front Immunol"},{"issue":"70","key":"1634_CR283","doi-asserted-by":"publisher","first-page":"114554","DOI":"10.18632\/oncotarget.23020","volume":"8","author":"H Zhu","year":"2017","unstructured":"Zhu H, Gu Y, Xue Y, Yuan M, Cao X, Liu Q. CXCR2(+) MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion. Oncotarget. 2017;8(70):114554\u201367.","journal-title":"Oncotarget"},{"issue":"9","key":"1634_CR284","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1001162","volume":"9","author":"B Toh","year":"2011","unstructured":"Toh B, Wang X, Keeble J, Sim WJ, Khoo K, Wong WC, et al. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol. 2011;9(9): e1001162.","journal-title":"PLoS Biol"},{"key":"1634_CR285","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3389\/fimmu.2018.00398","volume":"9","author":"V Fleming","year":"2018","unstructured":"Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, et al. Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front Immunol. 2018;9:398.","journal-title":"Front Immunol"},{"issue":"9","key":"1634_CR286","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1214787","volume":"5","author":"P Trikha","year":"2016","unstructured":"Trikha P, Plews RL, Stiff A, Gautam S, Hsu V, Abood D, et al. Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator. Oncoimmunology. 2016;5(9): e1214787.","journal-title":"Oncoimmunology"},{"key":"1634_CR287","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3389\/fonc.2019.00855","volume":"9","author":"X Ma","year":"2019","unstructured":"Ma X, Wang M, Yin T, Zhao Y, Wei X. Myeloid-derived suppressor cells promote metastasis in breast cancer after the stress of operative removal of the primary cancer. Front Oncol. 2019;9:855.","journal-title":"Front Oncol"},{"issue":"1","key":"1634_CR288","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6(1):362.","journal-title":"Signal Transduct Target Ther"},{"key":"1634_CR289","doi-asserted-by":"publisher","first-page":"1157537","DOI":"10.3389\/fimmu.2023.1157537","volume":"14","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Du J, Shen X. Targeting myeloid-derived suppressor cells in tumor immunotherapy: current, future and beyond. Front Immunol. 2023;14:1157537.","journal-title":"Front Immunol"},{"issue":"1","key":"1634_CR290","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40364-023-00475-8","volume":"11","author":"S Wang","year":"2023","unstructured":"Wang S, Zhao X, Wu S, Cui D, Xu Z. Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies. Biomark Res. 2023;11(1):34.","journal-title":"Biomark Res"},{"issue":"14","key":"1634_CR291","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.3390\/cells12141912","volume":"12","author":"K Ok\u0142a","year":"2023","unstructured":"Ok\u0142a K. Myeloid-derived suppressor cells (MDSCs) in ovarian cancer-looking back and forward. Cells. 2023;12(14):1912.","journal-title":"Cells"},{"issue":"1","key":"1634_CR292","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-024-00505-7","volume":"13","author":"J Lu","year":"2024","unstructured":"Lu J, Luo Y, Rao D, Wang T, Lei Z, Chen X, et al. Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion. Exp Hematol Oncol. 2024;13(1):39.","journal-title":"Exp Hematol Oncol"},{"key":"1634_CR293","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ircmb.2019.07.004","volume":"348","author":"S Balan","year":"2019","unstructured":"Balan S, Saxena M, Bhardwaj N. Dendritic cell subsets and locations. Int Rev Cell Mol Biol. 2019;348:1\u201368.","journal-title":"Int Rev Cell Mol Biol"},{"issue":"5","key":"1634_CR294","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3390\/cancers16050981","volume":"16","author":"L Hato","year":"2024","unstructured":"Hato L, Vizcay A, Eguren I, P\u00e9rez-Gracia JL, Rodr\u00edguez J, G\u00e1llego P\u00e9rez-Larraya J, et al. Dendritic cells in cancer immunology and immunotherapy. Cancers (Basel). 2024;16(5):981.","journal-title":"Cancers (Basel)."},{"issue":"15","key":"1634_CR295","doi-asserted-by":"publisher","first-page":"8044","DOI":"10.3390\/ijms22158044","volume":"22","author":"MY Zanna","year":"2021","unstructured":"Zanna MY, Yasmin AR, Omar AR, Arshad SS, Mariatulqabtiah AR, Nur-Fazila SH, et al. Review of dendritic cells, their role in clinical immunology, and distribution in various animal species. Int J Mol Sci. 2021;22(15):8044.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1634_CR296","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.ccell.2014.11.010","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014;26(6):938.","journal-title":"Cancer Cell"},{"issue":"1","key":"1634_CR297","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/2159-8290.CD-15-0510","volume":"6","author":"AR S\u00e1nchez-Paulete","year":"2016","unstructured":"S\u00e1nchez-Paulete AR, Cueto FJ, Mart\u00ednez-L\u00f3pez M, Labiano S, Morales-Kastresana A, Rodr\u00edguez-Ruiz ME, et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov. 2016;6(1):71\u20139.","journal-title":"Cancer Discov"},{"issue":"11","key":"1634_CR298","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.trecan.2018.09.001","volume":"4","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher JP, Reis e Sousa C. The role of type 1 conventional dendritic cells in cancer immunity. Trends Cancer. 2018;4(11):784\u201392.","journal-title":"Trends Cancer."},{"issue":"5","key":"1634_CR299","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"A Del Prete","year":"2023","unstructured":"Del Prete A, Salvi V, Soriani A, Laffranchi M, Sozio F, Bosisio D, et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol. 2023;20(5):432\u201347.","journal-title":"Cell Mol Immunol"},{"issue":"8","key":"1634_CR300","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1080\/10428194.2020.1751840","volume":"61","author":"Y Gu","year":"2020","unstructured":"Gu Y, Jin Y, Ding J, Yujie W, Shi Q, Qu X, et al. Low absolute CD4+ T cell counts in peripheral blood predict poor prognosis in patients with newly diagnosed multiple myeloma. Leuk Lymphoma. 2020;61(8):1869\u201376.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1634_CR301","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41467-024-44779-1","volume":"15","author":"C Zhou","year":"2024","unstructured":"Zhou C, Li W, Liang Z, Wu X, Cheng S, Peng J, et al. Mutant KRAS-activated circATXN7 fosters tumor immunoescape by sensitizing tumor-specific T cells to activation-induced cell death. Nat Commun. 2024;15(1):499.","journal-title":"Nat Commun"},{"issue":"9","key":"1634_CR302","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.cell.2024.03.019","volume":"187","author":"S Deng","year":"2024","unstructured":"Deng S, Zhang Y, Wang H, Liang W, Xie L, Li N, et al. ITPRIPL1 binds CD3\u03b5 to impede T cell activation and enable tumor immune evasion. Cell. 2024;187(9):2305-23.e33.","journal-title":"Cell"},{"issue":"7","key":"1634_CR303","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.cell.2024.02.022","volume":"187","author":"D Jia","year":"2024","unstructured":"Jia D, Wang Q, Qi Y, Jiang Y, He J, Lin Y, et al. Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer. Cell. 2024;187(7):1651-65.e21.","journal-title":"Cell"},{"issue":"1","key":"1634_CR304","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/sj.jid.5700001","volume":"126","author":"MH Andersen","year":"2006","unstructured":"Andersen MH, Schrama D, Thor Straten P, Becker JC. Cytotoxic T cells. J Invest Dermatol. 2006;126(1):32\u201341.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1634_CR305","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00281-022-00966-0","volume":"45","author":"MH Andersen","year":"2023","unstructured":"Andersen MH. Tumor microenvironment antigens. Semin Immunopathol. 2023;45(2):253\u201364.","journal-title":"Semin Immunopathol"},{"issue":"11","key":"1634_CR306","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651\u201368.","journal-title":"Nat Rev Immunol"},{"key":"1634_CR307","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fimmu.2012.00051","volume":"3","author":"A Schmidt","year":"2012","unstructured":"Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of treg-mediated T cell suppression. Front Immunol. 2012;3:51.","journal-title":"Front Immunol"},{"issue":"7","key":"1634_CR308","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1158\/2326-6066.CIR-18-0500","volume":"7","author":"J Cursons","year":"2019","unstructured":"Cursons J, Souza-Fonseca-Guimaraes F, Foroutan M, Anderson A, Hollande F, Hediyeh-Zadeh S, et al. A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients. Cancer Immunol Res. 2019;7(7):1162\u201374.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1634_CR309","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12876-020-1177-8","volume":"20","author":"YP Tang","year":"2020","unstructured":"Tang YP, Xie MZ, Li KZ, Li JL, Cai ZM, Hu BL. Prognostic value of peripheral blood natural killer cells in colorectal cancer. BMC Gastroenterol. 2020;20(1):31.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"1634_CR310","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-23-0334","volume":"14","author":"C He","year":"2024","unstructured":"He C, Wang D, Shukla SK, Hu T, Thakur R, Fu X, et al. Vitamin B6 competition in the tumor microenvironment hampers antitumor functions of NK cells. Cancer Discov. 2024;14(1):176\u201393.","journal-title":"Cancer Discov"},{"issue":"8000","key":"1634_CR311","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier E, Rebuffet L, Narni-Mancinelli E, Cornen S, Igarashi RY, Fantin VR. Natural killer cell therapies. Nature. 2024;626(8000):727\u201336.","journal-title":"Nature"},{"key":"1634_CR312","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","volume":"8","author":"S Paul","year":"2017","unstructured":"Paul S, Lal G. The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. Front Immunol. 2017;8:1124.","journal-title":"Front Immunol"},{"issue":"2","key":"1634_CR313","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2023","unstructured":"Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol. 2023;23(2):90\u2013105.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1634_CR314","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40164-024-00511-9","volume":"13","author":"J Hou","year":"2024","unstructured":"Hou J, Xie S, Gao J, Jiang T, Zhu E, Yang X, et al. NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice. Exp Hematol Oncol. 2024;13(1):48.","journal-title":"Exp Hematol Oncol"},{"key":"1634_CR315","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.750022","volume":"9","author":"A Vuleti\u0107","year":"2021","unstructured":"Vuleti\u0107 A, Mirja\u010di\u0107 Martinovi\u0107 K, Ti\u0161ma Mileti\u0107 N, Zoidakis J, Castellvi-Bel S, \u010cavi\u0107 M. Cross-talk between tumor cells undergoing epithelial to mesenchymal transition and natural killer cells in tumor microenvironment in colorectal cancer. Front Cell Dev Biol. 2021;9: 750022.","journal-title":"Front Cell Dev Biol"},{"key":"1634_CR316","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3389\/fonc.2020.00587","volume":"10","author":"V Fedele","year":"2020","unstructured":"Fedele V, Melisi D. Permissive state of EMT: the role of immune cell compartment. Front Oncol. 2020;10:587.","journal-title":"Front Oncol"},{"issue":"4","key":"1634_CR317","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/hep.30317","volume":"69","author":"Y Chen","year":"2019","unstructured":"Chen Y, Hao X, Sun R, Wei H, Tian Z. Natural killer cell-derived interferon-gamma promotes hepatocellular carcinoma through the epithelial cell adhesion molecule-epithelial-to-mesenchymal transition axis in hepatitis b virus transgenic mice. Hepatology. 2019;69(4):1735\u201350.","journal-title":"Hepatology"},{"issue":"14","key":"1634_CR318","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1158\/0008-5472.CAN-17-1891","volume":"78","author":"L Huergo-Zapico","year":"2018","unstructured":"Huergo-Zapico L, Parodi M, Cantoni C, Lavarello C, Fernandez-Martinez JL, Petretto A, et al. NK-cell editing mediates epithelial-to-mesenchymal transition via phenotypic and proteomic changes in melanoma cell linES. Cancer Res. 2018;78(14):3913\u201325.","journal-title":"Cancer Res"},{"issue":"4","key":"1634_CR319","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2014.1000083","volume":"4","author":"L Goebel","year":"2015","unstructured":"Goebel L, Grage-Griebenow E, Gorys A, Helm O, Genrich G, Lenk L, et al. CD4(+) T cells potently induce epithelial-mesenchymal-transition in premalignant and malignant pancreatic ductal epithelial cells-novel implications of CD4(+) T cells in pancreatic cancer development. Oncoimmunology. 2015;4(4): e1000083.","journal-title":"Oncoimmunology"},{"key":"1634_CR320","doi-asserted-by":"crossref","unstructured":"Chen R, Wang K, Feng Z, Zhang MY, Wu J, Geng JJ, et al. CD147 deficiency in T cells prevents thymic involution by inhibiting the EMT process in TECs in the presence of TGFbeta. Cell Mol Immunol. 2020.","DOI":"10.1038\/s41423-019-0353-7"},{"issue":"4","key":"1634_CR321","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19(4):237\u201353.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1634_CR322","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2014.1000083","volume":"4","author":"L Goebel","year":"2015","unstructured":"Goebel L, Grage-Griebenow E, Gorys A, Helm O, Genrich G, Lenk L, et al. CD4+ T cells potently induce epithelial-mesenchymal-transition in premalignant and malignant pancreatic ductal epithelial cells-novel implications of CD4+ T cells in pancreatic cancer development. Oncoimmunology. 2015;4(4): e1000083.","journal-title":"Oncoimmunology"},{"issue":"11","key":"1634_CR323","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3390\/cells8111387","volume":"8","author":"E Oh","year":"2019","unstructured":"Oh E, Hong J, Yun C-O. Regulatory T cells induce metastasis by activating tgf-\u03b2 and enhancing the epithelial-mesenchymal transition. Cells. 2019;8(11):1387.","journal-title":"Cells"},{"key":"1634_CR324","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/OTT.S172417","volume":"12","author":"C Shi","year":"2019","unstructured":"Shi C, Chen Y, Yang Y, Bing W, Qi J. CD4+ CD25+ regulatory T cells promote hepatocellular carcinoma invasion via TGF-\u03b21-induced epithelial-mesenchymal transition. Onco Targets Ther. 2019;12:279\u201389.","journal-title":"Onco Targets Ther"},{"key":"1634_CR325","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/OTT.S172417","volume":"12","author":"C Shi","year":"2019","unstructured":"Shi C, Chen Y, Chen Y, Yang Y, Bing W, Qi J. CD4+ CD25+ regulatory T cells promote hepatocellular carcinoma invasion via TGF-\u03b21-induced epithelial\u2013mesenchymal transition. Onco Targets Ther. 2019;12:279.","journal-title":"Onco Targets Ther"},{"issue":"5","key":"1634_CR326","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.3390\/pharmaceutics15051465","volume":"15","author":"H Jo","year":"2023","unstructured":"Jo H, Shim K, Jeoung D. Exosomes: diagnostic and therapeutic implications in cancer. Pharmaceutics. 2023;15(5):1465.","journal-title":"Pharmaceutics"},{"key":"1634_CR327","doi-asserted-by":"publisher","first-page":"1149551","DOI":"10.3389\/fonc.2023.1149551","volume":"13","author":"X Fang","year":"2023","unstructured":"Fang X, Lan H, Jin K, Qian J. Pancreatic cancer and exosomes: role in progression, diagnosis, monitoring, and treatment. Front Oncol. 2023;13:1149551.","journal-title":"Front Oncol"},{"issue":"3","key":"1634_CR328","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/mc.23378","volume":"61","author":"MN Rizwan","year":"2022","unstructured":"Rizwan MN, Ma Y, Nenkov M, Jin L, Schr\u00f6der DC, Westermann M, et al. Tumor-derived exosomes: key players in non-small cell lung cancer metastasis and their implication for targeted therapy. Mol Carcinog. 2022;61(3):269\u201380.","journal-title":"Mol Carcinog"},{"issue":"1","key":"1634_CR329","doi-asserted-by":"publisher","first-page":"1887552","DOI":"10.1080\/2162402X.2021.1887552","volume":"10","author":"C Han","year":"2021","unstructured":"Han C, Zhang C, Wang H, Zhao L. Exosome-mediated communication between tumor cells and tumor-associated macrophages: implications for tumor microenvironment. Oncoimmunology. 2021;10(1):1887552.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1634_CR330","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12885-023-11791-5","volume":"24","author":"C Yang","year":"2024","unstructured":"Yang C, Zhang Y, Yan M, Wang J, Wang M, Xuan Y, et al. Exosomes derived from cancer-associated fibroblasts promote tumorigenesis, metastasis and chemoresistance of colorectal cancer by upregulating circ_0067557 to target Lin28. BMC Cancer. 2024;24(1):64.","journal-title":"BMC Cancer"},{"key":"1634_CR331","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2024.111182","volume":"119","author":"Z Sheng","year":"2024","unstructured":"Sheng Z, Wang X, Ding X, Zheng Y, Guo A, Cui J, et al. Exosomal miRNA-92a derived from cancer-associated fibroblasts promote invasion and metastasis in breast cancer by regulating G3BP2. Cell Signal. 2024;119: 111182.","journal-title":"Cell Signal"},{"key":"1634_CR332","doi-asserted-by":"publisher","first-page":"1378302","DOI":"10.3389\/fcell.2024.1378302","volume":"12","author":"Z Gou","year":"2024","unstructured":"Gou Z, Li J, Liu J, Yang N. The hidden messengers: cancer associated fibroblasts-derived exosomal miRNAs as key regulators of cancer malignancy. Front Cell Dev Biol. 2024;12:1378302.","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"1634_CR333","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.tcb.2023.01.002","volume":"33","author":"DK Jeppesen","year":"2023","unstructured":"Jeppesen DK, Zhang Q, Franklin JL, Coffey RJ. Extracellular vesicles and nanoparticles: emerging complexities. Trends Cell Biol. 2023;33(8):667\u201381.","journal-title":"Trends Cell Biol"},{"key":"1634_CR334","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ebiom.2018.09.006","volume":"36","author":"Y-y Li","year":"2018","unstructured":"Li Y-y, Tao Y-w, Gao S, Li P, Zheng J-m, Zhang S-e, et al. Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p. EBioMedicine. 2018;36:209\u201320.","journal-title":"EBioMedicine"},{"issue":"34","key":"1634_CR335","doi-asserted-by":"publisher","first-page":"54852","DOI":"10.18632\/oncotarget.10243","volume":"7","author":"MA Rahman","year":"2016","unstructured":"Rahman MA, Barger JF, Lovat F, Gao M, Otterson GA, Nana-Sinkam P. Lung cancer exosomes as drivers of epithelial mesenchymal transition. Oncotarget. 2016;7(34):54852\u201366.","journal-title":"Oncotarget"},{"key":"1634_CR336","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3389\/fonc.2018.00066","volume":"8","author":"C Rajagopal","year":"2018","unstructured":"Rajagopal C, Harikumar KB. The origin and functions of exosomes in cancer. Front Oncol. 2018;8:66.","journal-title":"Front Oncol"},{"issue":"1","key":"1634_CR337","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/jcm8010026","volume":"8","author":"A Conigliaro","year":"2018","unstructured":"Conigliaro A, Cicchini C. Exosome-mediated signaling in epithelial to mesenchymal transition and tumor progression. J Clin Med. 2018;8(1):26.","journal-title":"J Clin Med"},{"key":"1634_CR338","doi-asserted-by":"publisher","first-page":"2931813","DOI":"10.1155\/2017\/2931813","volume":"2017","author":"L Santangelo","year":"2017","unstructured":"Santangelo L, Battistelli C, Montaldo C, Citarella F, Strippoli R, Cicchini C. Functional roles and therapeutic applications of exosomes in hepatocellular carcinoma. Biomed Res Int. 2017;2017:2931813.","journal-title":"Biomed Res Int"},{"issue":"10","key":"1634_CR339","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1111\/jcmm.12873","volume":"20","author":"C Corrado","year":"2016","unstructured":"Corrado C, Saieva L, Raimondo S, Santoro A, De Leo G, Alessandro R. Chronic myelogenous leukaemia exosomes modulate bone marrow microenvironment through activation of epidermal growth factor receptor. J Cell Mol Med. 2016;20(10):1829\u201339.","journal-title":"J Cell Mol Med"},{"issue":"8","key":"1634_CR340","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/qjmed\/hcz093","volume":"112","author":"J You","year":"2019","unstructured":"You J, Li M, Cao L, Gu Q, Deng P, Tan Y, et al. Snail1-dependent cancer-associated fibroblasts induce epithelial-mesenchymal transition in lung cancer cells via exosomes. QJM Int J Med. 2019;112(8):581\u201390.","journal-title":"QJM Int J Med."},{"issue":"33","key":"1634_CR341","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1038\/onc.2017.100","volume":"36","author":"Y Chen","year":"2017","unstructured":"Chen Y, Zeng C, Zhan Y, Wang H, Jiang X, Li W. Aberrant low expression of p85alpha in stromal fibroblasts promotes breast cancer cell metastasis through exosome-mediated paracrine Wnt10b. Oncogene. 2017;36(33):4692\u2013705.","journal-title":"Oncogene"},{"issue":"1","key":"1634_CR342","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13287-019-1220-2","volume":"10","author":"S Wang","year":"2019","unstructured":"Wang S, Su X, Xu M, Xiao X, Li X, Li H, et al. Exosomes secreted by mesenchymal stromal\/stem cell-derived adipocytes promote breast cancer cell growth via activation of Hippo signaling pathway. Stem Cell Res Ther. 2019;10(1):117.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"1634_CR343","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12943-020-01245-y","volume":"19","author":"AN Ariston Gabriel","year":"2020","unstructured":"Ariston Gabriel AN, Wang F, Jiao Q, Yvette U, Yang \nX, Al-Ameri SA, et al. The involvement of exosomes in the diagnosis and treatment of pancreatic cancer. Mol Cancer. 2020;19(1):132.","journal-title":"Mol Cancer"},{"issue":"Pt 1","key":"1634_CR344","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2023.116115","volume":"231","author":"S Mirzaei","year":"2023","unstructured":"Mirzaei S, Gholami MH, Aghdaei HA, Hashemi M, Parivar K, Karamian A, et al. Exosome-mediated miR-200a delivery into TGF-\u03b2-treated AGS cells abolished epithelial-mesenchymal transition with normalization of ZEB1, vimentin and Snail1 expression. Environ Res. 2023;231(Pt 1): 116115.","journal-title":"Environ Res"},{"issue":"11","key":"1634_CR345","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1111\/jcmm.17755","volume":"27","author":"R Dhar","year":"2023","unstructured":"Dhar R, Devi A, Gorai S, Jha SK, Alexiou A, Papadakis M. Exosome and epithelial-mesenchymal transition: a complex secret of cancer progression. J Cell Mol Med. 2023;27(11):1603\u20137.","journal-title":"J Cell Mol Med"},{"issue":"7","key":"1634_CR346","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.3390\/cancers15072156","volume":"15","author":"NS Mastronikolis","year":"2023","unstructured":"Mastronikolis NS, Kyrodimos E, Spyropoulou D, Delides A, Giotakis E, Piperigkou Z, et al. The role of exosomes in epithelial-to-mesenchymal transition and cell functional properties in head and neck cancer. Cancers (Basel). 2023;15(7):2156.","journal-title":"Cancers (Basel)."},{"issue":"4","key":"1634_CR347","doi-asserted-by":"publisher","DOI":"10.1002\/adbi.202300532","volume":"8","author":"FM Zablon","year":"2024","unstructured":"Zablon FM, Desai P, Dellinger K, Aravamudhan S. Cellular and exosomal MicroRNAs: emerging clinical relevance as targets for breast cancer diagnosis and prognosis. Adv Biol (Weinh). 2024;8(4): e2300532.","journal-title":"Adv Biol (Weinh)"},{"key":"1634_CR348","doi-asserted-by":"publisher","first-page":"1330144","DOI":"10.3389\/fmolb.2024.1330144","volume":"11","author":"R Gulati","year":"2024","unstructured":"Gulati R, Mitra T, Rajiv R, Rajan EJE, Pierret C, Enninga EAL, et al. Exosomal microRNAs in breast cancer: towards theranostic applications. Front Mol Biosci. 2024;11:1330144.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"1634_CR349","doi-asserted-by":"publisher","first-page":"8902","DOI":"10.1038\/s41598-024-58536-3","volume":"14","author":"T Bakhsh","year":"2024","unstructured":"Bakhsh T, Alhazmi S, Farsi A, Yusuf AS, Alharthi A, Qahl SH, et al. Molecular detection of exosomal miRNAs of blood serum for prognosis of colorectal cancer. Sci Rep. 2024;14(1):8902.","journal-title":"Sci Rep"},{"issue":"11","key":"1634_CR350","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.ymthe.2019.07.011","volume":"27","author":"X Yue","year":"2019","unstructured":"Yue X, Lan F, Xia T. Hypoxic glioma cell-secreted exosomal miR-301a activates Wnt\/beta-catenin signaling and promotes radiation resistance by targeting TCEAL7. Mol Ther. 2019;27(11):1939\u201349.","journal-title":"Mol Ther"},{"issue":"10","key":"1634_CR351","doi-asserted-by":"publisher","first-page":"6843","DOI":"10.1002\/jcp.29578","volume":"235","author":"Y Xia","year":"2020","unstructured":"Xia Y, Wei K, Hu LQ, Zhou CR, Lu ZB, Zhan GS, et al. Exosome-mediated transfer of miR-1260b promotes cell invasion through Wnt\/\u03b2-catenin signaling pathway in lung adenocarcinoma. J Cell Physiol. 2020;235(10):6843\u201353.","journal-title":"J Cell Physiol"},{"issue":"10","key":"1634_CR352","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41419-018-0978-y","volume":"9","author":"Y Hu","year":"2018","unstructured":"Hu Y, Yang C, Yang S, Cheng F, Rao J, Wang X. miR-665 promotes hepatocellular carcinoma cell migration, invasion, and proliferation by decreasing Hippo signaling through targeting PTPRB. Cell Death Dis. 2018;9(10):954.","journal-title":"Cell Death Dis"},{"issue":"12","key":"1634_CR353","doi-asserted-by":"publisher","first-page":"19592","DOI":"10.18632\/oncotarget.14752","volume":"8","author":"E Donnarumma","year":"2017","unstructured":"Donnarumma E, Fiore D, Nappa M, Roscigno G, Adamo A, Iaboni M, et al. Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer. Oncotarget. 2017;8(12):19592.","journal-title":"Oncotarget"},{"issue":"1","key":"1634_CR354","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12943-019-1019-x","volume":"18","author":"J Hu","year":"2019","unstructured":"Hu J, Wang W, Lan X, Zeng Z, Liang Y, Yan Y, et al. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Mol Cancer. 2019;18(1):91.","journal-title":"Mol Cancer"},{"issue":"9","key":"1634_CR355","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41419-020-02827-w","volume":"11","author":"W Dai","year":"2020","unstructured":"Dai W, Jin X, Han L, Huang H, Ji Z, Xu X, et al. Exosomal lncRNA DOCK9-AS2 derived from cancer stem cell-like cells activated Wnt\/\u03b2-catenin pathway to aggravate stemness, proliferation, migration, and invasion in papillary thyroid carcinoma. Cell Death Dis. 2020;11(9):743.","journal-title":"Cell Death Dis"},{"issue":"4","key":"1634_CR356","doi-asserted-by":"publisher","first-page":"109350","DOI":"10.1016\/j.isci.2024.109350","volume":"27","author":"E Yimin","year":"2024","unstructured":"Yimin E, Lu C, Zhu K, Li W, Sun J, Ji P, et al. Function and mechanism of exosomes derived from different cells as communication mediators in colorectal cancer metastasis. iScience. 2024;27(4):109350.","journal-title":"iScience."},{"issue":"1","key":"1634_CR357","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12967-020-02648-7","volume":"19","author":"L Zhou","year":"2021","unstructured":"Zhou L, Li J, Tang Y, Yang M. Exosomal LncRNA LINC00659 transferred from cancer-associated fibroblasts promotes colorectal cancer cell progression via miR-342-3p\/ANXA2 axis. J Transl Med. 2021;19(1):8.","journal-title":"J Transl Med"},{"issue":"2","key":"1634_CR358","doi-asserted-by":"publisher","first-page":"10136","DOI":"10.1080\/21655979.2021.2000745","volume":"12","author":"Q Lin","year":"2021","unstructured":"Lin Q, Qi Q, Hou S, Chen Z, Jiang N, Zhang L, et al. Exosomal circular RNA hsa_circ_007293 promotes proliferation, migration, invasion, and epithelial-mesenchymal transition of papillary thyroid carcinoma cells through regulation of the microRNA-653-5p\/paired box 6 axis. Bioengineered. 2021;12(2):10136\u201349.","journal-title":"Bioengineered"},{"key":"1634_CR359","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.omtn.2021.01.028","volume":"23","author":"J Zhou","year":"2021","unstructured":"Zhou J, Wang H, Sun Q, Liu X, Wu Z, Wang X, et al. miR-224-5p-enriched exosomes promote tumorigenesis by directly targeting androgen receptor in non-small cell lung cancer. Mol Therapy Nucleic Acids. 2021;23:1217\u201328.","journal-title":"Mol Therapy Nucleic Acids"},{"key":"1634_CR360","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.omtn.2019.11.024","volume":"19","author":"H Wang","year":"2020","unstructured":"Wang H, Wei H, Wang J, Li L, Chen A, Li Z. MicroRNA-181d-5p-containing exosomes derived from CAFs promote EMT by regulating CDX2\/HOXA5 in breast cancer. Mol Therapy Nucleic Acids. 2020;19:654\u201367.","journal-title":"Mol Therapy Nucleic Acids"},{"issue":"1","key":"1634_CR361","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41419-021-04461-6","volume":"13","author":"B Zhong","year":"2021","unstructured":"Zhong B, Cheng B, Huang X, Xiao Q, Niu Z, Chen YF, et al. Colorectal cancer-associated fibroblasts promote metastasis by up-regulating LRG1 through stromal IL-6\/STAT3 signaling. Cell Death Dis. 2021;13(1):16.","journal-title":"Cell Death Dis"},{"issue":"10","key":"1634_CR362","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/s41419-021-04150-4","volume":"12","author":"Y Ren","year":"2021","unstructured":"Ren Y, Cao L, Wang L, Zheng S, Zhang Q, Guo X, et al. Autophagic secretion of HMGB1 from cancer-associated fibroblasts promotes metastatic potential of non-small cell lung cancer cells via NF\u03baB signaling. Cell Death Dis. 2021;12(10):858.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1634_CR363","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1038\/s41598-019-39553-z","volume":"9","author":"B Gok Yavuz","year":"2019","unstructured":"Gok Yavuz B, Gunaydin G, Gedik ME, Kosemehmetoglu K, Karakoc D, Ozgur F, et al. Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1(+) TAMs. Sci Rep. 2019;9(1):3172.","journal-title":"Sci Rep"},{"issue":"8","key":"1634_CR364","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.3390\/ijms25084485","volume":"25","author":"J Tian","year":"2024","unstructured":"Tian J, Bai X, Quek C. Single-cell informatics for tumor microenvironment and immunotherapy. Int J Mol Sci. 2024;25(8):4485.","journal-title":"Int J Mol Sci"},{"key":"1634_CR365","doi-asserted-by":"publisher","first-page":"1285540","DOI":"10.3389\/fimmu.2023.1285540","volume":"14","author":"S Chen","year":"2023","unstructured":"Chen S, Zhou Z, Li Y, Du Y, Chen G. Application of single-cell sequencing to the research of tumor microenvironment. Front Immunol. 2023;14:1285540.","journal-title":"Front Immunol"},{"issue":"1","key":"1634_CR366","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.tranon.2019.10.001","volume":"13","author":"S Zhong","year":"2020","unstructured":"Zhong S, Jeong JH, Chen Z, Luo JL. Targeting tumor microenvironment by small-molecule inhibitors. Transl Oncol. 2020;13(1):57\u201369.","journal-title":"Transl Oncol"},{"key":"1634_CR367","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221: 107753.","journal-title":"Pharmacol Ther"},{"issue":"9","key":"1634_CR368","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.3390\/cancers13092053","volume":"13","author":"CM Neophytou","year":"2021","unstructured":"Neophytou CM, Panagi M, Stylianopoulos T, Papageorgis P. The role of tumor microenvironment in cancer metastasis: molecular mechanisms and therapeutic opportunities. Cancers (Basel). 2021;13(9):2053.","journal-title":"Cancers (Basel)."},{"key":"1634_CR369","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104216","volume":"83","author":"NK Verma","year":"2022","unstructured":"Verma NK, Wong BHS, Poh ZS, Udayakumar A, Verma R, Goh RKJ, et al. Obstacles for T-lymphocytes in the tumour microenvironment: Therapeutic challenges, advances and opportunities beyond immune checkpoint. EBioMedicine. 2022;83: 104216.","journal-title":"EBioMedicine"},{"issue":"6","key":"1634_CR370","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2023.166746","volume":"1869","author":"Q Babar","year":"2023","unstructured":"Babar Q, Saeed A, Tabish TA, Sarwar M, Thorat ND. Targeting the tumor microenvironment: potential strategy for cancer therapeutics. Biochim Biophys Acta Mol Basis Dis. 2023;1869(6): 166746.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"23","key":"1634_CR371","doi-asserted-by":"publisher","first-page":"16771","DOI":"10.3390\/ijms242316771","volume":"24","author":"MA Dom\u00ednguez-Cejudo","year":"2023","unstructured":"Dom\u00ednguez-Cejudo MA, Gil-Torralvo A, Cejuela M, Molina-Pinelo S, Salvador BJ. Targeting the tumor microenvironment in breast cancer: prognostic and predictive significance and therapeutic opportunities. Int J Mol Sci. 2023;24(23):16771.","journal-title":"Int J Mol Sci"},{"key":"1634_CR372","doi-asserted-by":"publisher","first-page":"1131874","DOI":"10.3389\/fimmu.2023.1131874","volume":"14","author":"IM Khan","year":"2023","unstructured":"Khan IM, Khan SU, Sala HSS, Khan MU, Ud Din MA, Khan S, et al. TME-targeted approaches of brain metastases and its clinical therapeutic evidence. Front Immunol. 2023;14:1131874.","journal-title":"Front Immunol"},{"issue":"7","key":"1634_CR373","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.3390\/pharmaceutics15071788","volume":"15","author":"W Ye","year":"2023","unstructured":"Ye W, Li M, Luo K. Therapies targeting immune cells in tumor microenvironment for non-small cell lung cancer. Pharmaceutics. 2023;15(7):1788.","journal-title":"Pharmaceutics"},{"key":"1634_CR374","doi-asserted-by":"publisher","first-page":"1384150","DOI":"10.3389\/fcell.2024.1384150","volume":"12","author":"B Giri","year":"2024","unstructured":"Giri B, Roy ST. Editorial: the role of cancer associated fibroblast (CAF) in EMT\/metastasis in malignancies of epithelial tissues. Front Cell Dev Biol. 2024;12:1384150.","journal-title":"Front Cell Dev Biol"},{"issue":"23","key":"1634_CR375","doi-asserted-by":"publisher","first-page":"6168","DOI":"10.1039\/c0dt01595d","volume":"40","author":"BM Zeglis","year":"2011","unstructured":"Zeglis BM, Lewis JS. A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. Dalton Trans. 2011;40(23):6168\u201395.","journal-title":"Dalton Trans"},{"issue":"11","key":"1634_CR376","doi-asserted-by":"publisher","first-page":"4819","DOI":"10.1039\/C4DT02846E","volume":"44","author":"PJ Blower","year":"2015","unstructured":"Blower PJ. A nuclear chocolate box: the periodic table of nuclear medicine. Dalton Trans. 2015;44(11):4819\u201344.","journal-title":"Dalton Trans"},{"issue":"9","key":"1634_CR377","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41551-017-0131-8","volume":"1","author":"K Heinzmann","year":"2017","unstructured":"Heinzmann K, Carter LM, Lewis JS, Aboagye EO. Multiplexed imaging for diagnosis and therapy. Nat Biomed Eng. 2017;1(9):697\u2013713.","journal-title":"Nat Biomed Eng"},{"issue":"2","key":"1634_CR378","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.drudis.2021.09.017","volume":"27","author":"TS Maurer","year":"2022","unstructured":"Maurer TS, Edwards M, Hepworth D, Verhoest P, Allerton CMN. Designing small molecules for therapeutic success: a contemporary perspective. Drug Discov Today. 2022;27(2):538\u201346.","journal-title":"Drug Discov Today"},{"issue":"1","key":"1634_CR379","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41392-023-01589-z","volume":"8","author":"X Xie","year":"2023","unstructured":"Xie X, Yu T, Li X, Zhang N, Foster LJ, Peng C, et al. Recent advances in targeting the \u201cundruggable\u201d proteins: from drug discovery to clinical trials. Signal Transduct Target Ther. 2023;8(1):335.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"1634_CR380","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41568-024-00692-9","volume":"24","author":"D Kirschenbaum","year":"2024","unstructured":"Kirschenbaum D. Investigating immune cells across time in vivo. Nat Rev Cancer. 2024;24(6):359.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1634_CR381","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24861","volume":"10","author":"H Cao","year":"2024","unstructured":"Cao H, Huang P, Qiu J, Gong X. Immune landscape of hepatocellular carcinoma tumor microenvironment identifies a prognostic relevant model. Heliyon. 2024;10(3): e24861.","journal-title":"Heliyon"},{"issue":"1","key":"1634_CR382","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41420-024-01865-z","volume":"10","author":"X Chen","year":"2024","unstructured":"Chen X, Ma Z, Yi Z, Wu E, Shang Z, Tuo B, et al. The effects of metabolism on the immune microenvironment in colorectal cancer. Cell Death Discov. 2024;10(1):118.","journal-title":"Cell Death Discov"},{"key":"1634_CR383","doi-asserted-by":"publisher","first-page":"1302587","DOI":"10.3389\/fimmu.2024.1302587","volume":"15","author":"T Akinsipe","year":"2024","unstructured":"Akinsipe T, Mohamedelhassan R, Akinpelu A, Pondugula SR, Mistriotis P, Avila LA, et al. Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics. Front Immunol. 2024;15:1302587.","journal-title":"Front Immunol"},{"issue":"8","key":"1634_CR384","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.cell.2023.02.039","volume":"186","author":"OK Dagher","year":"2023","unstructured":"Dagher OK, Schwab RD, Brookens SK, Posey AD. Advances in cancer immunotherapies. Cell. 2023;186(8):1814.","journal-title":"Cell"},{"issue":"8","key":"1634_CR385","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41416-023-02361-4","volume":"129","author":"MM Wang","year":"2023","unstructured":"Wang MM, Coupland SE, Aittokallio T, Figueiredo CR. Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities. Br J Cancer. 2023;129(8):1212\u201324.","journal-title":"Br J Cancer"},{"issue":"4","key":"1634_CR386","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254\u201367.","journal-title":"Nat Rev Clin Oncol"},{"key":"1634_CR387","doi-asserted-by":"publisher","first-page":"1113882","DOI":"10.3389\/fimmu.2023.1113882","volume":"14","author":"A Daei Sorkhabi","year":"2023","unstructured":"Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, Mardi A, Aghebati-Maleki A, Aghebati-Maleki L, et al. The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies. Front Immunol. 2023;14:1113882.","journal-title":"Front Immunol"},{"issue":"4","key":"1634_CR388","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41591-022-01765-8","volume":"28","author":"AV Finck","year":"2022","unstructured":"Finck AV, Blanchard T, Roselle CP, Golinelli G, June CH. Engineered cellular immunotherapies in cancer and beyond. Nat Med. 2022;28(4):678\u201389.","journal-title":"Nat Med"},{"issue":"1","key":"1634_CR389","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40164-024-00506-6","volume":"13","author":"MY Xu","year":"2024","unstructured":"Xu MY, Zeng N, Liu CQ, Sun JX, An Y, Zhang SH, et al. Enhanced cellular therapy: revolutionizing adoptive cellular therapy. Exp Hematol Oncol. 2024;13(1):47.","journal-title":"Exp Hematol Oncol"},{"key":"1634_CR390","doi-asserted-by":"publisher","first-page":"1368732","DOI":"10.3389\/fonc.2024.1368732","volume":"14","author":"Y Lv","year":"2024","unstructured":"Lv Y, Luo X, Xie Z, Qiu J, Yang J, Deng Y, et al. Prospects and challenges of CAR-T cell therapy combined with ICIs. Front Oncol. 2024;14:1368732.","journal-title":"Front Oncol"},{"issue":"7","key":"1634_CR391","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","volume":"21","author":"AJ Korman","year":"2022","unstructured":"Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov. 2022;21(7):509\u201328.","journal-title":"Nat Rev Drug Discov"},{"key":"1634_CR392","doi-asserted-by":"publisher","first-page":"1298571","DOI":"10.3389\/fimmu.2023.1298571","volume":"14","author":"LV Mej\u00eda-Guarnizo","year":"2023","unstructured":"Mej\u00eda-Guarnizo LV, Monroy-Camacho PS, Turizo-Smith AD, Rodr\u00edguez-Garc\u00eda JA. The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy. Front Immunol. 2023;14:1298571.","journal-title":"Front Immunol"},{"issue":"2","key":"1634_CR393","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellin.2024.100146","volume":"3","author":"R Liu","year":"2024","unstructured":"Liu R, Li HF, Li S. PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapy. Cell Insight. 2024;3(2): 100146.","journal-title":"Cell Insight"},{"issue":"1","key":"1634_CR394","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-022-01325-0","volume":"15","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhang H, Liu C, Wang Z, Wu W, Zhang N, et al. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. J Hematol Oncol. 2022;15(1):111.","journal-title":"J Hematol Oncol"},{"key":"1634_CR395","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114824","volume":"163","author":"K Mortezaee","year":"2023","unstructured":"Mortezaee K, Majidpoor J. Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1. Biomed Pharmacother. 2023;163: 114824.","journal-title":"Biomed Pharmacother"},{"issue":"710","key":"1634_CR396","doi-asserted-by":"publisher","first-page":"eaad868","DOI":"10.1126\/scitranslmed.add1868","volume":"15","author":"KB Bennion","year":"2023","unstructured":"Bennion KB, Tariq M, Wyatt MM, Duneton C, Baecher KM, Paulos CM, et al. Fc\u03b3RIIB expressed on CD8+ T cells limits responsiveness to PD-1 checkpoint inhibition in cancer. Sci Transl Med. 2023;15(710):eaad868.","journal-title":"Sci Transl Med."},{"issue":"11","key":"1634_CR397","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.cell.2024.04.015","volume":"187","author":"C Wang","year":"2024","unstructured":"Wang C, Zeng Q, G\u00fcl ZM, Wang S, Pick R, Cheng P, et al. Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy. Cell. 2024;187(11):2690-702.e17.","journal-title":"Cell"},{"issue":"1","key":"1634_CR398","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13046-022-02264-x","volume":"41","author":"A Archilla-Ortega","year":"2022","unstructured":"Archilla-Ortega A, Domuro C, Martin-Liberal J, Mu\u00f1oz P. Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity. J Exp Clin Cancer Res. 2022;41(1):62.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"1634_CR399","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/1078-0432.CCR-23-2566","volume":"30","author":"A Bessede","year":"2024","unstructured":"Bessede A, Peyraud F, Besse B, Cousin S, Cabart M, Chomy F, et al. TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2024;30(4):779\u201385.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1634_CR400","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ccell.2023.12.003","volume":"42","author":"B Routy","year":"2024","unstructured":"Routy B, Jackson T, M\u00e4hlmann L, Baumgartner CK, Blaser M, Byrd A, et al. Melanoma and microbiota: current understanding and future directions. Cancer Cell. 2024;42(1):16\u201334.","journal-title":"Cancer Cell"},{"issue":"1","key":"1634_CR401","doi-asserted-by":"publisher","first-page":"2308097","DOI":"10.1080\/15384047.2024.2308097","volume":"25","author":"GS Santiago-S\u00e1nchez","year":"2024","unstructured":"Santiago-S\u00e1nchez GS, Fabian KP, Hodge JW. A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance. Cancer Biol Ther. 2024;25(1):2308097.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"1634_CR402","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1038\/s41467-024-47425-y","volume":"15","author":"M Lauss","year":"2024","unstructured":"Lauss M, Phung B, Borch TH, Harbst K, Kaminska K, Ebbesson A, et al. Molecular patterns of resistance to immune checkpoint blockade in melanoma. Nat Commun. 2024;15(1):3075.","journal-title":"Nat Commun"},{"key":"1634_CR403","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","volume":"224","author":"BT Fife","year":"2008","unstructured":"Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008;224:166\u201382.","journal-title":"Immunol Rev"},{"issue":"3","key":"1634_CR404","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727\u201342.","journal-title":"Am J Cancer Res"},{"issue":"2","key":"1634_CR405","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1159\/000490025","volume":"47","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Yang W, Huang Y, Cui R, Li X, Li B. Evolving roles for targeting CTLA-4 in cancer immunotherapy. Cell Physiol Biochem. 2018;47(2):721\u201334.","journal-title":"Cell Physiol Biochem"},{"issue":"4","key":"1634_CR406","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s13577-023-00893-8","volume":"36","author":"P Azimnasab-Sorkhabi","year":"2023","unstructured":"Azimnasab-Sorkhabi P, Soltani-Asl M, Kfoury Junior JR. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) as an undetermined tool in tumor cells. Hum Cell. 2023;36(4):1225\u201332.","journal-title":"Hum Cell"},{"issue":"2","key":"1634_CR407","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/cei.13407","volume":"200","author":"H Harjunp\u00e4\u00e4","year":"2020","unstructured":"Harjunp\u00e4\u00e4 H, Guillerey C. TIGIT as an emerging immune checkpoint. Clin Exp Immunol. 2020;200(2):108\u201319.","journal-title":"Clin Exp Immunol"},{"key":"1634_CR408","doi-asserted-by":"publisher","first-page":"1060112","DOI":"10.3389\/fonc.2023.1060112","volume":"13","author":"N Jantz-Naeem","year":"2023","unstructured":"Jantz-Naeem N, B\u00f6ttcher-Loschinski R, Borucki K, Mitchell-Flack M, B\u00f6ttcher M, Schraven B, et al. TIGIT signaling and its influence on T cell metabolism and immune cell function in the tumor microenvironment. Front Oncol. 2023;13:1060112.","journal-title":"Front Oncol"},{"issue":"1","key":"1634_CR409","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ccell.2017.11.019","volume":"33","author":"P\u00c1 de Mingo","year":"2018","unstructured":"de Mingo P\u00c1, Gardner A, Hiebler S, Soliman H, Rugo HS, Krummel MF, et al. TIM-3 Regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer. Cancer Cell. 2018;33(1):60-74.e6.","journal-title":"Cancer Cell"},{"issue":"6","key":"1634_CR410","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.3390\/cancers15061697","volume":"15","author":"G Cazzato","year":"2023","unstructured":"Cazzato G, Cascardi E, Colagrande A, Lettini T, Filosa A, Arezzo F, et al. T cell immunoglobulin and mucin domain 3 (TIM-3) in cutaneous melanoma: a narrative review. Cancers (Basel). 2023;15(6):1697.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1634_CR411","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/imr.12519","volume":"276","author":"LP Andrews","year":"2017","unstructured":"Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276(1):80\u201396.","journal-title":"Immunol Rev"},{"key":"1634_CR412","doi-asserted-by":"crossref","unstructured":"Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint inhibitor. Nat Immunol. 2023.","DOI":"10.1038\/s41590-023-01569-z"},{"issue":"11","key":"1634_CR413","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","volume":"21","author":"S Kumagai","year":"2020","unstructured":"Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 2020;21(11):1346\u201358.","journal-title":"Nat Immunol"},{"issue":"1","key":"1634_CR414","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12974-018-1330-2","volume":"15","author":"J Qian","year":"2018","unstructured":"Qian J, Wang C, Wang B, Yang J, Wang Y, Luo F, et al. The IFN-\u03b3\/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1\/PD-L1 therapy. J Neuroinflammation. 2018;15(1):290.","journal-title":"J Neuroinflammation"},{"issue":"5","key":"1634_CR415","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","volume":"22","author":"YL Kasamon","year":"2017","unstructured":"Kasamon YL, de Claro RA, Wang Y, Shen YL, Farrell AT, Pazdur R. FDA approval summary: nivolumab for the treatment of relapsed or progressive classical hodgkin lymphoma. Oncologist. 2017;22(5):585\u201391.","journal-title":"Oncologist"},{"issue":"4","key":"1634_CR416","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","volume":"22","author":"J Kuruvilla","year":"2021","unstructured":"Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021;22(4):512\u201324.","journal-title":"Lancet Oncol"},{"issue":"21","key":"1634_CR417","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018\u201328.","journal-title":"N Engl J Med"},{"issue":"26","key":"1634_CR418","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med"},{"issue":"4","key":"1634_CR419","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330.","journal-title":"N Engl J Med"},{"issue":"4","key":"1634_CR420","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341\u201351.","journal-title":"N Engl J Med"},{"key":"1634_CR421","doi-asserted-by":"publisher","first-page":"175883592110661","DOI":"10.1177\/17588359211066147","volume":"14","author":"CM Davis","year":"2022","unstructured":"Davis CM, Lewis KD. Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again. Ther Adv Med Oncol. 2022;14:17588359211066148.","journal-title":"Ther Adv Med Oncol"},{"key":"1634_CR422","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2147\/CMAR.S325856","volume":"15","author":"J Ahn","year":"2023","unstructured":"Ahn J, Nagasaka M. Spotlight on cemiplimab-rwlc in the treatment of non-small cell lung cancer (NSCLC): focus on patient selection and considerations. Cancer Manag Res. 2023;15:627\u201334.","journal-title":"Cancer Manag Res"},{"issue":"23","key":"1634_CR423","doi-asserted-by":"publisher","first-page":"6413","DOI":"10.1158\/1078-0432.CCR-21-0822","volume":"27","author":"C Even","year":"2021","unstructured":"Even C, Wang HM, Li SH, Ngan RK, Dechaphunkul A, Zhang L, et al. Phase II, randomized study of spartalizumab (PDR001), an anti-PD-1 antibody, versus chemotherapy in patients with recurrent\/metastatic nasopharyngeal cancer. Clin Cancer Res. 2021;27(23):6413\u201323.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1634_CR424","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6(1):8.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"1634_CR425","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s43018-020-0075-x","volume":"1","author":"SA Oh","year":"2020","unstructured":"Oh SA, Wu DC, Cheung J, Navarro A, Xiong H, Cubas R, et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat Cancer. 2020;1(7):681\u201391.","journal-title":"Nat Cancer"},{"issue":"7","key":"1634_CR426","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41423-023-01027-8","volume":"20","author":"Y Hao","year":"2023","unstructured":"Hao Y, Miraghazadeh B, Chand R, Davies AR, Cardinez C, Kwong K, et al. CTLA4 protects against maladaptive cytotoxicity during the differentiation of effector and follicular CD4. Cell Mol Immunol. 2023;20(7):777\u201393.","journal-title":"Cell Mol Immunol"},{"key":"1634_CR427","first-page":"5","volume":"13","author":"JF Grosso","year":"2013","unstructured":"Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 2013;13:5.","journal-title":"Cancer Immun"},{"issue":"8","key":"1634_CR428","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"2","key":"1634_CR429","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1158\/1078-0432.CCR-21-2182","volume":"28","author":"S Adams","year":"2022","unstructured":"Adams S, Othus M, Patel SP, Miller KD, Chugh R, Schuetze SM, et al. A multicenter phase II trial of ipilimumab and nivolumab in unresectable or metastatic metaplastic breast cancer: cohort 36 of dual anti-CTLA-4 and ANTI-PD-1 blockade in rare tumors (DART, SWOG S1609). Clin Cancer Res. 2022;28(2):271\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1634_CR430","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40364-023-00543-z","volume":"12","author":"P Zhang","year":"2024","unstructured":"Zhang P, Liu X, Gu Z, Jiang Z, Zhao S, Song Y, et al. Targeting TIGIT for cancer immunotherapy: recent advances and future directions. Biomark Res. 2024;12(1):7.","journal-title":"Biomark Res"},{"issue":"5","key":"1634_CR431","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/CJI.0000000000000511","volume":"47","author":"Y Lang","year":"2024","unstructured":"Lang Y, Huang H, Jiang H, Wu S, Chen Y, Xu B, et al. TIGIT blockade reshapes the tumor microenvironment based on the single-cell RNA-sequencing analysis. J Immunother. 2024;47(5):172\u201381.","journal-title":"J Immunother"},{"issue":"2","key":"1634_CR432","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation. Immunity. 2024;57(2):206\u201322.","journal-title":"Immunity"},{"issue":"1","key":"1634_CR433","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12943-023-01800-3","volume":"22","author":"X Chu","year":"2023","unstructured":"Chu X, Tian W, Wang Z, Zhang J, Zhou R. Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: mechanisms and clinical trials. Mol Cancer. 2023;22(1):93.","journal-title":"Mol Cancer"},{"issue":"12","key":"1634_CR434","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-15-2626","volume":"22","author":"Y Kong","year":"2016","unstructured":"Kong Y, Zhu L, Schell TD, Zhang J, Claxton DF, Ehmann WC, et al. T-Cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients. Clin Cancer Res. 2016;22(12):3057\u201366.","journal-title":"Clin Cancer Res"},{"key":"1634_CR435","doi-asserted-by":"crossref","unstructured":"Fourcade J, Sun Z, Chauvin JM, Ka M, Davar D, Pagliano O, et al. CD226 opposes TIGIT to disrupt Tregs in melanoma. JCI Insight. 2018;3(14).","DOI":"10.1172\/jci.insight.121157"},{"issue":"6","key":"1634_CR436","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23(6):781\u201392.","journal-title":"Lancet Oncol"},{"key":"1634_CR437","first-page":"1","volume":"14","author":"D Brazel","year":"2023","unstructured":"Brazel D, Ou SI, Nagasaka M. Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno. Lung Cancer (Auckl). 2023;14:1\u20139.","journal-title":"Lung Cancer (Auckl)"},{"issue":"4","key":"1634_CR438","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS374","volume":"40","author":"KA Goodman","year":"2022","unstructured":"Goodman KA, Xu R-H, Chau I, Chen MH, Cho BC, Shah MA, et al. SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy. J Clin Oncology. 2022;40(4):374.","journal-title":"J Clin Oncology."},{"issue":"17","key":"1634_CR439","first-page":"2","volume":"40","author":"CM Rudin","year":"2022","unstructured":"Rudin CM, Liu SV, Lu S, Soo RA, Hong MH, Lee J-S, et al. Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC). J Clin Oncology. 2022;40(17):2.","journal-title":"J Clin Oncology."},{"issue":"5","key":"1634_CR440","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989\u20131004.","journal-title":"Immunity"},{"issue":"1","key":"1634_CR441","doi-asserted-by":"publisher","first-page":"e6844","DOI":"10.1002\/cam4.6844","volume":"13","author":"J Lim","year":"2023","unstructured":"Lim J, Kurzrock R, Nishizaki D, Miyashita H, Adashek JJ, Lee S, et al. Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity. Cancer Med. 2023;13(1):e6844.","journal-title":"Cancer Med"},{"issue":"10","key":"1634_CR442","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.3390\/cancers16101888","volume":"16","author":"M Sakuma","year":"2024","unstructured":"Sakuma M, Katagata M, Okayama H, Nakajima S, Saito K, Sato T, et al. TIM-3 expression on dendritic cells in colorectal cancer. Cancers (Basel). 2024;16(10):1888.","journal-title":"Cancers (Basel)."},{"issue":"12","key":"1634_CR443","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245\u201352.","journal-title":"Nat Immunol"},{"key":"1634_CR444","doi-asserted-by":"publisher","first-page":"15659","DOI":"10.1038\/srep15659","volume":"5","author":"CW Kang","year":"2015","unstructured":"Kang CW, Dutta A, Chang LY, Mahalingam J, Lin YC, Chiang JM, et al. Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer. Sci Rep. 2015;5:15659.","journal-title":"Sci Rep"},{"issue":"10","key":"1634_CR445","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.3390\/cancers15102735","volume":"15","author":"LM Berclaz","year":"2023","unstructured":"Berclaz LM, Altendorf-Hofmann A, Lindner LH, Burkhard-Meier A, Di Gioia D, D\u00fcrr HR, et al. TIM-3 qualifies as a potential immunotherapeutic target in specific subsets of patients with high-risk soft tissue sarcomas (HR-STS). Cancers (Basel). 2023;15(10):2735.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1634_CR446","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40164-023-00421-2","volume":"12","author":"J Tan","year":"2023","unstructured":"Tan J, Tan H, Li Y. Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting. Exp Hematol Oncol. 2023;12(1):62.","journal-title":"Exp Hematol Oncol"},{"issue":"19","key":"1634_CR447","doi-asserted-by":"publisher","first-page":"31705","DOI":"10.18632\/oncotarget.15954","volume":"8","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Cai P, Liang T, Wang L, Hu L. TIM-3 is a potential prognostic marker for patients with solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8(19):31705\u201313.","journal-title":"Oncotarget"},{"issue":"8","key":"1634_CR448","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2217\/imt-2017-0024","volume":"9","author":"AW Hahn","year":"2017","unstructured":"Hahn AW, Gill DM, Pal SK, Agarwal N. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy. 2017;9(8):681\u201392.","journal-title":"Immunotherapy"},{"issue":"9","key":"1634_CR449","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2217\/fon-2022-1237","volume":"19","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Giagounidis A, Sekeres MA, Xiao Z, Sanz GF, Hoef MV, et al. STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Future Oncol. 2023;19(9):631\u201342.","journal-title":"Future Oncol"},{"issue":"8","key":"1634_CR450","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1158\/1078-0432.CCR-20-4405","volume":"27","author":"JJ Harding","year":"2021","unstructured":"Harding JJ, Moreno V, Bang YJ, Hong MH, Patnaik A, Trigo J, et al. Blocking TIM-3 in treatment-refractory advanced solid tumors: a phase Ia\/b study of LY3321367 with or without an Anti-PD-L1 antibody. Clin Cancer Res. 2021;27(8):2168\u201378.","journal-title":"Clin Cancer Res"},{"issue":"637","key":"1634_CR451","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1182\/blood-2022-160282","volume":"140","author":"V Santini","year":"2022","unstructured":"Santini V, Platzbecker U, Fenaux P, Giagounidis A, Miyazaki Y, Sekeres MA, et al. Disease characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in adult patients with higher-risk myelodysplastic syndromes (MDS) participating in two Randomized, Double-Blind, placebo-controlled studies with intravenous Sabatolimab added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2). Blood. 2022;140(637):1340\u20132.","journal-title":"Blood"},{"issue":"637","key":"1634_CR452","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1182\/blood-2022-158612","volume":"140","author":"AM Zeidan","year":"2022","unstructured":"Zeidan AM, Ando K, Rauzy O, Turgut M, Wang M-C, Cairoli R, et al. Primary results of Stimulus-MDS1: a Randomized, Double-Blind, placebo-controlled phase II study of TIM-3 inhibition with Sabatolimab added to \nHypomethylating Agents (HMAs) in adult patients with higher-risk myelodysplastic syndromes (MDS). Blood. 2022;140(637):2063\u20135.","journal-title":"Blood"},{"issue":"3","key":"1634_CR453","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.apsb.2023.12.011","volume":"14","author":"Y Qian","year":"2024","unstructured":"Qian Y, Sun Y, Shi P, Zhou X, Zhang Q, Dong Q, et al. Development of LAG-3\/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy. Acta Pharm Sin B. 2024;14(3):1150\u201365.","journal-title":"Acta Pharm Sin B"},{"issue":"4","key":"1634_CR454","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","volume":"30","author":"RJ Kelly","year":"2024","unstructured":"Kelly RJ, Landon BV, Zaidi AH, Singh D, Canzoniero JV, Balan A, et al. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses. Nat Med. 2024;30(4):1023\u201334.","journal-title":"Nat Med"},{"issue":"1","key":"1634_CR455","doi-asserted-by":"publisher","first-page":"368","DOI":"10.62347\/MVDH5025","volume":"14","author":"JJ Adashek","year":"2024","unstructured":"Adashek JJ, Kato S, Nishizaki D, Pabla S, Nesline MK, Previs RA, et al. LAG-3 transcriptomic expression correlates linearly with other checkpoints, but not with clinical outcomes. Am J Cancer Res. 2024;14(1):368\u201377.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"1634_CR456","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.","journal-title":"Mol Cancer"},{"issue":"1","key":"1634_CR457","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1249561","volume":"6","author":"RY Huang","year":"2017","unstructured":"Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6(1): e1249561.","journal-title":"Oncoimmunology"},{"issue":"29","key":"1634_CR458","doi-asserted-by":"publisher","first-page":"27359","DOI":"10.18632\/oncotarget.4751","volume":"6","author":"RY Huang","year":"2015","unstructured":"Huang RY, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget. 2015;6(29):27359\u201377.","journal-title":"Oncotarget"},{"issue":"1","key":"1634_CR459","doi-asserted-by":"publisher","first-page":"1736792","DOI":"10.1080\/2162402X.2020.1736792","volume":"9","author":"N Gestermann","year":"2020","unstructured":"Gestermann N, Saugy D, Martignier C, Till\u00e9 L, Fuertes Marraco SA, Zettl M, et al. LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma\/T cell co-cultures. Oncoimmunology. 2020;9(1):1736792.","journal-title":"Oncoimmunology"},{"key":"1634_CR460","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.831407","volume":"12","author":"Y Wei","year":"2022","unstructured":"Wei Y, Li Z. LAG3-PD-1 combo overcome the disadvantage of drug resistance. Front Oncol. 2022;12: 831407.","journal-title":"Front Oncol"},{"issue":"2","key":"1634_CR461","doi-asserted-by":"publisher","first-page":"e003776","DOI":"10.1136\/jitc-2021-003776","volume":"10","author":"P Sch\u00f6ffski","year":"2022","unstructured":"Sch\u00f6ffski P, Tan DSW, Mart\u00edn M, Ochoa-de-Olza M, Sarantopoulos J, Carvajal RD, et al. Phase I\/II study of the LAG-3 inhibitor ieramilimab (LAG525) \u00b1 anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J Immunother Cancer. 2022;10(2):e003776.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1634_CR462","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24\u201334.","journal-title":"N Engl J Med"},{"issue":"15","key":"1634_CR463","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1200\/JCO.22.02072","volume":"41","author":"PA Ascierto","year":"2023","unstructured":"Ascierto PA, Lipson EJ, Dummer R, Larkin J, Long GV, Sanborn RE, et al. Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti-programmed death-1\/programmed death ligand 1 therapy: results from the phase I\/IIa relativity-020 trial. J Clin Oncol. 2023;41(15):2724\u201335.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1634_CR464","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40265-022-01723-1","volume":"82","author":"J Paik","year":"2022","unstructured":"Paik J. Nivolumab plus relatlimab: first approval. Drugs. 2022;82(8):925\u201331.","journal-title":"Drugs"},{"issue":"1","key":"1634_CR465","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s42003-021-02191-1","volume":"4","author":"PG Sasikumar","year":"2021","unstructured":"Sasikumar PG, Sudarshan NS, Adurthi S, Ramachandra RK, Samiulla DS, Lakshminarasimhan A, et al. PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy. Commun Biol. 2021;4(1):699.","journal-title":"Commun Biol"},{"issue":"16","key":"1634_CR466","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1158\/1078-0432.CCR-21-4020","volume":"28","author":"TW Kim","year":"2022","unstructured":"Kim TW, Burris HA, de Miguel Luken MJ, Pishvaian MJ, Bang YJ, Gordon M, et al. First-In-human phase I study of the OX40 agonist MOXR0916 in patients with advanced solid tumors. Clin Cancer Res. 2022;28(16):3452\u201363.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1634_CR467","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1158\/1078-0432.CCR-21-4256","volume":"28","author":"TA Yap","year":"2022","unstructured":"Yap TA, Gainor JF, Callahan MK, Falchook GS, Pachynski RK, LoRusso P, et al. First-in-human phase I\/II ICONIC Trial of the ICOS agonist vopratelimab alone and with nivolumab: ICOS-High CD4 T-cell populations and predictors of response. Clin Cancer Res. 2022;28(17):3695\u2013708.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1634_CR468","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00428-018-2484-0","volume":"474","author":"MW Rohaan","year":"2019","unstructured":"Rohaan MW, Wilgenhof S, Haanen JBAG. Adoptive cellular therapies: the current landscape. Virchows Arch. 2019;474(4):449\u201361.","journal-title":"Virchows Arch"},{"issue":"4","key":"1634_CR469","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.ccell.2023.03.003","volume":"41","author":"SA Rosenberg","year":"2023","unstructured":"Rosenberg SA, Parkhurst MR, Robbins PF. Adoptive cell transfer immunotherapy for patients with solid epithelial cancers. Cancer Cell. 2023;41(4):646\u20138.","journal-title":"Cancer Cell"},{"key":"1634_CR470","doi-asserted-by":"publisher","first-page":"1352805","DOI":"10.3389\/fimmu.2024.1352805","volume":"15","author":"V Albarr\u00e1n","year":"2024","unstructured":"Albarr\u00e1n V, San Rom\u00e1n M, Pozas J, Chamorro J, Rosero DI, Guerrero P, et al. Adoptive T cell therapy for solid tumors: current landscape and future challenges. Front Immunol. 2024;15:1352805.","journal-title":"Front Immunol"},{"issue":"7999","key":"1634_CR471","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41586-024-07018-7","volume":"626","author":"J Garcia","year":"2024","unstructured":"Garcia J, Daniels J, Lee Y, Zhu I, Cheng K, Liu Q, et al. Naturally occurring T cell mutations enhance engineered T cell therapies. \nNature. 2024;626(7999):626\u201334.","journal-title":"Nature"},{"issue":"1","key":"1634_CR472","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/s12967-024-05206-7","volume":"22","author":"Y Li","year":"2024","unstructured":"Li Y, Zheng Y, Liu T, Liao C, Shen G, He Z. The potential and promise for clinical application of adoptive T cell therapy in cancer. J Transl Med. 2024;22(1):413.","journal-title":"J Transl Med"},{"issue":"12","key":"1634_CR473","doi-asserted-by":"publisher","first-page":"8571","DOI":"10.1021\/acsnano.3c10180","volume":"18","author":"F Hou","year":"2024","unstructured":"Hou F, Guo Z, Ho MT, Hui Y, Zhao CX. Particle-based artificial antigen-presenting cell systems for T cell activation in adoptive T cell therapy. ACS Nano. 2024;18(12):8571\u201399.","journal-title":"ACS Nano"},{"issue":"1","key":"1634_CR474","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-023-01735-9","volume":"22","author":"Q Liu","year":"2023","unstructured":"Liu Q, Li J, Zheng H, Yang S, Hua Y, Huang N, et al. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. Mol Cancer. 2023;22(1):28.","journal-title":"Mol Cancer"},{"issue":"4","key":"1634_CR475","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3390\/pharmaceutics15041295","volume":"15","author":"AR Blaudszun","year":"2023","unstructured":"Blaudszun AR, Kim WJ, Um W, Yoon HY, Shim MK, Kim K. Adoptive transfer of photosensitizer-loaded cytotoxic T cells for combinational photodynamic therapy and cancer immuno-therapy. Pharmaceutics. 2023;15(4):1295.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1634_CR476","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1038\/s41467-023-39330-7","volume":"14","author":"K Adu-Berchie","year":"2023","unstructured":"Adu-Berchie K, Brockman JM, Liu Y, To TW, Zhang DKY, Najibi AJ, et al. Adoptive T cell transfer and host antigen-presenting cell recruitment with cryogel scaffolds promotes long-term protection against solid tumors. Nat Commun. 2023;14(1):3546.","journal-title":"Nat Commun"},{"issue":"1","key":"1634_CR477","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/imr.12132","volume":"257","author":"CS Hinrichs","year":"2014","unstructured":"Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2014;257(1):56\u201371.","journal-title":"Immunol Rev"},{"issue":"11","key":"1634_CR478","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s41416-021-01353-6","volume":"124","author":"M Morotti","year":"2021","unstructured":"Morotti M, Albukhari A, Alsaadi A, Artibani M, Brenton JD, Curbishley SM, et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br J Cancer. 2021;124(11):1759\u201376.","journal-title":"Br J Cancer"},{"issue":"9","key":"1634_CR479","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1016\/j.ymthe.2023.07.015","volume":"31","author":"MD Tennant","year":"2023","unstructured":"Tennant MD, New C, Ferreira LMR, O\u2019Neil RT. Efficient T cell adoptive transfer in lymphoreplete hosts mediated by transient activation of Stat5 signaling. Mol Ther. 2023;31(9):2591\u20139.","journal-title":"Mol Ther"},{"issue":"1","key":"1634_CR480","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/cancers16010039","volume":"16","author":"A Majumder","year":"2023","unstructured":"Majumder A. Evolving CAR-T-cell therapy for cancer treatment: from scientific discovery to cures. Cancers (Basel). 2023;16(1):39.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1634_CR481","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/cancers16010124","volume":"16","author":"DF Chamorro","year":"2023","unstructured":"Chamorro DF, Somes LK, Hoyos V. Engineered adoptive T-cell therapies for breast cancer: current progress, challenges, and potential. Cancers (Basel). 2023;16(1):124.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1634_CR482","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12943-023-01914-8","volume":"23","author":"OL Gammelgaard","year":"2024","unstructured":"Gammelgaard OL, Terp MG, Kirkin AF, Johansen S, Traynor S, Vever H, et al. Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis. Mol Cancer. 2024;23(1):6.","journal-title":"Mol Cancer"},{"issue":"1","key":"1634_CR483","doi-asserted-by":"publisher","first-page":"e007735","DOI":"10.1136\/jitc-2023-007735","volume":"12","author":"C Ma","year":"2024","unstructured":"Ma C, Chen P, Du J, Wang L, Lu N, Sun J, et al. Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentical hematopoietic stem cell transplantation. J Immunother Cancer. 2024;12(1):e007735.","journal-title":"J Immunother Cancer"},{"issue":"13","key":"1634_CR484","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550\u20137.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"1634_CR485","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, Borch TH, van den Berg JH, Met \u00d6, Kessels R, Geukes Foppen MH, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med. 2022;387(23):2113\u201325.","journal-title":"N Engl J Med"},{"key":"1634_CR486","doi-asserted-by":"crossref","unstructured":"Creelan B, Wang C, Teer J, Toloza E, Mullinax J, Yao J, et al. Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial. proceedings of the annual meeting of the american association for cancer research (AACR); Philadelphia, Pennsylvania, USA: Cancer Research; 2020.","DOI":"10.1158\/1538-7445.AM2020-CT056"},{"key":"1634_CR487","doi-asserted-by":"publisher","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang H, Lan H, Wu J, Xiao Y. CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies. Front Immunol. 2023;14:1101495.","journal-title":"Front Immunol"},{"issue":"7953","key":"1634_CR488","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","volume":"615","author":"SP Foy","year":"2023","unstructured":"Foy SP, Jacoby K, Bota DA, Hunter T, Pan Z, Stawiski E, et al. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature. 2023;615(7953):687\u201396.","journal-title":"Nature"},{"issue":"4","key":"1634_CR489","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"key":"1634_CR490","doi-asserted-by":"publisher","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","volume":"14","author":"A Mitra","year":"2023","unstructured":"Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023;14:1188049.","journal-title":"Front Immunol"},{"issue":"1","key":"1634_CR491","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","volume":"21","author":"G Dagar","year":"2023","unstructured":"Dagar G, Gupta A, Masoodi T, Nisar S, Merhi M, Hashem S, et al. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. J Transl Med. 2023;21(1):449.","journal-title":"J Transl Med"},{"key":"1634_CR492","doi-asserted-by":"publisher","first-page":"1121030","DOI":"10.3389\/fimmu.2023.1121030","volume":"14","author":"M Hiltensperger","year":"2023","unstructured":"Hiltensperger M, Krackhardt AM. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells. Front Immunol. 2023;14:1121030.","journal-title":"Front Immunol"},{"issue":"6","key":"1634_CR493","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"1634_CR494","doi-asserted-by":"publisher","first-page":"6300","DOI":"10.3390\/ijms24076300","volume":"24","author":"RC De Marco","year":"2023","unstructured":"De Marco RC, Monzo HJ, Ojala PM. CAR T Cell Therapy: A Versatile Living Drug. Int J Mol Sci. 2023;24(7):6300.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1634_CR495","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/cells13020146","volume":"13","author":"C Lonez","year":"2024","unstructured":"Lonez C, Breman E. Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met? Cells. 2024;13(2):146.","journal-title":"Cells"},{"key":"1634_CR496","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.844866","volume":"13","author":"BC Taylor","year":"2022","unstructured":"Taylor BC, Balko JM. Mechanisms of MHC-I downregulation and role in immunotherapy response. Front Immunol. 2022;13: 844866.","journal-title":"Front Immunol"},{"issue":"1","key":"1634_CR497","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40164-024-00485-8","volume":"13","author":"J Yang","year":"2024","unstructured":"Yang J, Guo H, Han L, Song Y, Zhou K. Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting. Exp Hematol Oncol. 2024;13(1):25.","journal-title":"Exp Hematol Oncol"},{"key":"1634_CR498","doi-asserted-by":"publisher","first-page":"1335424","DOI":"10.3389\/fimmu.2024.1335424","volume":"15","author":"S Smirnov","year":"2024","unstructured":"Smirnov S, Mateikovich P, Samochernykh K, Shlyakhto E. Recent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic. Front Immunol. 2024;15:1335424.","journal-title":"Front Immunol"},{"issue":"8","key":"1634_CR499","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3390\/cells13080662","volume":"13","author":"D Khvorost","year":"2024","unstructured":"Khvorost D, Kendall B, Jazirehi AR. Immunotherapy of hematological malignancies of human B-cell origin with CD19 CAR T lymphocytes. Cells. 2024;13(8):662.","journal-title":"Cells"},{"key":"1634_CR500","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.omtm.2019.01.010","volume":"13","author":"G Detela","year":"2019","unstructured":"Detela G, Lodge A. EU regulatory pathways for ATMPs: standard, accelerated and adaptive pathways to marketing authorisation. Mol Ther Methods Clin Dev. 2019;13:205\u201332.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1634_CR501","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.3389\/fimmu.2019.02250","volume":"10","author":"L Zhao","year":"2019","unstructured":"Zhao L, Cao YJ. Engineered T cell therapy for cancer in the clinic. Front Immunol. 2019;10:2250.","journal-title":"Front Immunol"},{"issue":"8","key":"1634_CR502","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, et al. CAR T cells targeting B7\u2013H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019;25(8):2560\u201374.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1634_CR503","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/sj.mt.6300104","volume":"15","author":"JR Park","year":"2007","unstructured":"Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 2007;15(4):825\u201333.","journal-title":"Mol Ther"},{"issue":"4","key":"1634_CR504","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38(4):473\u201388.","journal-title":"Cancer Cell"},{"issue":"6","key":"1634_CR505","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","volume":"13","author":"HJ Jackson","year":"2016","unstructured":"Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016;13(6):370\u201383.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"1634_CR506","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","volume":"35","author":"NF Kuhn","year":"2019","unstructured":"Kuhn NF, Purdon TJ, van Leeuwen DG, Lopez AV, Curran KJ, Daniyan AF, et al. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell. 2019;35(3):473-88.e6.","journal-title":"Cancer Cell"},{"issue":"17","key":"1634_CR507","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011;71(17):5697\u2013706.","journal-title":"Cancer Res"},{"issue":"9","key":"1634_CR508","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046241","volume":"7","author":"J Zhao","year":"2012","unstructured":"Zhao J, Perlman S. Differential effects of IL-12 on Tregs and non-Treg T cells: roles of IFN-\u03b3, IL-2 and IL-2R. PLoS ONE. 2012;7(9): e46241.","journal-title":"PLoS ONE"},{"issue":"1","key":"1634_CR509","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12943-022-01669-8","volume":"21","author":"C Qu","year":"2022","unstructured":"Qu C, Zhang H, Cao H, Tang L, Mo H, Liu F, et al. Tumor buster - where will the CAR-T cell therapy \u201cmissile\u201d go? Mol Cancer. 2022;21(1):201.","journal-title":"Mol Cancer"},{"issue":"1","key":"1634_CR510","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12929-022-00866-3","volume":"29","author":"A Tiwari","year":"2022","unstructured":"Tiwari A, Trivedi R, Lin SY. Tumor microenvironment: barrier or opportunity towards effective cancer therapy. J Biomed Sci. 2022;29(1):83.","journal-title":"J Biomed Sci"},{"key":"1634_CR511","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.903562","volume":"13","author":"P Kandra","year":"2022","unstructured":"Kandra P, Nandigama R, Eul B, Huber M, Kobold S, Seeger W, et al. Utility and drawbacks of chimeric antigen receptor T cell (CAR-T) therapy in lung cancer. Front Immunol. 2022;13: 903562.","journal-title":"Front Immunol"},{"key":"1634_CR512","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.2147\/IJN.S445101","volume":"19","author":"D Hu","year":"2024","unstructured":"Hu D, Yang R, Wang G, Li H, Fan X, Liang G. Emerging strategies to overcome current CAR-T therapy dilemmas - exosomes derived from CAR-T cells. Int J Nanomedicine. 2024;19:2773\u201391.","journal-title":"Int J Nanomedicine"},{"key":"1634_CR513","doi-asserted-by":"publisher","first-page":"577773","DOI":"10.3389\/fonc.2020.577773","volume":"10","author":"S Krebs","year":"2020","unstructured":"Krebs S, Dacek MM, Carter LM, Scheinberg DA, Larson SM. CAR Chase: where do engineered cells go in humans? Front Oncol. 2020;10:577773.","journal-title":"Front Oncol"},{"issue":"15","key":"1634_CR514","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.7150\/thno.87489","volume":"13","author":"K Kurtz","year":"2023","unstructured":"Kurtz K, Eibler L, Dacek MM, Carter LM, Veach DR, Lovibond S, et al. Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications. Theranostics. 2023;13(15):5469\u201382.","journal-title":"Theranostics"},{"issue":"3","key":"1634_CR515","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.4049\/jimmunol.1700236","volume":"200","author":"DT Harris","year":"2018","unstructured":"Harris DT, Hager MV, Smith SN, Cai Q, Stone JD, Kruger P, et al. Comparison of T cell activities mediated by human TCRs and CARs that use the same recognition domains. J Immunol. 2018;200(3):1088\u2013100.","journal-title":"J Immunol"},{"issue":"1","key":"1634_CR516","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13045-021-01115-0","volume":"14","author":"AM Tsimberidou","year":"2021","unstructured":"Tsimberidou AM, Van Morris K, Vo HH, Eck S, Lin YF, Rivas JM, et al. T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. J Hematol Oncol. 2021;14(1):102.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1634_CR517","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40164-022-00291-0","volume":"11","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Liu Z, Wei W, Li Y. TCR engineered T cells for solid tumor immunotherapy. Exp Hematol Oncol. 2022;11(1):38.","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"1634_CR518","doi-asserted-by":"publisher","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Sci Adv. 2023;9(7):eadf3700.","journal-title":"Sci Adv"},{"issue":"1","key":"1634_CR519","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","volume":"15","author":"J Liu","year":"2022","unstructured":"Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15(1):28.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"1634_CR520","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri.2017.131","volume":"18","author":"Z Hu","year":"2018","unstructured":"Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168\u201382.","journal-title":"Nat Rev Immunol"},{"key":"1634_CR521","doi-asserted-by":"crossref","unstructured":"Khattak A, Carlino M, Meniawy T, Ansstas G, Medina T, Taylor MH, et al. A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201\/Keynote-942 trial. (Abstract CT001). AACR 2023; Orlando, FL, USA: AACR; 2023.","DOI":"10.1158\/1538-7445.AM2023-CT001"},{"issue":"9","key":"1634_CR522","doi-asserted-by":"publisher","first-page":"401","DOI":"10.18609\/ioi.2022.043","volume":"3","author":"MH Andersen","year":"2022","unstructured":"Andersen MH. Immune modulatory vaccines: the safe way to inflame the tumor microenvironment & guide anti-cancer immunotherapies. Immuno-Oncology Insights. 2022;3(9):401\u20137.","journal-title":"Immuno-Oncology Insights"},{"issue":"9","key":"1634_CR523","doi-asserted-by":"publisher","first-page":"djv154","DOI":"10.1093\/jnci\/djv154","volume":"107","author":"MH Andersen","year":"2015","unstructured":"Andersen MH. Immune regulation by self-recognition: novel possibilities for anticancer immunotherapy. J Natl Cancer Inst. 2015;107(9):djv154.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"1634_CR524","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00281-016-0593-x","volume":"39","author":"MH Andersen","year":"2017","unstructured":"Andersen MH. Anti-regulatory T cells. Semin Immunopathol. 2017;39(3):317\u201326.","journal-title":"Semin Immunopathol"},{"issue":"12","key":"1634_CR525","doi-asserted-by":"publisher","first-page":"e005491","DOI":"10.1136\/jitc-2022-005491","volume":"10","author":"M Perez-Penco","year":"2022","unstructured":"Perez-Penco M, Weis-Banke SE, Schina A, Siersb\u00e6k M, H\u00fcbbe ML, J\u00f8rgensen MA, et al. TGF\u03b2-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer. J Immunother Cancer. 2022;10(12):e005491.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"1634_CR526","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1158\/2326-6066.CIR-21-0280","volume":"9","author":"M Aaboe J\u00f8rgensen","year":"2021","unstructured":"Aaboe J\u00f8rgensen M, Ugel S, Linder H\u00fcbbe M, Carretta M, Perez-Penco M, Weis-Banke SE, et al. Arginase 1-based immune modulatory vaccines induce anticancer immunity and synergize with anti-PD-1 checkpoint blockade. Cancer Immunol Res. 2021;9(11):1316\u201326.","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"1634_CR527","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1182\/blood-2010-06-288498","volume":"117","author":"RB S\u00f8rensen","year":"2011","unstructured":"S\u00f8rensen RB, Hadrup SR, Svane IM, Hjorts\u00f8 MC, Thor Straten P, Andersen MH. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood. 2011;117(7):2200\u201310.","journal-title":"Blood"},{"issue":"2","key":"1634_CR528","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41423-020-00593-5","volume":"18","author":"MO Holmstr\u00f6m","year":"2021","unstructured":"Holmstr\u00f6m MO, Mortensen REJ, Pavlidis AM, Martinenaite E, Weis-Banke SE, Aaboe-J\u00f8rgensen M, et al. Cytotoxic T cells isolated from healthy donors and cancer patients kill TGF\u03b2-expressing cancer cells in a TGF\u03b2-dependent manner. Cell Mol Immunol. 2021;18(2):415\u201326.","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"1634_CR529","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1158\/0008-5472.CAN-12-3507","volume":"73","author":"S Munir","year":"2013","unstructured":"Munir S, Andersen GH, Met \u00d6, Donia M, Fr\u00f8sig TM, Larsen SK, et al. HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res. 2013;73(6):1764\u201376.","journal-title":"Cancer Res"},{"issue":"11","key":"1634_CR530","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1038\/s41423-021-00770-0","volume":"18","author":"REJ Mortensen","year":"2021","unstructured":"Mortensen REJ, Holmstr\u00f6m MO, Andersen MH. Characterization of TGF\u03b2-specific CD4+T cells through the modulation of TGF\u03b2 expression in malignant myeloid cells. Cell Mol Immunol. 2021;18(11):2575\u20137.","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"1634_CR531","doi-asserted-by":"publisher","first-page":"e000605","DOI":"10.1136\/jitc-2020-000605","volume":"8","author":"S Dey","year":"2020","unstructured":"Dey S, Sutanto-Ward E, Kopp KL, DuHadaway J, Mondal A, Ghaban D, et al. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses. J Immunother Cancer. 2020;8(2):e000605.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1634_CR532","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1038\/s41591-021-01544-x","volume":"27","author":"JW Kjeldsen","year":"2021","unstructured":"Kjeldsen JW, Lorentzen CL, Martinenaite E, Ellebaek E, Donia M, Holmstroem RB, et al. A phase 1\/2 trial of an immune-modulatory vaccine against IDO\/PD-L1 in combination with nivolumab in metastatic melanoma. Nat Med. 2021;27(12):2212\u201323.","journal-title":"Nat Med"},{"issue":"5","key":"1634_CR533","doi-asserted-by":"publisher","first-page":"e006755","DOI":"10.1136\/jitc-2023-006755","volume":"11","author":"CL Lorentzen","year":"2023","unstructured":"Lorentzen CL, Kjeldsen JW, Ehrnrooth E, Andersen MH, Marie SI. Long-term follow-up of anti-PD-1 na\u00efve patients with metastatic melanoma treated with IDO\/PD-L1 targeting peptide vaccine and nivolumab. J Immunother Cancer. 2023;11(5):e006755.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"1634_CR534","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","volume":"19","author":"WH Fridman","year":"2022","unstructured":"Fridman WH, Meylan M, Petitprez F, Sun CM, Italiano A, Saut\u00e8s-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol. 2022;19(7):441\u201357.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1634_CR535","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3390\/cancers15051517","volume":"15","author":"M Li","year":"2023","unstructured":"Li M, Quintana A, Alberts E, Hung MS, Boulat V, Ripoll MM, et al. B cells in breast cancer pathology. Cancers (Basel). 2023;15(5):1517.","journal-title":"Cancers (Basel)."},{"issue":"7969","key":"1634_CR536","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-023-06231-0","volume":"619","author":"L Bod","year":"2023","unstructured":"Bod L, Kye YC, Shi J, Torlai Triglia E, Schnell A, Fessler J, et al. B-cell-specific checkpoint molecules that regulate anti-tumour immunity. Nature. 2023;619(7969):348\u201356.","journal-title":"Nature"},{"issue":"12","key":"1634_CR537","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1182\/blood.2023021002","volume":"143","author":"L Cerchietti","year":"2024","unstructured":"Cerchietti L. Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B-cell lymphoma. Blood. 2024;143(12):1101\u201311.","journal-title":"Blood"},{"issue":"1","key":"1634_CR538","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1038\/s41467-024-46873-w","volume":"15","author":"L Kasikova","year":"2024","unstructured":"Kasikova L, Rakova J, Hensler M, Lanickova T, Tomankova J, Pasulka J, et al. Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer. Nat Commun. 2024;15(1):2528.","journal-title":"Nat Commun"},{"issue":"4","key":"1634_CR539","doi-asserted-by":"publisher","first-page":"e008636","DOI":"10.1136\/jitc-2023-008636","volume":"12","author":"R Flippot","year":"2024","unstructured":"Flippot R, Teixeira M, Rey-Cardenas M, Carril-Ajuria L, Rainho L, Naoun N, et al. B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors. J Immunother Cancer. 2024;12(4):e008636.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1634_CR540","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","volume":"15","author":"A Alu","year":"2022","unstructured":"Alu A, Lei H, Han X, Wei Y, Wei X. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. J Hematol Oncol. 2022;15(1):138.","journal-title":"J Hematol Oncol"},{"issue":"14","key":"1634_CR541","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.3390\/cancers15143648","volume":"15","author":"S Montoya","year":"2023","unstructured":"Montoya S, Thompson MC. Non-covalent bruton\u2019s tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Cancers (Basel). 2023;15(14):3648.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1634_CR542","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/hon.3144","volume":"41","author":"SS Chen","year":"2023","unstructured":"Chen SS, Chiorazzi N. Functional consequences of inhibition of Bruton\u2019s tyrosine kinase by ibrutinib in chronic lymphocytic leukemia. Hematol Oncol. 2023;41(1):119\u201328.","journal-title":"Hematol Oncol"},{"issue":"5","key":"1634_CR543","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.3390\/molecules28052400","volume":"28","author":"D Rozkiewicz","year":"2023","unstructured":"Rozkiewicz D, Hermanowicz JM, Kwiatkowska I, Krupa A, Pawlak D. Bruton\u2019s tyrosine kinase inhibitors (BTKIs): review of preclinical studies and evaluation of clinical trials. Molecules. 2023;28(5):2400.","journal-title":"Molecules"},{"key":"1634_CR544","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.687458","volume":"12","author":"IE Ahn","year":"2021","unstructured":"Ahn IE, Brown JR. Targeting bruton\u2019s tyrosine kinase in CLL. Front Immunol. 2021;12: 687458.","journal-title":"Front Immunol"},{"issue":"9","key":"1634_CR545","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.3390\/cancers15092596","volume":"15","author":"TA Eyre","year":"2023","unstructured":"Eyre TA, Riches JC. The evolution of therapies targeting bruton tyrosine kinase for the treatment of chronic lymphocytic leukaemia: future perspectives. Cancers (Basel). 2023;15(9):2596.","journal-title":"Cancers (Basel)."},{"key":"1634_CR546","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1182\/blood-2021-146610","volume":"138","author":"S Sharma","year":"2021","unstructured":"Sharma S, Pepin X, Burri H, Zheng L, Kuptsova-Clarkson N, De Jong A, et al. New acalabrutinib formulation enables co-administration with proton pump inhibitors and dosing in patients unable to swallow capsules (ELEVATE-PLUS). Blood. 2021;138:4365.","journal-title":"Blood"},{"issue":"16","key":"1634_CR547","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","volume":"21","author":"RA de Claro","year":"2015","unstructured":"de Claro RA, McGinn KM, Verdun N, Lee SL, Chiu HJ, Saber H, et al. FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin Cancer Res. 2015;21(16):3586\u201390.","journal-title":"Clin Cancer Res"},{"key":"1634_CR548","unstructured":"Raedler LA. Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenstr\u00f6m's Macroglobulinemia. Am Health Drug Benefits. 2016;9(Spec Feature):89\u201392."},{"key":"1634_CR549","doi-asserted-by":"crossref","unstructured":"Zimmer J, Juri\u0161i\u0107 V. (2023) Special Issue \u201cNew Developments in Natural Killer Cells for Immunotherapy\u201d. Cells. 12 (11): 1496","DOI":"10.3390\/cells12111496"},{"key":"1634_CR550","doi-asserted-by":"publisher","first-page":"1192128","DOI":"10.3389\/fonc.2023.1192128","volume":"13","author":"Q Xiong","year":"2023","unstructured":"Xiong Q, Zhu J, Zhang Y, Deng H. CAR-NK cell therapy for glioblastoma: what to do next? Front Oncol. 2023;13:1192128.","journal-title":"Front Oncol"},{"key":"1634_CR551","doi-asserted-by":"publisher","first-page":"1166038","DOI":"10.3389\/fimmu.2023.1166038","volume":"14","author":"MK Kilgour","year":"2023","unstructured":"Kilgour MK, Bastin DJ, Lee SH, Ardolino M, McComb S, Visram A. Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy. Front Immunol. 2023;14:1166038.","journal-title":"Front Immunol"},{"issue":"1","key":"1634_CR552","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20.","journal-title":"Mol Cancer"},{"key":"1634_CR553","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720501","volume":"11","author":"H Lu","year":"2021","unstructured":"Lu H, Zhao X, Li Z, Hu Y, Wang H. From CAR-T cells to CAR-NK cells: a developing immunotherapy method for hematological malignancies. Front Oncol. 2021;11: 720501.","journal-title":"Front Oncol"},{"key":"1634_CR554","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28147","volume":"3","author":"H Klingemann","year":"2014","unstructured":"Klingemann H. Are natural killer cells superior CAR drivers? Oncoimmunology. 2014;3: e28147.","journal-title":"Oncoimmunology"},{"issue":"6","key":"1634_CR555","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545\u201353.","journal-title":"N Engl J Med"},{"key":"1634_CR556","doi-asserted-by":"publisher","first-page":"1199631","DOI":"10.3389\/fimmu.2023.1199631","volume":"14","author":"S Xu","year":"2023","unstructured":"Xu S, Wang C, Yang L, Wu J, Li M, Xiao P, et al. Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy. Front Immunol. 2023;14:1199631.","journal-title":"Front Immunol"},{"issue":"2","key":"1634_CR557","doi-asserted-by":"publisher","first-page":"e005968","DOI":"10.1136\/jitc-2022-005968","volume":"11","author":"I Truxova","year":"2023","unstructured":"Truxova I, Cibula D, Spisek R, Fucikova J. \nTargeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma. J Immunother Cancer. 2023;11(2):e005968.","journal-title":"J Immunother Cancer"},{"issue":"31","key":"1634_CR558","doi-asserted-by":"publisher","first-page":"49349","DOI":"10.18632\/oncotarget.9885","volume":"7","author":"WB Fang","year":"2016","unstructured":"Fang WB, Yao M, Brummer G, Acevedo D, Alhakamy N, Berkland C, et al. Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment. Oncotarget. 2016;7(31):49349\u201367.","journal-title":"Oncotarget"},{"key":"1634_CR559","doi-asserted-by":"publisher","first-page":"1295257","DOI":"10.3389\/fimmu.2023.1295257","volume":"14","author":"U Basak","year":"2023","unstructured":"Basak U, Sarkar T, Mukherjee S, Chakraborty S, Dutta A, Dutta S, et al. Tumor-associated macrophages: an effective player of the tumor microenvironment. Front Immunol. 2023;14:1295257.","journal-title":"Front Immunol"},{"issue":"3","key":"1634_CR560","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3390\/cancers16030559","volume":"16","author":"AA Lekan","year":"2024","unstructured":"Lekan AA, Weiner LM. The role of chemokines in orchestrating the immune response to pancreatic ductal adenocarcinoma. Cancers (Basel). 2024;16(3):559.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1634_CR561","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12964-020-00589-8","volume":"18","author":"Q Hao","year":"2020","unstructured":"Hao Q, Vadgama JV, Wang P. CCL2\/CCR2 signaling in cancer pathogenesis. Cell Commun Signal. 2020;18(1):82.","journal-title":"Cell Commun Signal"},{"issue":"7355","key":"1634_CR562","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature10138","volume":"475","author":"BZ Qian","year":"2011","unstructured":"Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222\u20135.","journal-title":"Nature"},{"issue":"1","key":"1634_CR563","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11523-014-0320-2","volume":"10","author":"I Brana","year":"2015","unstructured":"Brana I, Calles A, LoRusso PM, Yee LK, Puchalski TA, Seetharam S, et al. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target Oncol. 2015;10(1):111\u201323.","journal-title":"Target Oncol"},{"issue":"5","key":"1634_CR564","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","volume":"17","author":"TM Nywening","year":"2016","unstructured":"Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17(5):651\u201362.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1634_CR565","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s10637-019-00830-3","volume":"38","author":"M Noel","year":"2020","unstructured":"Noel M, O\u2019Reilly EM, Wolpin BM, Ryan DP, Bullock AJ, Britten CD, et al. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel\/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. Invest New Drugs. 2020;38(3):800\u201311.","journal-title":"Invest New Drugs"},{"issue":"2","key":"1634_CR566","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/hep.26094","volume":"57","author":"L Zhao","year":"2013","unstructured":"Zhao L, Lim SY, Gordon-Weeks AN, Tapmeier TT, Im JH, Cao Y, et al. Recruitment of a myeloid cell subset (CD11b\/Gr1 mid) via CCL2\/CCR2 promotes the development of \ncolorectal cancer liver metastasis. Hepatology. 2013;57(2):829\u201339.","journal-title":"Hepatology"},{"issue":"7525","key":"1634_CR567","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nature13862","volume":"515","author":"L Bonapace","year":"2014","unstructured":"Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Junt T, et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature. 2014;515(7525):130\u20133.","journal-title":"Nature"},{"issue":"11","key":"1634_CR568","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21(11):799\u2013820.","journal-title":"Nat Rev Drug Discov"},{"issue":"Pt 1","key":"1634_CR569","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114884","volume":"245","author":"J Wen","year":"2023","unstructured":"Wen J, Wang S, Guo R, Liu D. CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment. Eur J Med Chem. 2023;245(Pt 1): 114884.","journal-title":"Eur J Med Chem"},{"key":"1634_CR570","doi-asserted-by":"publisher","first-page":"1159819","DOI":"10.3389\/fbioe.2023.1159819","volume":"11","author":"M Rodriguez-Perdigon","year":"2023","unstructured":"Rodriguez-Perdigon M, Haeni L, Rothen-Rutishauser B, R\u00fcegg C. Dual CSF1R inhibition and CD40 activation demonstrates anti-tumor activity in a 3D macrophage- HER2. Front Bioeng Biotechnol. 2023;11:1159819.","journal-title":"Front Bioeng Biotechnol"},{"issue":"7","key":"1634_CR571","first-page":"3257","volume":"13","author":"A Moeller","year":"2023","unstructured":"Moeller A, Kurzrock R, Botta GP, Adashek JJ, Patel H, Lee S, et al. Challenges and prospects of CSF1R targeting for advanced malignancies. Am J Cancer Res. 2023;13(7):3257\u201365.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"1634_CR572","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12964-023-01384-x","volume":"22","author":"B Zhou","year":"2024","unstructured":"Zhou B, Yang Y, Kang Y, Hou J. Targeting the macrophage immunocheckpoint: a novel insight into solid tumor immunotherapy. Cell Commun Signal. 2024;22(1):66.","journal-title":"Cell Commun Signal"},{"issue":"2","key":"1634_CR573","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/cancers16020282","volume":"16","author":"F Cersosimo","year":"2024","unstructured":"Cersosimo F, Lonardi S, Ulivieri C, Martini P, Morrione A, Vermi W, et al. CSF-1R in cancer: more than a myeloid cell receptor. Cancers (Basel). 2024;16(2):282.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1634_CR574","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","volume":"6","author":"X Xiang","year":"2021","unstructured":"Xiang X, Wang J, Lu D, Xu X. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct Target Ther. 2021;6(1):75.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1634_CR575","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ni.3341","volume":"17","author":"EG Perdiguero","year":"2016","unstructured":"Perdiguero EG, Geissmann F. The development and maintenance of resident macrophages. Nat Immunol. 2016;17(1):2\u20138.","journal-title":"Nat Immunol"},{"issue":"8","key":"1634_CR576","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2217\/imt-2018-0156","volume":"11","author":"J Kowal","year":"2019","unstructured":"Kowal J, Kornete M, Joyce JA. Re-education of macrophages as a therapeutic strategy in cancer. Immunotherapy. 2019;11(8):677\u201389.","journal-title":"Immunotherapy"},{"issue":"10","key":"1634_CR577","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat \nMed. 2013;19(10):1264\u201372.","journal-title":"Nat Med"},{"issue":"3","key":"1634_CR578","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.04.023","volume":"11","author":"M Yu","year":"2024","unstructured":"Yu M, Wu Y, Li Q, Hong W, Yang Y, Hu X, et al. Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer. Genes Dis. 2024;11(3): 100989.","journal-title":"Genes Dis"},{"issue":"1","key":"1634_CR579","doi-asserted-by":"publisher","first-page":"9032","DOI":"10.1038\/s41598-024-59650-y","volume":"14","author":"T Yang","year":"2024","unstructured":"Yang T, Ke H, Liu J, An X, Xue J, Ning J, et al. Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models. Sci Rep. 2024;14(1):9032.","journal-title":"Sci Rep"},{"key":"1634_CR580","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw7843","author":"L Akkari","year":"2020","unstructured":"Akkari L, Bowman RL, Tessier J, Klemm F, Handgraaf SM, de Groot M, et al. Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance. Sci Transl Med. 2020. https:\/\/doi.org\/10.1126\/scitranslmed.aaw7843.","journal-title":"Sci Transl Med."},{"issue":"43","key":"1634_CR581","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.1038\/onc.2017.261","volume":"36","author":"D Yan","year":"2017","unstructured":"Yan D, Kowal J, Akkari L, Schuhmacher AJ, Huse JT, West BL, et al. Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas. Oncogene. 2017;36(43):6049\u201358.","journal-title":"Oncogene"},{"issue":"1","key":"1634_CR582","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.celrep.2017.03.038","volume":"19","author":"OC Olson","year":"2017","unstructured":"Olson OC, Kim H, Quail DF, Foley EA, Joyce JA. Tumor-associated macrophages suppress the cytotoxic activity of antimitotic agents. Cell Rep. 2017;19(1):101\u201313.","journal-title":"Cell Rep"},{"issue":"4","key":"1634_CR583","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/nov245","volume":"18","author":"N Butowski","year":"2016","unstructured":"Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016;18(4):557\u201364.","journal-title":"Neuro Oncol"},{"issue":"10197","key":"1634_CR584","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","volume":"394","author":"WD Tap","year":"2019","unstructured":"Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394(10197):478\u201387.","journal-title":"Lancet"},{"issue":"16","key":"1634_CR585","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","volume":"79","author":"YN Lamb","year":"2019","unstructured":"Lamb YN. Pexidartinib: first approval. Drugs. 2019;79(16):1805\u201312.","journal-title":"Drugs"},{"issue":"6288","key":"1634_CR586","doi-asserted-by":"publisher","first-page":"aad3018","DOI":"10.1126\/science.aad3018","volume":"352","author":"DF Quail","year":"2016","unstructured":"Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT, et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science. 2016;352(6288):aad3018.","journal-title":"Science"},{"key":"1634_CR587","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.690306","volume":"9","author":"A Turdo","year":"2021","unstructured":"Turdo A, D\u2019Accardo C, Glaviano A, Porcelli G, Colarossi C, Colarossi L, et al. Targeting phosphatases and kinases: how to checkmate cancer. Front Cell Dev Biol. 2021;9: 690306.","journal-title":"Front Cell Dev Biol"},{"key":"1634_CR588","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101103","volume":"76","author":"A Glaviano","year":"2024","unstructured":"Glaviano A, Wander SA, Baird RD, Yap KC, Lam HY, Toi M, et al. Mechanisms of sensitivity and resistance to CDK4\/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. Drug Resist Updat. 2024;76: 101103.","journal-title":"Drug Resist Updat"},{"issue":"7","key":"1634_CR589","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","volume":"181","author":"F Klemm","year":"2020","unstructured":"Klemm F, Maas RR, Bowman RL, Kornete M, Soukup K, Nassiri S, et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell. 2020;181(7):1643-60.e17.","journal-title":"Cell"},{"issue":"2","key":"1634_CR590","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41388-020-01528-0","volume":"40","author":"D He","year":"2021","unstructured":"He D, Wang D, Lu P, Yang N, Xue Z, Zhu X, et al. Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations. Oncogene. 2021;40(2):355\u201368.","journal-title":"Oncogene"},{"issue":"1","key":"1634_CR591","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","volume":"5","author":"MA Cannarile","year":"2017","unstructured":"Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, R\u00fcttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. 2017;5(1):53.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1634_CR592","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12943-021-01442-3","volume":"20","author":"C Yan","year":"2021","unstructured":"Yan C, Richmond A. Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy. Mol Cancer. 2021;20(1):146.","journal-title":"Mol Cancer"},{"issue":"1","key":"1634_CR593","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12865-023-00547-2","volume":"24","author":"H Choi","year":"2023","unstructured":"Choi H, Lee HJ, Sohn HJ, Kim TG. CD40 ligand stimulation affects the number and memory phenotypes of human peripheral CD8. BMC Immunol. 2023;24(1):15.","journal-title":"BMC Immunol"},{"issue":"7","key":"1634_CR594","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.4049\/jimmunol.180.7.4382","volume":"180","author":"MG Hernandez","year":"2008","unstructured":"Hernandez MG, Shen L, Rock KL. CD40 on APCs is needed for optimal programming, maintenance, and recall of CD8+ T cell memory even in the absence of CD4+ T cell help. J Immunol. 2008;180(7):4382\u201390.","journal-title":"J Immunol"},{"key":"1634_CR595","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","volume":"71","author":"RH Vonderheide","year":"2020","unstructured":"Vonderheide RH. CD40 Agonist Antibodies in Cancer Immunotherapy. Annu Rev Med. 2020;71:47\u201358.","journal-title":"Annu Rev Med"},{"issue":"2","key":"1634_CR596","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/21645515.2019.1653744","volume":"16","author":"DM Richards","year":"2020","unstructured":"Richards DM, Sefrin JP, Gieffers C, Hill O, Merz C. Concepts for agonistic targeting of CD40 in immuno-oncology. Hum Vaccin Immunother. 2020;16(2):377\u201387.","journal-title":"Hum Vaccin Immunother"},{"issue":"6024","key":"1634_CR597","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331(6024):1612\u20136.","journal-title":"Science"},{"issue":"3","key":"1634_CR598","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1084\/jem.20171440","volume":"215","author":"S Hoves","year":"2018","unstructured":"Hoves S, Ooi CH, Wolter C, Sade H, Bissinger S, Schmittnaegel M, et al. Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. J Exp Med. 2018;215(3):859\u201376.","journal-title":"J Exp Med"},{"issue":"1","key":"1634_CR599","doi-asserted-by":"publisher","DOI":"10.4161\/onci.23033","volume":"2","author":"RH Vonderheide","year":"2013","unstructured":"Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, et al. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology. 2013;2(1): e23033.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1634_CR600","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","volume":"22","author":"MH O'Hara","year":"2021","unstructured":"O\u2019Hara MH, O\u2019Reilly EM, Varadhachary G, Wolff RA, Wainberg ZA, Ko AH, et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 2021;22(1):118\u201331.","journal-title":"Lancet Oncol"},{"issue":"13","key":"1634_CR601","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1200\/JCO.2001.19.13.3280","volume":"19","author":"RH Vonderheide","year":"2001","unstructured":"Vonderheide RH, Dutcher JP, Anderson JE, Eckhardt SG, Stephans KF, Razvillas B, et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol. 2001;19(13):3280\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1634_CR602","doi-asserted-by":"publisher","first-page":"e001408","DOI":"10.1136\/jitc-2020-001408","volume":"8","author":"M Lecoultre","year":"2020","unstructured":"Lecoultre M, Dutoit V, Walker PR. Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review. J Immunother Cancer. 2020;8(2):e001408.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"1634_CR603","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00432-024-05777-4","volume":"150","author":"R Huang","year":"2024","unstructured":"Huang R, Kang T, Chen S. The role of tumor-associated macrophages in tumor immune evasion. J Cancer Res Clin Oncol. 2024;150(5):238.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"1634_CR604","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41568-019-0183-z","volume":"19","author":"M Feng","year":"2019","unstructured":"Feng M, Jiang W, Kim BYS, Zhang CC, Fu YX, Weissman IL. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer. 2019;19(10):568\u201386.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1634_CR605","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40364-022-00373-5","volume":"10","author":"T Qu","year":"2022","unstructured":"Qu T, Li B, Wang Y. Targeting CD47\/SIRP\u03b1 as a therapeutic strategy, where we are and where we are headed. Biomark Res. 2022;10(1):20.","journal-title":"Biomark Res"},{"issue":"1","key":"1634_CR606","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/imr.12527","volume":"276","author":"HL Matlung","year":"2017","unstructured":"Matlung HL, Szilagyi K, Barclay NA, van den Berg TK. The CD47-SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer. Immunol Rev. \n2017;276(1):145\u201364.","journal-title":"Immunol Rev"},{"issue":"17","key":"1634_CR607","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1073\/pnas.1121629109","volume":"109","author":"B Edris","year":"2012","unstructured":"Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci U S A. 2012;109(17):6656\u201361.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1634_CR608","doi-asserted-by":"publisher","first-page":"1027235","DOI":"10.3389\/fimmu.2022.1027235","volume":"13","author":"J Son","year":"2022","unstructured":"Son J, Hsieh RC, Lin HY, Krause KJ, Yuan Y, Biter AB, et al. Inhibition of the CD47-SIRP\u03b1 axis for cancer therapy: a systematic review and meta-analysis of emerging clinical data. Front Immunol. 2022;13:1027235.","journal-title":"Front Immunol"},{"issue":"5","key":"1634_CR609","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1021\/acs.molpharmaceut.2c00073","volume":"19","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhao C, Liu Y, Wang C, Jiang H, Hu Y, et al. Recent advances of tumor therapy based on the CD47-SIRP\u03b1 axis. Mol Pharm. 2022;19(5):1273\u201393.","journal-title":"Mol Pharm"},{"issue":"381","key":"1634_CR610","doi-asserted-by":"publisher","first-page":"eaaf2968","DOI":"10.1126\/scitranslmed.aaf2968","volume":"9","author":"S Gholamin","year":"2017","unstructured":"Gholamin S, Mitra SS, Feroze AH, Liu J, Kahn SA, Zhang M, et al. Disrupting the CD47-SIRP\u03b1 anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci Transl Med. 2017;9(381):eaaf2968.","journal-title":"Sci Transl Med."},{"issue":"3","key":"1634_CR611","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00277-021-04734-2","volume":"101","author":"AM Zeidan","year":"2022","unstructured":"Zeidan AM, DeAngelo DJ, Palmer J, Seet CS, Tallman MS, Wei X, et al. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Ann Hematol. 2022;101(3):557\u201369.","journal-title":"Ann Hematol"},{"key":"1634_CR612","doi-asserted-by":"crossref","unstructured":"Wan B, Fang X, Li S, Shi W, Li H, Bellovin D, et al. Abstract 498: ZL-1201, a differentiated CD47 therapeutic antibody with improved hematological safety profile. Proceedings of the American Association for Cancer Research (AACR) Annual Meeting; Philadelphia (PA), USA.: Cancer Research; 2021.","DOI":"10.1158\/1538-7445.AM2021-498"},{"issue":"3","key":"1634_CR613","doi-asserted-by":"publisher","first-page":"109844","DOI":"10.1016\/j.celrep.2021.109844","volume":"37","author":"M Binnewies","year":"2021","unstructured":"Binnewies M, Pollack JL, Rudolph J, Dash S, Abushawish M, Lee T, et al. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell Rep. 2021;37(3):109844.","journal-title":"Cell Rep"},{"issue":"6","key":"1634_CR614","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.medj.2021.05.001","volume":"2","author":"M Molgora","year":"2021","unstructured":"Molgora M, Colonna M. Turning enemies into allies-reprogramming tumor-associated macrophages for cancer therapy. Med. 2021;2(6):666\u201381.","journal-title":"Med"},{"key":"1634_CR615","doi-asserted-by":"publisher","first-page":"984193","DOI":"10.3389\/fonc.2022.984193","volume":"12","author":"EM Wolf","year":"2022","unstructured":"Wolf EM, Fingleton B, Hasty AH. The therapeutic potential of TREM2 in cancer. Front Oncol. 2022;12:984193.","journal-title":"Front Oncol"},{"issue":"95","key":"1634_CR616","doi-asserted-by":"publisher","first-page":"eadi5374","DOI":"10.1126\/sciimmunol.adi5374","volume":"9","author":"B Di Luccia","year":"2024","unstructured":"Di Luccia B, Molgora M, Khantakova D, Jaeger N, Chang HW, Czepielewski RS, et al. TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti-PD-1 tumor immunotherapy. Sci Immunol. 2024;9(95):eadi5374.","journal-title":"Sci Immunol."},{"key":"1634_CR617","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.716710","volume":"12","author":"H Q iu","year":"2021","unstructured":"Qiu H, Shao Z, Wen X, Jiang J, Ma Q, Wang Y, et al. TREM2: keeping pace with immune checkpoint inhibitors in cancer immunotherapy. Front Immunol. 2021;12: 716710.","journal-title":"Front Immunol"},{"issue":"6","key":"1634_CR618","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.cell.2020.05.003","volume":"181","author":"A Deczkowska","year":"2020","unstructured":"Deczkowska A, Weiner A, Amit I. The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell. 2020;181(6):1207\u201317.","journal-title":"Cell"},{"issue":"4","key":"1634_CR619","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","volume":"182","author":"M Molgora","year":"2020","unstructured":"Molgora M, Esaulova E, Vermi W, Hou J, Chen Y, Luo J, et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-pd-1 immunotherapy. Cell. 2020;182(4):886-900.e17.","journal-title":"Cell"},{"issue":"4","key":"1634_CR620","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.cell.2020.06.032","volume":"182","author":"Y Katzenelenbogen","year":"2020","unstructured":"Katzenelenbogen Y, Sheban F, Yalin A, Yofe I, Svetlichnyy D, Jaitin DA, et al. Coupled scRNA-Seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer. Cell. 2020;182(4):872-85.e19.","journal-title":"Cell"},{"issue":"16","key":"1634_CR621","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1200\/JCO.2022.40.16_suppl.2648","volume":"40","author":"A Patnaik","year":"2022","unstructured":"Patnaik A, Hamilton EP, Winer IS, Tan W, Hubbard JM, Schenk EL, et al. A phase 1a dose-escalation study of PY314, a TREM2 (triggering receptor expressed on macrophages 2) targeting monoclonal antibody. J Clin Oncology. 2022;40(16):2648.","journal-title":"J Clin Oncology."},{"issue":"11","key":"1634_CR622","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41577-022-00701-8","volume":"22","author":"SM Lanahan","year":"2022","unstructured":"Lanahan SM, Wymann MP, Lucas CL. The role of PI3K\u03b3 in the immune system: new insights and translational implications. Nat Rev Immunol. 2022;22(11):687\u2013700.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1634_CR623","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138.","journal-title":"Mol Cancer"},{"issue":"7629","key":"1634_CR624","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature19834","volume":"539","author":"MM Kaneda","year":"2016","unstructured":"Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, et al. PI3K\u03b3 is a molecular switch that controls immune suppression. Nature. 2016;539(7629):437\u201342.","journal-title":"Nature"},{"issue":"8","key":"1634_CR625","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1007\/s10238-023-01227-6","volume":"23","author":"S Heller","year":"2023","unstructured":"Heller S, Glaeske S, Gluske K, Paul J, B\u00f6hme A, Janzer A, et al. Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses. Clin Exp Med. 2023;23(8):5445\u201361.","journal-title":"Clin Exp Med"},{"issue":"6","key":"1634_CR626","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijo.2024.5648","volume":"64","author":"P Su","year":"2024","unstructured":"Su P, Li O, Ke K, Jiang Z, Wu J, Wang \nY, et al. Targeting tumor-associated macrophages: critical players in tumor progression and therapeutic strategies (Review). Int J Oncol. 2024;64(6):1\u201321.","journal-title":"Int J Oncol"},{"issue":"7629","key":"1634_CR627","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature20554","volume":"539","author":"O De Henau","year":"2016","unstructured":"De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells. Nature. 2016;539(7629):443\u20137.","journal-title":"Nature"},{"issue":"12","key":"1634_CR628","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-22-3313","volume":"29","author":"DS Hong","year":"2023","unstructured":"Hong DS, Postow M, Chmielowski B, Sullivan R, Patnaik A, Cohen EEW, et al. Eganelisib, a First-in-Class PI3K\u03b3 Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1\/1b MARIO-1 Trial. Clin Cancer Res. 2023;29(12):2210\u20139.","journal-title":"Clin Cancer Res"},{"key":"1634_CR629","doi-asserted-by":"publisher","first-page":"108114","DOI":"10.1016\/j.pharmthera.2022.108114","volume":"235","author":"S Joshi","year":"2022","unstructured":"Joshi S, Sharabi A. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy. Pharmacol Ther. 2022;235:108114.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"1634_CR630","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/2326-6066.CIR-15-0193","volume":"4","author":"J Weber","year":"2016","unstructured":"Weber J, Gibney G, Kudchadkar R, Yu B, Cheng P, Martinez AJ, et al. Phase I\/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol Res. 2016;4(4):345\u201353.","journal-title":"Cancer Immunol Res"},{"key":"1634_CR631","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3389\/fimmu.2018.01310","volume":"9","author":"R Weber","year":"2018","unstructured":"Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, et al. Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front Immunol. 2018;9:1310.","journal-title":"Front Immunol"},{"issue":"6","key":"1634_CR632","doi-asserted-by":"publisher","first-page":"e1431082","DOI":"10.1080\/2162402X.2018.1431082","volume":"7","author":"L-H Tai","year":"2018","unstructured":"Tai L-H, Alkayyal AA, Leslie AL, Sahi S, Bennett S, Tanese de Souza C, et al. Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of natural killer cell cytotoxicity. Oncoimmunology. 2018;7(6):e1431082.","journal-title":"Oncoimmunology."},{"issue":"12","key":"1634_CR633","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1084\/jem.20061104","volume":"203","author":"P Serafini","year":"2006","unstructured":"Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203(12):2691\u2013702.","journal-title":"J Exp Med"},{"issue":"3","key":"1634_CR634","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3390\/cells9030561","volume":"9","author":"AMK Law","year":"2020","unstructured":"Law AMK, Valdes-Mora F, Gallego-Ortega D. Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells. 2020;9(3):561.","journal-title":"Cells"},{"issue":"5","key":"1634_CR635","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.ccell.2017.10.005","volume":"32","author":"V Kumar","year":"2017","unstructured":"Kumar V, Donthireddy L, Marvel D, Condamine T, Wang F, Lavilla-Alonso S, et al. Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors. Cancer Cell. 2017;32(5):654-68.e5.","journal-title":"Cancer Cell"},{"issue":"9","key":"1634_CR636","doi-asserted-by":"publisher","first-page":"e1326440","DOI":"10.1080\/2162402X.2017.1326440","volume":"6","author":"JC Hassel","year":"2017","unstructured":"Hassel JC, Jiang H, Bender C, Winkler J, Sevko A, Shevchenko I, et al. Tadalafil has biologic activity in human melanoma Results of a pilot trial with Ta dalafil in patients with metastatic melanoma (TaMe). Oncoimmunology. 2017;6(9):e1326440.","journal-title":"Oncoimmunology."},{"issue":"1","key":"1634_CR637","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1158\/1078-0432.CCR-14-1711","volume":"21","author":"DT Weed","year":"2015","unstructured":"Weed DT, Vella JL, Reis IM, De la Fuente AC, Gomez C, Sargi Z, et al. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2015;21(1):39\u201348.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1634_CR638","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","volume":"29","author":"CW Steele","year":"2016","unstructured":"Steele CW, Karim SA, Leach JD, Bailey P, Upstill-Goddard R, Rishi L, et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell. 2016;29(6):832\u201345.","journal-title":"Cancer Cell"},{"issue":"6282","key":"1634_CR639","first-page":"145","volume":"352","author":"T T\u00fcting","year":"2016","unstructured":"T\u00fcting T, de Visser KE. Cancer. How neutrophils promote metastasis Science. 2016;352(6282):145\u20136.","journal-title":"How neutrophils promote metastasis Science"},{"issue":"1","key":"1634_CR640","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-021-01187-y","volume":"14","author":"S Xiong","year":"2021","unstructured":"Xiong S, Dong L, Cheng L. Neutrophils in cancer carcinogenesis and metastasis. J Hematol Oncol. 2021;14(1):173.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1634_CR641","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12672-024-01010-3","volume":"15","author":"W Jia","year":"2024","unstructured":"Jia W, Mao Y, Luo Q, Wu J, Guan Q. Targeting neutrophil elastase is a promising direction for future cancer treatment. Discov Oncol. 2024;15(1):167.","journal-title":"Discov Oncol"},{"issue":"1","key":"1634_CR642","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-024-02004-z","volume":"23","author":"X Huang","year":"2024","unstructured":"Huang X, Nepovimova E, Adam V, Sivak L, Heger Z, Valko M, et al. Neutrophils in cancer immunotherapy: friends or foes? Mol Cancer. 2024;23(1):107.","journal-title":"Mol Cancer"},{"issue":"7","key":"1634_CR643","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrc.2016.52","volume":"16","author":"SB Coffelt","year":"2016","unstructured":"Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer. 2016;16(7):431\u201346.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1634_CR644","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41573-019-0054-z","volume":"19","author":"T N\u00e9meth","year":"2020","unstructured":"N\u00e9meth T, Sperandio M, M\u00f3csai A. Neutrophils as emerging therapeutic targets. Nat Rev Drug Discov. 2020;19(4):253\u201375.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"1634_CR645","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ccell.2023.01.002","volume":"41","author":"IL Linde","year":"2023","unstructured":"Linde IL, Prestwood TR, Qiu J, Pilarowski G, Linde MH, Zhang X, et al. Neutrophil-activating therapy for the treatment of cancer. Cancer Cell. 2023;41(2):356-72.e10.","journal-title":"Cancer Cell"},{"issue":"1","key":"1634_CR646","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/cr.2016.157","volume":"27","author":"RL Sabado","year":"2017","unstructured":"Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 2017;27(1):74\u201395.","journal-title":"Cell Res"},{"issue":"6342","key":"1634_CR647","doi-asserted-by":"publisher","first-page":"eaag3009","DOI":"10.1126\/science.aag3009","volume":"356","author":"P See","year":"2017","unstructured":"See P, Dutertre CA, Chen J, G\u00fcnther P, McGovern N, Irac SE, et al. Mapping the human DC lineage through the integration of high-dimensional techniques. Science. 2017;356(6342):eaag3009.","journal-title":"Science"},{"issue":"4","key":"1634_CR648","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.3390\/ijms24044253","volume":"24","author":"D Galati","year":"2023","unstructured":"Galati D, Zanotta S. Dendritic cell and cancer therapy. Int J Mol Sci. 2023;24(4):4253.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1634_CR649","doi-asserted-by":"publisher","first-page":"5408","DOI":"10.1038\/s41467-019-13368-y","volume":"10","author":"CR Perez","year":"2019","unstructured":"Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat Commun. 2019;10(1):5408.","journal-title":"Nat Commun"},{"key":"1634_CR650","doi-asserted-by":"publisher","first-page":"1391046","DOI":"10.3389\/fmolb.2024.1391046","volume":"11","author":"W Qian","year":"2024","unstructured":"Qian W, Ye J, Xia S. DNA sensing of dendritic cells in cancer immunotherapy. Front Mol Biosci. 2024;11:1391046.","journal-title":"Front Mol Biosci"},{"key":"1634_CR651","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.733800","volume":"13","author":"YH Gupta","year":"2022","unstructured":"Gupta YH, Khanom A, Acton SE. Control of dendritic cell function within the tumour microenvironment. Front Immunol. 2022;13: 733800.","journal-title":"Front Immunol"},{"issue":"1","key":"1634_CR652","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7\u201324.","journal-title":"Nat Rev Immunol"},{"key":"1634_CR653","doi-asserted-by":"publisher","first-page":"1058963","DOI":"10.3389\/fimmu.2022.1058963","volume":"13","author":"SM Lellahi","year":"2022","unstructured":"Lellahi SM, Azeem W, Hua Y, Gabriel B, Paulsen Rye K, Reikvam H, et al. GM-CSF, Flt3-L and IL-4 affect viability and function of conventional dendritic cell types 1 and 2. Front Immunol. 2022;13:1058963.","journal-title":"Front Immunol"},{"issue":"2","key":"1634_CR654","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1182\/blood-2007-03-079681","volume":"111","author":"D Metcalf","year":"2008","unstructured":"Metcalf D. Hematopoietic cytokines. Blood. 2008;111(2):485\u201391.","journal-title":"Blood"},{"issue":"7","key":"1634_CR655","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2016.64","volume":"48","author":"IS Hong","year":"2016","unstructured":"Hong IS. Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types. Exp Mol Med. 2016;48(7): e242.","journal-title":"Exp Mol Med"},{"issue":"19","key":"1634_CR656","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1200\/JCO.2007.13.9048","volume":"26","author":"AI Daud","year":"2008","unstructured":"Daud AI, Mirza N, Lenox B, Andrews S, Urbas P, Gao GX, et al. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol. 2008;26(19):3235\u201341.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1634_CR657","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/CJI.0b013e3181a7d60d","volume":"32","author":"LE Spitler","year":"2009","unstructured":"Spitler LE, Weber RW, Allen RE, Meyer J, Cruickshank S, Garbe E, et al. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma. J Immunother. 2009;32(6):632\u20137.","journal-title":"J Immunother"},{"issue":"1","key":"1634_CR658","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10549-022-06562-y","volume":"194","author":"KS Anderson","year":"2022","unstructured":"Anderson KS, Erick TK, Chen M, Daley H, Campbell M, Colson Y, et al. The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers. Breast Cancer Res Treat. 2022;194(1):65\u201378.","journal-title":"Breast Cancer Res Treat"},{"issue":"24","key":"1634_CR659","doi-asserted-by":"publisher","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-21-1916","volume":"27","author":"L Biavati","year":"2021","unstructured":"Biavati L, Huff CA, Ferguson A, Sidorski A, Stevens MA, Rudraraju L, et al. An allogeneic multiple myeloma GM-CSF-secreting vaccine with lenalidomide induces long-term immunity and durable clinical responses in patients in near complete remission. Clin Cancer Res. 2021;27(24):6696\u2013708.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1634_CR660","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/annonc\/mdl158","volume":"18","author":"G Parmiani","year":"2007","unstructured":"Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol. 2007;18(2):226\u201332.","journal-title":"Ann Oncol"},{"issue":"14","key":"1634_CR661","doi-asserted-by":"publisher","first-page":"12369","DOI":"10.18632\/oncotarget.3682","volume":"6","author":"I Dufait","year":"2015","unstructured":"Dufait I, Schwarze JK, Liechtenstein T, Leonard W, Jiang H, Escors D, et al. Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer. Oncotarget. 2015;6(14):12369\u201382.","journal-title":"Oncotarget"},{"issue":"25","key":"1634_CR662","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780\u20138.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1634_CR663","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/imcb.12484","volume":"99","author":"KR Wilson","year":"2021","unstructured":"Wilson KR, Villadangos JA, Mintern JD. Dendritic cell Flt3 - regulation, roles and repercussions for immunotherapy. Immunol Cell Biol. 2021;99(9):962\u201371.","journal-title":"Immunol Cell Biol"},{"key":"1634_CR664","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.699128","volume":"12","author":"MS Molina","year":"2021","unstructured":"Molina MS, Hoffman EA, Stokes J, Kummet N, Smith KA, Baker F, et al. Regulatory dendritic cells induced by bendamustine are associated With enhanced Flt3 expression and alloreactive T-cell death. Front Immunol. 2021;12: 699128.","journal-title":"Front Immunol"},{"issue":"4","key":"1634_CR665","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","volume":"44","author":"H Salmon","year":"2016","unstructured":"Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, et al. Expansion and activation of CD103(+) Dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity. 2016;44(4):924\u201338.","journal-title":"Immunity"},{"issue":"7","key":"1634_CR666","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3390\/cancers13071525","volume":"13","author":"FJ Cueto","year":"2021","unstructured":"Cueto FJ, Sancho D. The Flt3L\/Flt3 axis in dendritic cell biology and cancer immunotherapy. Cancers (Basel). 2021;13(7):1525.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1634_CR667","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11912-020-00993-w","volume":"23","author":"V Agrawal","year":"2020","unstructured":"Agrawal V, Benjamin KT, Ko EC. Radiotherapy and immunotherapy combinations for lung cancer. Curr Oncol Rep. 2020;23(1):4.","journal-title":"Curr Oncol Rep"},{"issue":"15","key":"1634_CR668","doi-asserted-by":"publisher","first-page":"9618","DOI":"10.1200\/JCO.2020.38.15_suppl.9618","volume":"38","author":"N Ohri","year":"2020","unstructured":"Ohri N, Halmos B, Garg M, Levsky JM, Cheng H, Gucalp RA, et al. FLT3 ligand (CDX-301) and stereotactic radiotherapy for advanced non-small cell lung cancer (Abstract). J Clin Oncology. 2020;38(15):9618.","journal-title":"J Clin Oncology."},{"issue":"2","key":"1634_CR669","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4049\/jimmunol.1701024","volume":"200","author":"PM Santos","year":"2018","unstructured":"Santos PM, Butterfield LH. Dendritic cell-based cancer vaccines. J Immunol. 2018;200(2):443\u20139.","journal-title":"J Immunol"},{"key":"1634_CR670","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.3389\/fimmu.2019.02303","volume":"10","author":"L Castiello","year":"2019","unstructured":"Castiello L, Aric\u00f2 E, D\u2019Agostino G, Santodonato L, Belardelli F. Vaccination by direct dendritic cell inoculation: the coming of age of an old idea? Front Immunol. 2019;10:2303.","journal-title":"Front Immunol"},{"issue":"4","key":"1634_CR671","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/vaccines8040706","volume":"8","author":"C Fu","year":"2020","unstructured":"Fu C, Zhou L, Mi QS, Jiang A. DC-based vaccines for cancer immunotherapy. Vaccines (Basel). 2020;8(4):706.","journal-title":"Vaccines (Basel)."},{"issue":"17","key":"1634_CR672","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.3390\/cells12172147","volume":"12","author":"KW Lee","year":"2023","unstructured":"Lee KW, Yam JWP, Mao X. Dendritic cell vaccines: a shift from conventional approach to new generations. Cells. 2023;12(17):2147.","journal-title":"Cells"},{"issue":"1","key":"1634_CR673","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","volume":"11","author":"J Yu","year":"2022","unstructured":"Yu J, Sun H, Cao W, Song Y, Jiang Z. Research progress on dendritic cell vaccines in cancer immunotherapy. Exp Hematol Oncol. 2022;11(1):3.","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"1634_CR674","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/jleuko\/qiad062","volume":"114","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Gao C, Liu L, Wang L, Song Z. The development and function of human monocyte-derived dendritic cells regulated by metabolic reprogramming. J Leukoc Biol. 2023;114(3):212\u201322.","journal-title":"J Leukoc Biol"},{"issue":"3","key":"1634_CR675","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3390\/cancers12030590","volume":"12","author":"AV Baldin","year":"2020","unstructured":"Baldin AV, Savvateeva LV, Bazhin AV, Zamyatnin AA. Dendritic cells in anticancer vaccination: rationale for ex vivo loading or in vivo targeting. Cancers (Basel). 2020;12(3):590.","journal-title":"Cancers (Basel)."},{"key":"1634_CR676","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.omto.2019.03.007","volume":"13","author":"RA Belderbos","year":"2019","unstructured":"Belderbos RA, Aerts JGJV, Vroman H. Enhancing dendritic cell therapy in solid tumors with immunomodulating conventional treatment. Mol Ther Oncolytics. 2019;13:67\u201381.","journal-title":"Mol Ther Oncolytics"},{"key":"1634_CR677","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3389\/fimmu.2019.00766","volume":"10","author":"B Mastelic-Gavillet","year":"2019","unstructured":"Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon PO, Kandalaft LE. Personalized dendritic cell vaccines-recent breakthroughs and encouraging clinical results. Front Immunol. 2019;10:766.","journal-title":"Front Immunol"},{"issue":"1","key":"1634_CR678","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41423-021-00741-5","volume":"19","author":"TL Murphy","year":"2022","unstructured":"Murphy TL, Murphy KM. Dendritic cells in cancer immunology. Cell Mol Immunol. 2022;19(1):3\u201313.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"1634_CR679","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.cell.2019.09.035","volume":"179","author":"CC Brown","year":"2019","unstructured":"Brown CC, Gudjonson H, Pritykin Y, Deep D, Lavall\u00e9e VP, Mendoza A, et al. Transcriptional basis of mouse and human dendritic cell heterogeneity. Cell. 2019;179(4):846-63.e24.","journal-title":"Cell"},{"key":"1634_CR680","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114954","volume":"164","author":"S Najafi","year":"2023","unstructured":"Najafi S, Mortezaee K. Advances in dendritic cell vaccination therapy of cancer. Biomed Pharmacother. 2023;164: 114954.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"1634_CR681","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","volume":"15","author":"KC Valkenburg","year":"2018","unstructured":"Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018;15(6):366\u201381.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"1634_CR682","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","volume":"55","author":"D Yang","year":"2023","unstructured":"Yang D, Liu J, Qian H, Zhuang Q. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp Mol Med. 2023;55(7):1322\u201332.","journal-title":"Exp Mol Med"},{"key":"1634_CR683","doi-asserted-by":"publisher","first-page":"1113378","DOI":"10.3389\/fphar.2023.1113378","volume":"14","author":"C Zhang","year":"2023","unstructured":"Zhang C, Fei Y, Wang H, Hu S, Liu C, Hu R, et al. CAFs orchestrates tumor immune microenvironment-A new target in cancer therapy? Front Pharmacol. 2023;14:1113378.","journal-title":"Front Pharmacol"},{"key":"1634_CR684","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.2147\/IJN.S451151","volume":"19","author":"M Wang","year":"2024","unstructured":"Wang M, Xue W, Yuan H, Wang Z, Yu L. Nano-drug delivery systems targeting CAFs: a promising treatment for pancreatic cancer. Int J Nanomedicine. 2024;19:2823\u201349.","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"1634_CR685","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1038\/s41467-024-46504-4","volume":"15","author":"MT Broz","year":"2024","unstructured":"Broz MT, Ko EY, Ishaya K, Xiao J, De Simone M, Hoi XP, et al. Metabolic targeting of cancer associated fibroblasts overcomes T-cell exclusion and chemoresistance in soft-tissue sarcomas. Nat Commun. 2024;15(1):2498.","journal-title":"Nat Commun"},{"key":"1634_CR686","doi-asserted-by":"publisher","first-page":"1343523","DOI":"10.3389\/fmolb.2024.1343523","volume":"11","author":"O Piwocka","year":"2024","unstructured":"Piwocka O, Piotrowski I, Suchorska WM, Kulcenty K. Dynamic interactions in the tumor niche: how the cross-talk between CAFs and the tumor microenvironment impacts resistance to therapy. Front Mol Biosci. 2024;11:1343523.","journal-title":"Front Mol Biosci"},{"issue":"10","key":"1634_CR687","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1038\/s41416-024-02639-1","volume":"130","author":"M Akai","year":"2024","unstructured":"Akai M, Noma K, Kato T, Nishimura S, Matsumoto H, Kawasaki K, et al. Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity. Br J Cancer. 2024;130(10):1647\u201358.","journal-title":"Br J Cancer"},{"issue":"1","key":"1634_CR688","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12943-022-01670-1","volume":"21","author":"M Xu","year":"2022","unstructured":"Xu M, Zhang T, Xia R, Wei Y, Wei X. Targeting the tumor stroma for cancer therapy. Mol Cancer. 2022;21(1):208.","journal-title":"Mol Cancer"},{"issue":"2","key":"1634_CR689","doi-asserted-by":"publisher","first-page":"465","DOI":"10.7150\/ijbs.72218","volume":"19","author":"H Wu","year":"2023","unstructured":"Wu H, Xiang Z, Huang G, He Q, Song J, Dou R, et al. BGN\/FAP\/STAT3 positive feedback loop mediated mutual interaction between tumor cells and mesothelial cells contributes to peritoneal metastasis of gastric cancer. Int J Biol Sci. 2023;19(2):465\u201383.","journal-title":"Int J Biol Sci"},{"issue":"13","key":"1634_CR690","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1158\/0008-5472.CAN-13-2259","volume":"74","author":"F Bruzzese","year":"2014","unstructured":"Bruzzese F, H\u00e4ggl\u00f6f C, Leone A, Sj\u00f6berg E, Roca MS, Kiflemariam S, et al. Local and systemic protumorigenic effects of cancer-associated fibroblast-derived GDF15. Cancer Res. 2014;74(13):3408\u201317.","journal-title":"Cancer Res"},{"issue":"7754","key":"1634_CR691","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41586-019-1130-6","volume":"569","author":"Y Shi","year":"2019","unstructured":"Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, et al. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature. 2019;569(7754):131\u20135.","journal-title":"Nature"},{"issue":"2","key":"1634_CR692","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discovery. 2019;18(2):99\u2013115.","journal-title":"Nat Rev Drug Discovery"},{"issue":"14","key":"1634_CR693","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-15-2973","volume":"76","author":"X Yang","year":"2016","unstructured":"Yang X, Lin Y, Shi Y, Li B, Liu W, Yin W, et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res. 2016;76(14):4124\u201335.","journal-title":"Cancer Res"},{"issue":"9","key":"1634_CR694","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","volume":"10","author":"Y Kieffer","year":"2020","unstructured":"Kieffer Y, Hocine HR, Gentric G, Pelon F, Bernard C, Bourachot B, et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 2020;10(9):1330\u201351.","journal-title":"Cancer Discov"},{"issue":"7","key":"1634_CR695","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1172\/JCI26532","volume":"116","author":"M Loeffler","year":"2006","unstructured":"Loeffler M, Kr\u00fcger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Investig. 2006;116(7):1955\u201362.","journal-title":"J Clin Investig"},{"issue":"8","key":"1634_CR696","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1038\/mt.2013.110","volume":"21","author":"S Kakarla","year":"2013","unstructured":"Kakarla S, Chow KK, Mata M, Shaffer DR, Song X-T, Wu M-F, et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther. 2013;21(8):1611\u201320.","journal-title":"Mol Ther"},{"issue":"2","key":"1634_CR697","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","volume":"2","author":"LC Wang","year":"2014","unstructured":"Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res. 2014;2(2):154\u201366.","journal-title":"Cancer Immunol Res"},{"issue":"14","key":"1634_CR698","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1158\/0008-5472.CAN-14-3041","volume":"75","author":"A Lo","year":"2015","unstructured":"Lo A, Wang LS, Scholler J, Monslow J, Avery D, Newick K, et al. Tumor-promoting desmoplasia is disrupted by depleting fap-expressing stromal cells. Cancer Res. 2015;75(14):2800\u201310.","journal-title":"Cancer Res"},{"issue":"5","key":"1634_CR699","first-page":"1639","volume":"9","author":"AM Scott","year":"2003","unstructured":"Scott AM, Wiseman G, Welt S, Adjei A, Lee F-T, Hopkins W, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003;9(5):1639\u201347.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1634_CR700","first-page":"44","volume":"26","author":"RD Hofheinz","year":"2003","unstructured":"Hofheinz RD, al-Batran SE, Hartmann F, Hartung G, J\u00e4ger D, Renner C, et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie. 2003;26(1):44\u20138.","journal-title":"Onkologie"},{"issue":"2","key":"1634_CR701","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/cancers15020335","volume":"15","author":"Y Shintani","year":"2023","unstructured":"Shintani Y, Kimura T, Funaki S, Ose N, Kanou T, Fukui E. Therapeutic targeting of cancer-associated fibroblasts in the non-small cell lung cancer tumor microenvironment. Cancers (Basel). 2023;15(2):335.","journal-title":"Cancers (Basel)."},{"issue":"5","key":"1634_CR702","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101532","volume":"5","author":"Y Mori","year":"2024","unstructured":"Mori Y, Okimoto Y, Sakai H, Kanda Y, Ohata H, Shiokawa D, et al. Targeting PDGF signaling of cancer-associated fibroblasts blocks feedback activation of HIF-1\u03b1 and tumor progression of clear cell ovarian cancer. Cell Rep Med. 2024;5(5): 101532.","journal-title":"Cell Rep Med"},{"issue":"4","key":"1634_CR703","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s12079-022-00673-3","volume":"16","author":"C Zeltz","year":"2022","unstructured":"Zeltz C, Navab R, Heljasvaara R, Kusche-Gullberg M, Lu N, Tsao MS, et al. Integrin \u03b111\u03b21 in tumor fibrosis: more than just another cancer-associated fibroblast biomarker? J Cell Commun Signal. 2022;16(4):649\u201360.","journal-title":"J Cell Commun Signal"},{"issue":"1","key":"1634_CR704","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12964-023-01338-3","volume":"22","author":"C Su","year":"2024","unstructured":"Su C, Mo J, Dong S, Liao Z, Zhang B, Zhu P. Integrin\u03b2-1 in disorders and cancers: molecular mechanisms and therapeutic targets. Cell Commun Signal. 2024;22(1):71.","journal-title":"Cell Commun Signal"},{"key":"1634_CR705","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2147\/OTT.S318332","volume":"15","author":"N Sayegh","year":"2022","unstructured":"Sayegh N, Tripathi N, Agarwal N, Swami U. Clinical evidence and selecting patients for treatment with erdafitinib in advanced urothelial carcinoma. Onco Targets Ther. 2022;15:1047\u201355.","journal-title":"Onco Targets Ther"},{"issue":"11","key":"1634_CR706","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s40265-018-0948-9","volume":"78","author":"JE Frampton","year":"2018","unstructured":"Frampton JE, Basset-S\u00e9guin N. Vismodegib: a review in advanced basal cell carcinoma. Drugs. 2018;78(11):1145\u201356.","journal-title":"Drugs"},{"key":"1634_CR707","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114491","volume":"161","author":"P Pandey","year":"2023","unstructured":"Pandey P, Khan F, Upadhyay TK, Seungjoon M, Park MN, Kim B. New insights about the PDGF\/PDGFR signaling pathway as a promising target to develop cancer therapeutic strategies. Biomed Pharmacother. 2023;161: 114491.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"1634_CR708","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S1470-2045(07)70285-1","volume":"8","author":"O Rixe","year":"2007","unstructured":"Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007;8(11):975\u201384.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1634_CR709","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-019-0770-1","volume":"12","author":"T Liu","year":"2019","unstructured":"Liu T, Han C, Wang S, Fang P, Ma Z, Xu L, et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol. 2019;12(1):86.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1634_CR710","doi-asserted-by":"publisher","first-page":"17444","DOI":"10.1038\/s41598-020-74368-3","volume":"10","author":"L Gorchs","year":"2020","unstructured":"Gorchs L, Ahmed S, Mayer C, Knauf A, Fern\u00e1ndez Moro C, Svensson M, et al. The vitamin D analogue calcipotriol promotes an anti-tumorigenic phenotype of human pancreatic CAFs but reduces T cell mediated immunity. Sci Rep. 2020;10(1):17444.","journal-title":"Sci Rep"},{"key":"1634_CR711","doi-asserted-by":"publisher","first-page":"1089068","DOI":"10.3389\/fcell.2023.1089068","volume":"11","author":"M Sarkar","year":"2023","unstructured":"Sarkar M, Nguyen T, Gundre E, Ogunlusi O, El-Sobky M, Giri B, et al. Cancer-associated fibroblasts: the chief architect in the tumor microenvironment. Front Cell Dev Biol. 2023;11:1089068.","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"1634_CR712","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000056","volume":"10","author":"RK Kelley","year":"2019","unstructured":"Kelley RK, Gane E, Assenat E, Siebler J, Galle PR, Merle P, et al. A phase 2 study of galunisertib (TGF-\u03b21 receptor type I inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma. Clin Transl Gastroenterol. 2019;10(7): e00056.","journal-title":"Clin Transl Gastroenterol"},{"issue":"9","key":"1634_CR713","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/S1470-2045(22)00446-6","volume":"23","author":"T Yamazaki","year":"2022","unstructured":"Yamazaki T, Gunderson AJ, Gilchrist M, Whiteford M, Kiely MX, Hayman A, et al. Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial. Lancet Oncol. 2022;23(9):1189\u2013200.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1634_CR714","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1182\/blood.V110.11.445.445","volume":"110","author":"J DiPersio","year":"2007","unstructured":"DiPersio J, Stadtmauer EA, Nademanee AP, Stiff P, Micallef I, Angell J, et al. A phase III multicenter randomized, double-blind placebo-controlled comparative trial of AMD3100 (Plerixafor)+G-CSF vs G-CSF+placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation (Abstract). Blood. 2007;110(11):445.","journal-title":"Blood"},{"issue":"28","key":"1634_CR715","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","volume":"27","author":"JF DiPersio","year":"2009","unstructured":"DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2009;27(28):4767\u201373.","journal-title":"J Clin Oncol"},{"key":"1634_CR716","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15","author":"R Kumar","year":"2014","unstructured":"Kumar R, Mateo J, Smith AD, Khan KH, Ruddle R, Swales KE, et al. First-in-human, first-in-class phase 1 study of a novel oral multi-AGC kinase inhibitor AT13148 in patients (pts) with advanced solid tumors (Abstract). J Clin Oncology. 2014. https:\/\/doi.org\/10.1200\/jco.2014.32.15.","journal-title":"J Clin Oncology."},{"issue":"15","key":"1634_CR717","doi-asserted-by":"publisher","first-page":"6026","DOI":"10.1200\/JCO.2021.39.15_suppl.6026","volume":"39","author":"L Ye","year":"2021","unstructured":"Ye L, Zhang L, Li R, Zhu G. Preliminary results of the efficacy and safety of all-trans retinoic acid combined with low-dose apatinib in the treatment of patients with recurrent\/metastatic adenoid cystic carcinoma of the head and neck (Abstract). J Clin Oncology. 2021;39(15):6026.","journal-title":"J Clin Oncology."},{"issue":"6","key":"1634_CR718","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","volume":"35","author":"U Platzbecker","year":"2017","unstructured":"Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017;35(6):605\u201312.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1634_CR719","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.ccell.2020.09.015","volume":"38","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Bian S, Zhou X, Cui Y, Wang W, Wen L, et al. Single-cell multiomics sequencing reveals prevalent genomic alterations in tumor stromal cells of human colorectal cancer. Cancer Cell. 2020;38(6):818-28.e5.","journal-title":"Cancer Cell"},{"issue":"4","key":"1634_CR720","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.cell.2018.01.009","volume":"172","author":"S Su","year":"2018","unstructured":"Su S, Chen J, Yao H, Liu J, Yu S, Lao L, et al. CD10+GPR77+ cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell. 2018;172(4):841-56.e16.","journal-title":"Cell"},{"issue":"9","key":"1634_CR721","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-20-0329","volume":"10","author":"GM Alicea","year":"2020","unstructured":"Alicea GM, Rebecca VW, Goldman AR, Fane ME, Douglass SM, Behera R, et al. Changes in aged fibroblast lipid metabolism induce age-dependent melanoma cell resistance to targeted therapy via the fatty acid transporter FATP2. Cancer Discov. 2020;10(9):1282\u201395.","journal-title":"Cancer Discov"},{"issue":"5","key":"1634_CR722","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-022-00410-w","volume":"21","author":"L Cheng","year":"2022","unstructured":"Cheng L, Hill AF. Therapeutically harnessing extracellular vesicles. Nat Rev Drug Discov. 2022;21(5):379\u201399.","journal-title":"Nat Rev Drug Discov"},{"key":"1634_CR723","doi-asserted-by":"publisher","first-page":"1200249","DOI":"10.3389\/fimmu.2023.1200249","volume":"14","author":"Y Li","year":"2023","unstructured":"Li Y, Liu F. The extracellular vesicles targeting tumor microenvironment: a promising therapeutic strategy for melanoma. Front Immunol. 2023;14:1200249.","journal-title":"Front Immunol"},{"key":"1634_CR724","doi-asserted-by":"publisher","first-page":"1376962","DOI":"10.3389\/fimmu.2024.1376962","volume":"15","author":"Z Huang","year":"2024","unstructured":"Huang Z, Liu X, Guo Q, Zhou Y, Shi L, Cai Q, et al. Extracellular vesicle-mediated communication between CD8. Front Immunol. 2024;15:1376962.","journal-title":"Front Immunol"},{"issue":"4","key":"1634_CR725","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s12276-024-01201-6","volume":"56","author":"HI Kim","year":"2024","unstructured":"Kim HI, Park J, Zhu Y, Wang X, Han Y, Zhang D. Recent advances in extracellular vesicles for therapeutic cargo delivery. Exp Mol Med. 2024;56(4):836\u201349.","journal-title":"Exp Mol Med"},{"issue":"5","key":"1634_CR726","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41419-024-06758-8","volume":"15","author":"S Yang","year":"2024","unstructured":"Yang S, Wei S, Wei F. Extracellular vesicles mediated gastric cancer immune response: tumor cell death or immune escape? Cell Death Dis. 2024;15(5):377.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1634_CR727","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","volume":"9","author":"MA Kumar","year":"2024","unstructured":"Kumar MA, Baba SK, Sadida HQ, Marzooqi SA, Jerobin J, Altemani FH, et al. Extracellular vesicles as tools and targets in therapy for diseases. Signal Transduct Target Ther. 2024;9(1):27.","journal-title":"Signal Transduct Target Ther"},{"key":"1634_CR728","doi-asserted-by":"crossref","unstructured":"Wiklander OPB, Mamand DR, Mohammad DK, Zheng W, Jawad Wiklander R, Sych T, et al. Antibody-displaying extracellular vesicles for targeted cancer therapy. Nat Biomed Eng. 2024.","DOI":"10.1038\/s41551-024-01214-6"},{"issue":"4","key":"1634_CR729","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.3390\/cancers15041307","volume":"15","author":"B Irmer","year":"2023","unstructured":"Irmer B, Chandrabalan S, Maas L, Bleckmann A, Menck K. Extracellular Vesicles in Liquid Biopsies as Biomarkers for Solid Tumors. Cancers (Basel). 2023;15(4):1307.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1634_CR730","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40364-023-00540-2","volume":"11","author":"K Asleh","year":"2023","unstructured":"Asleh K, Dery V, Taylor C, Davey M, Djeungoue-Petga MA, Ouellette RJ. Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology. Biomark Res. 2023;11(1):99.","journal-title":"Biomark Res"},{"issue":"1","key":"1634_CR731","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3390\/ijms24010885","volume":"24","author":"A Nicoletti","year":"2023","unstructured":"Nicoletti A, Negri M, Paratore M, Vitale F, Ainora ME, Nista EC, et al. Diagnostic and prognostic role of extracellular vesicles in pancreatic cancer: current evidence and future perspectives. Int J Mol Sci. 2023;24(1):885.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1634_CR732","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12943-024-01932-0","volume":"23","author":"C Zhang","year":"2024","unstructured":"Zhang C, Qin C, Dewanjee S, Bhattacharya H, Chakraborty P, Jha NK, et al. Tumor-derived small extracellular vesicles in cancer invasion and metastasis: molecular mechanisms, and clinical significance. Mol Cancer. 2024;23(1):18.","journal-title":"Mol Cancer"},{"issue":"4","key":"1634_CR733","doi-asserted-by":"publisher","first-page":"109506","DOI":"10.1016\/j.isci.2024.109506","volume":"27","author":"F Xu","year":"2024","unstructured":"Xu F, Wang K, Zhu C, Fan L, Zhu Y, Wang JF, et al. Tumor-derived extracellular vesicles as a biomarker for breast cancer diagnosis and metastasis monitoring. iScience. 2024;27(4):109506.","journal-title":"iScience."},{"issue":"1","key":"1634_CR734","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s12885-024-11819-4","volume":"24","author":"M Andre","year":"2024","unstructured":"Andre M, Caobi A, Miles JS, Vashist A, Ruiz MA, Raymond AD. Diagnostic potential of exosomal extracellular vesicles in oncology. BMC Cancer. 2024;24(1):322.","journal-title":"BMC Cancer"},{"issue":"1","key":"1634_CR735","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/clinchem\/hvad176","volume":"70","author":"S Rayamajhi","year":"2024","unstructured":"Rayamajhi S, Sipes J, Tetlow AL, Saha S, Bansal A, Godwin AK. Extracellular vesicles as liquid biopsy biomarkers across the cancer journey: from early detection to recurrence. Clin Chem. 2024;70(1):206\u201319.","journal-title":"Clin Chem"},{"issue":"12","key":"1634_CR736","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41568-020-00299-w","volume":"20","author":"A M\u00f6ller","year":"2020","unstructured":"M\u00f6ller A, Lobb RJ. The evolving translational potential of small extracellular vesicles in cancer. Nat Rev Cancer. 2020;20(12):697\u2013709.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1634_CR737","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1038\/s41467-020-19933-0","volume":"11","author":"YH Park","year":"2020","unstructured":"Park YH, Lal S, Lee JE, Choi YL, Wen J, Ram S, et al. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nat Commun. 2020;11(1):6175.","journal-title":"Nat Commun"},{"issue":"1","key":"1634_CR738","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41392-020-00261-0","volume":"5","author":"J Dai","year":"2020","unstructured":"Dai J, Su Y, Zhong S, Cong L, Liu B, Yang J, et al. Exosomes: key players in cancer and potential therapeutic strategy. Signal Transduct Target Ther. 2020;5(1):145.","journal-title":"Signal Transduct Target Ther"},{"key":"1634_CR739","doi-asserted-by":"publisher","first-page":"864980","DOI":"10.3389\/fonc.2022.864980","volume":"12","author":"J Jiang","year":"2022","unstructured":"Jiang J, Li J, Zhou X, Zhao X, Huang B, Qin Y. Exosomes regulate the epithelial-mesenchymal transition in cancer. Front Oncol. 2022;12:864980.","journal-title":"Front Oncol"},{"issue":"1","key":"1634_CR740","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12575-024-00245-2","volume":"26","author":"Y Wu","year":"2024","unstructured":"Wu Y, Cao Y, Chen L, Lai X, Zhang S, Wang S. Role of exosomes in cancer and aptamer-modified exosomes as a promising platform for cancer targeted therapy. Biol Proced Online. 2024;26(1):15.","journal-title":"Biol Proced Online"},{"issue":"1","key":"1634_CR741","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/biomedicines12010123","volume":"12","author":"S Rahimian","year":"2024","unstructured":"Rahimian S, Najafi H, Afzali B, Doroudian M. Extracellular vesicles and exosomes: novel insights and perspectives on lung cancer from early detection to targeted treatment. Biomedicines. 2024;12(1):123.","journal-title":"Biomedicines."},{"issue":"4","key":"1634_CR742","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s12276-024-01209-y","volume":"56","author":"YJ Lee","year":"2024","unstructured":"Lee YJ, Shin KJ, Chae YC. Regulation of cargo selection in exosome biogenesis and its biomedical applications in cancer. Exp Mol Med. 2024;56(4):877\u201389.","journal-title":"Exp Mol Med"},{"issue":"49","key":"1634_CR743","doi-asserted-by":"publisher","first-page":"34211","DOI":"10.1074\/jbc.M109.041152","volume":"284","author":"I Parolini","year":"2009","unstructured":"Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem. 2009;284(49):34211\u201322.","journal-title":"J Biol Chem"},{"issue":"1","key":"1634_CR744","doi-asserted-by":"publisher","first-page":"30","DOI":"10.21873\/cgp.20362","volume":"20","author":"S Nambara","year":"2023","unstructured":"Nambara S, Masuda T, Hirose K, Hu Q, Tobo T, Ozato Y, et al. Rab27b, a regulator of exosome secretion, is associated with peritoneal metastases in gastric cancer. Cancer Genomics Proteomics. 2023;20(1):30\u20139.","journal-title":"Cancer Genomics Proteomics"},{"issue":"19","key":"1634_CR745","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1158\/0008-5472.CAN-12-0925","volume":"72","author":"A Bobrie","year":"2012","unstructured":"Bobrie A, Krumeich S, Reyal F, Recchi C, Moita LF, Seabra MC, et al. Rab27a supports exosome-dependent and-independent mechanisms that modify the tumor microenvironment and can promote tumor progression. Can Res. 2012;72(19):4920\u201330.","journal-title":"Can Res"},{"issue":"6","key":"1634_CR746","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nm.2753","volume":"18","author":"H Peinado","year":"2012","unstructured":"Peinado H, Ale\u010dkovi\u0107 M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18(6):883\u201391.","journal-title":"Nat Med"},{"issue":"2","key":"1634_CR747","doi-asserted-by":"publisher","first-page":"e0148454","DOI":"10.1371\/journal.pone.0148454","volume":"11","author":"S Sento","year":"2016","unstructured":"Sento S, Sasabe E, Yamamoto T. Application of a persistent heparin treatment inhibits the malignant potential of oral squamous carcinoma cells induced by tumor cell-derived exosomes. PLoS ONE. 2016;11(2):e0148454.","journal-title":"PLoS ONE"},{"issue":"8","key":"1634_CR748","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1038\/oncsis.2015.21","volume":"4","author":"C Franzen","year":"2015","unstructured":"Franzen C, Blackwell R, Todorovic V, Greco K, Foreman K, Flanigan R, et al. Urothelial cells undergo epithelial-to-mesenchymal transition after exposure to muscle invasive bladder cancer exosomes. Oncogenesis. 2015;4(8):e163.","journal-title":"Oncogenesis"},{"issue":"43","key":"1634_CR749","doi-asserted-by":"publisher","first-page":"17380","DOI":"10.1073\/pnas.1304266110","volume":"110","author":"HC Christianson","year":"2013","unstructured":"Christianson HC, Svensson KJ, van Kuppevelt TH, Li J-P, Belting M. Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. Proc Natl Acad Sci. 2013;110(43):17380\u20135.","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"1634_CR750","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.tips.2016.04.006","volume":"37","author":"N Syn","year":"2016","unstructured":"Syn N, Wang L, Sethi G, Thiery JP, Goh BC. Exosome-mediated metastasis: from epithelial-mesenchymal transition to escape from immunosurveillance. Trends Pharmacol Sci. 2016;37(7):606\u201317.","journal-title":"Trends Pharmacol Sci"},{"issue":"6801","key":"1634_CR751","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35025220","volume":"407","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249\u201357.","journal-title":"Nature"},{"issue":"5","key":"1634_CR752","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.semcancer.2009.05.003","volume":"19","author":"V Baeriswyl","year":"2009","unstructured":"Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol. 2009;19(5):329\u201337.","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"1634_CR753","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm.2537","volume":"17","author":"SM Weis","year":"2011","unstructured":"Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011;17(11):1359\u201370.","journal-title":"Nat Med"},{"issue":"2","key":"1634_CR754","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41419-017-0061-0","volume":"9","author":"MB Schaaf","year":"2018","unstructured":"Schaaf MB, Garg AD, Agostinis P. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death Dis. 2018;9(2):115.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1634_CR755","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8(1):198.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"1634_CR756","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.3390\/ijms24054422","volume":"24","author":"HT Tzeng","year":"2023","unstructured":"Tzeng HT, Huang YJ. Tumor vasculature as an emerging pharmacological target to promote anti-tumor immunity. Int J Mol Sci. 2023;24(5):4422.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1634_CR757","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc.2017.51","volume":"17","author":"M De Palma","year":"2017","unstructured":"De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017;17(8):457\u201374.","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"1634_CR758","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","volume":"31","author":"RK Jain","year":"2013","unstructured":"Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013;31(17):2205\u201318.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1634_CR759","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri3064","volume":"11","author":"GT Motz","year":"2011","unstructured":"Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol. 2011;11(10):702\u201311.","journal-title":"Nat Rev Immunol"},{"issue":"22","key":"1634_CR760","doi-asserted-by":"publisher","first-page":"e2020803118","DOI":"10.1073\/pnas.2020803118","volume":"118","author":"N Zhang","year":"2021","unstructured":"Zhang N, Yin R, Zhou P, Liu X, Fan P, Qian L, et al. DLL1 orchestrates CD8(+) T cells to induce long-term vascular normalization and tumor regression. Proc Natl Acad Sci U S A. 2021;118(22):e2020803118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1634_CR761","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.canlet.2020.05.015","volume":"487","author":"L Schito","year":"2020","unstructured":"Schito L, Rey S. Hypoxia: turning vessels into vassals of cancer immunotolerance. Cancer Lett. 2020;487:74\u201384.","journal-title":"Cancer Lett"},{"key":"1634_CR762","volume":"12","author":"Z Lamplugh","year":"2021","unstructured":"Lamplugh Z, Fan Y. Vascular microenvironment. Tumor Immunity and Immunotherapy Front Immunol. 2021;12: 811485.","journal-title":"Tumor Immunity and Immunotherapy Front Immunol"},{"key":"1634_CR763","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-bioeng-071813-105259","volume":"16","author":"RK Jain","year":"2014","unstructured":"Jain RK, Martin JD, Stylianopoulos T. The role of mechanical forces in tumor growth and therapy. Annu Rev Biomed Eng. 2014;16:321\u201346.","journal-title":"Annu Rev Biomed Eng"},{"issue":"4","key":"1634_CR764","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253\u201368.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"1634_CR765","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/imm.12380","volume":"143","author":"V Kumar","year":"2014","unstructured":"Kumar V, Gabrilovich DI. Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology. 2014;143(4):512\u20139.","journal-title":"Immunology"},{"issue":"10","key":"1634_CR766","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.3390\/cells10102712","volume":"10","author":"JK Hennigs","year":"2021","unstructured":"Hennigs JK, Matuszcak C, Trepel M, K\u00f6rbelin J. Vascular endothelial cells: heterogeneity and targeting approaches. Cells. 2021;10(10):2712.","journal-title":"Cells"},{"issue":"4","key":"1634_CR767","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.3390\/ijms22041631","volume":"22","author":"HO Alsaab","year":"2021","unstructured":"Alsaab HO, Al-Hibs AS, Alzhrani R, Alrabighi KK, Alqathama A, Alwithenani A, et al. Nanomaterials for antiangiogenic therapies for cancer: a promising tool for personalized medicine. Int J Mol Sci. 2021;22(4):1631.","journal-title":"Int J Mol Sci"},{"key":"1634_CR768","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.802846","volume":"13","author":"H Hu","year":"2022","unstructured":"Hu H, Chen Y, Tan S, Wu S, Huang Y, Fu S, et al. The Research progress of antiangiogenic therapy, immune therapy and tumor microenvironment. Front Immunol. 2022;13: 802846.","journal-title":"Front Immunol"},{"key":"1634_CR769","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100849","volume":"64","author":"M Huang","year":"2022","unstructured":"Huang M, Lin Y, Wang C, Deng L, Chen M, Assaraf YG, et al. New insights into antiangiogenic therapy resistance in cancer: mechanisms and therapeutic aspects. Drug Resist Updat. 2022;64: 100849.","journal-title":"Drug Resist Updat"},{"issue":"3","key":"1634_CR770","doi-asserted-by":"publisher","first-page":"e006680","DOI":"10.1136\/jitc-2023-006680","volume":"11","author":"JA Park","year":"2023","unstructured":"Park JA, Espinosa-Cotton M, Guo HF, Monette S, Cheung NV. Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody. J Immunother Cancer. 2023;11(3):e006680.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1634_CR771","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.189020","volume":"1878","author":"RN Gacche","year":"2023","unstructured":"Gacche RN. Changing landscape of anti-angiogenic therapy: Novel approaches and clinical perspectives. Biochim Biophys Acta Rev Cancer. 2023;1878(6): 189020.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1634_CR772","doi-asserted-by":"publisher","first-page":"9077926","DOI":"10.1155\/2024\/9077926","volume":"2024","author":"A Pathak","year":"2024","unstructured":"Pathak A, Pal AK, Roy S, Nandave M, Jain K. Role of angiogenesis and its biomarkers in development of targeted tumor therapies. Stem Cells Int. 2024;2024:9077926.","journal-title":"Stem Cells Int"},{"issue":"11","key":"1634_CR773","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7349","volume":"13","author":"S Li","year":"2024","unstructured":"Li S, Yu ZS, Liu HZ, Li SJ, Wang MY, Ning FL, et al. Immunotherapy combined with antiangiogenic therapy as third- or further-line therapy for stage IV non-small cell lung cancer patients with ECOG performance status 2: A retrospective study. Cancer Med. 2024;13(11): e7349.","journal-title":"Cancer Med"},{"issue":"2","key":"1634_CR774","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3390\/ijms25020921","volume":"25","author":"I Carrera-Aguado","year":"2024","unstructured":"Carrera-Aguado I, Marcos-Zazo L, Carrancio-Sal\u00e1n P, Guerra-Paes E, S\u00e1nchez-Juanes F, Mu\u00f1oz-F\u00e9lix JM. The inhibition of vessel co-option as an emerging strategy for cancer therapy. Int J Mol Sci. 2024;25(2):921.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1634_CR775","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3390\/biomedicines12040827","volume":"12","author":"G Kaur","year":"2024","unstructured":"Kaur G, Roy B. Decoding tumor angiogenesis for therapeutic advancements: mechanistic insights. Biomedicines. 2024;12(4):827.","journal-title":"Biomedicines."},{"key":"1634_CR776","doi-asserted-by":"publisher","first-page":"676342","DOI":"10.3389\/fcell.2021.676342","volume":"9","author":"R Sun","year":"2021","unstructured":"Sun R, Kong X, Qiu X, Huang C, Wong pp. The Emerging Roles of Pericytes in Modulating Tumor Microenvironment. Front Cell Dev Biol. 2021;9:676342.","journal-title":"Front Cell Dev Biol."},{"issue":"12","key":"1634_CR777","doi-asserted-by":"publisher","first-page":"5109","DOI":"10.1158\/0008-5472.CAN-09-4245","volume":"70","author":"MH Nisancioglu","year":"2010","unstructured":"Nisancioglu MH, Betsholtz C, Genov\u00e9 G. The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade. Cancer Res. 2010;70(12):5109\u201315.","journal-title":"Cancer Res"},{"issue":"19","key":"1634_CR778","doi-asserted-by":"publisher","first-page":"8066","DOI":"10.1158\/0008-5472.CAN-08-0287","volume":"68","author":"PC Maciag","year":"2008","unstructured":"Maciag PC, Seavey MM, Pan ZK, Ferrone S, Paterson Y. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res. 2008;68(19):8066\u201375.","journal-title":"Cancer Res"},{"issue":"1","key":"1634_CR779","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1349-7006.2009.01369.x","volume":"101","author":"IA Boere","year":"2010","unstructured":"Boere IA, Hamberg P, Sleijfer S. It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies. Cancer Sci. 2010;101(1):7\u201315.","journal-title":"Cancer Sci"},{"key":"1634_CR780","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584723","volume":"11","author":"G Duru","year":"2020","unstructured":"Duru G, van Egmond M, Heemskerk N. A window of opportunity: targeting cancer endothelium to enhance immunotherapy. Front Immunol. 2020;11: 584723.","journal-title":"Front Immunol"},{"key":"1634_CR781","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, et al. Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86: 102017.","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"1634_CR782","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1158\/1078-0432.CCR-20-3407","volume":"27","author":"SJ Casak","year":"2021","unstructured":"Casak SJ, Donoghue M, Fashoyin-Aje L, Jiang X, Rodriguez L, Shen YL, et al. FDA approval summary: atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma. Clin Cancer Res. 2021;27(7):1836\u201341.","journal-title":"Clin Cancer Res"},{"key":"1634_CR783","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2147\/OTT.S155425","volume":"12","author":"C Marchetti","year":"2019","unstructured":"Marchetti C, Muzii L, Romito A, Benedetti PP. First-line treatment of women with advanced ovarian cancer: focus on bevacizumab. Onco Targets Ther. 2019;12:1095\u2013103.","journal-title":"Onco Targets Ther"},{"key":"1634_CR784","doi-asserted-by":"publisher","first-page":"8605","DOI":"10.2147\/OTT.S171724","volume":"11","author":"R Xu","year":"2018","unstructured":"Xu R, Xu C, Liu C, Cui C, Zhu J. Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer. Onco Targets Ther. 2018;11:8605\u201321.","journal-title":"Onco Targets Ther"},{"issue":"4","key":"1634_CR785","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/annonc\/mdw665","volume":"28","author":"R Bell","year":"2017","unstructured":"Bell R, Brown J, Parmar M, Toi M, Suter T, Steger GG, et al. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Ann Oncol. 2017;28(4):754\u201360.","journal-title":"Ann Oncol"},{"issue":"12","key":"1634_CR786","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s40265-015-0444-4","volume":"75","author":"YY Syed","year":"2015","unstructured":"Syed YY, McKeage K. Aflibercept: A Review in Metastatic Colorectal Cancer. Drugs. 2015;75(12):1435\u201345.","journal-title":"Drugs"},{"key":"1634_CR787","first-page":"13","volume":"8","author":"A Patel","year":"2014","unstructured":"Patel A, Sun W. Ziv-aflibercept in metastatic colorectal cancer Biologics. 2014;8:13\u201325.","journal-title":"Ziv-aflibercept in metastatic colorectal cancer Biologics"},{"issue":"5","key":"1634_CR788","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","volume":"28","author":"JL Spratlin","year":"2010","unstructured":"Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010;28(5):780\u20137.","journal-title":"J Clin Oncol"},{"issue":"15","key":"1634_CR789","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1158\/1078-0432.CCR-15-0600","volume":"21","author":"SJ Casak","year":"2015","unstructured":"Casak SJ, Fashoyin-Aje I, Lemery SJ, Zhang L, Jin R, Li H, et al. FDA approval summary: ramucirumab for gastric cancer. Clin Cancer Res. 2015;21(15):3372\u20136.","journal-title":"Clin Cancer Res"},{"key":"1634_CR790","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.2147\/CMAR.S216220","volume":"12","author":"E De Luca","year":"2020","unstructured":"De Luca E, Marino D, Di \nMaio M. Ramucirumab, a second-line option for patients with hepatocellular carcinoma: a review of the evidence. Cancer Manag Res. 2020;12:3721\u20139.","journal-title":"Cancer Manag Res"},{"issue":"3","key":"1634_CR791","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1177\/1758834016635888","volume":"8","author":"H Verdaguer","year":"2016","unstructured":"Verdaguer H, Tabernero J, Macarulla T. Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Ther Adv Med Oncol. 2016;8(3):230\u201342.","journal-title":"Ther Adv Med Oncol"},{"issue":"11","key":"1634_CR792","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1634\/theoncologist.2015-0221","volume":"20","author":"E Larkins","year":"2015","unstructured":"Larkins E, Scepura B, Blumenthal GM, Bloomquist E, Tang S, Biable M, et al. US food and drug administration approval summary: ramucirumab for the treatment of metastatic non-small cell lung cancer following disease progression on or after platinum-based chemotherapy. Oncologist. 2015;20(11):1320\u20135.","journal-title":"Oncologist"},{"issue":"26","key":"1634_CR793","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","volume":"31","author":"TT Batchelor","year":"2013","unstructured":"Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31(26):3212\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1634_CR794","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4161\/cam.22124","volume":"7","author":"P Uhrin","year":"2013","unstructured":"Uhrin P, Breuss JM. uPAR: a modulator of VEGF-induced angiogenesis. Cell Adh Migr. 2013;7(1):23\u20136.","journal-title":"Cell Adh Migr"},{"issue":"1","key":"1634_CR795","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12967-022-03329-3","volume":"20","author":"BT Zhai","year":"2022","unstructured":"Zhai BT, Tian H, Sun J, Zou JB, Zhang XF, Cheng JX, et al. Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer. J Transl Med. 2022;20(1):135.","journal-title":"J Transl Med"},{"issue":"15","key":"1634_CR796","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1200\/jco.2010.28.15_suppl.tps131","volume":"28","author":"LJ Goldstein","year":"2010","unstructured":"Goldstein LJ, Stemmer SM, Schmalfeldt B, Gottschalk N, F. C, H. D, et al. Phase II two-arm double-blind multicenter randomized study of the combination of oral WX-671 plus capecitabine versus capecitabine in first-line HER2-negative metastatic breast cancer (MBC). J Clin Oncology. 2010;28(15):131.","journal-title":"J Clin Oncology."},{"issue":"3","key":"1634_CR797","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/cancers14030498","volume":"14","author":"MT Masucci","year":"2022","unstructured":"Masucci MT, Minopoli M, Di Carluccio G, Motti ML, Carriero MV. Therapeutic strategies targeting urokinase and its receptor in cancer. Cancers (Basel). 2022;14(3):498.","journal-title":"Cancers (Basel)."},{"issue":"11","key":"1634_CR798","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.3390\/ijms19113491","volume":"19","author":"T Yamaoka","year":"2018","unstructured":"Yamaoka T, Kusumoto S, Ando K, Ohba M, Ohmori T. Receptor tyrosine kinase-targeted cancer therapy. Int J Mol Sci. 2018;19(11):3491.","journal-title":"Int J Mol Sci"},{"issue":"24","key":"1634_CR799","doi-asserted-by":"publisher","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","volume":"12","author":"RC Kane","year":"2006","unstructured":"Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2006;12(24):7271\u20138.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1634_CR800","first-page":"379","volume":"134","author":"L Lang","year":"2008","unstructured":"Lang L. FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology. 2008;134(2):379.","journal-title":"Gastroenterology"},{"key":"1634_CR801","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.2147\/OTT.S49430","volume":"7","author":"DC McFarland","year":"2014","unstructured":"McFarland DC, Misiukiewicz KJ. Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer. Onco Targets Ther. 2014;7:1291\u20139.","journal-title":"Onco Targets Ther"},{"issue":"5","key":"1634_CR802","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","volume":"13","author":"VL Goodman","year":"2007","unstructured":"Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007;13(5):1367\u201373.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1634_CR803","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1634\/theoncologist.2012-0044","volume":"17","author":"GM Blumenthal","year":"2012","unstructured":"Blumenthal GM, Cortazar P, Zhang JJ, Tang S, Sridhara R, Murgo A, et al. FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. Oncologist. 2012;17(8):1108\u201313.","journal-title":"Oncologist"},{"issue":"1","key":"1634_CR804","first-page":"53","volume":"4","author":"DT Nguyen","year":"2013","unstructured":"Nguyen DT, Shayahi S. Pazopanib: approval for soft-tissue sarcoma. J Adv Pract Oncol. 2013;4(1):53\u20137.","journal-title":"J Adv Pract Oncol"},{"issue":"6","key":"1634_CR805","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","volume":"14","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552\u201362.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1634_CR806","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11912-019-0771-9","volume":"21","author":"J Gillen","year":"2019","unstructured":"Gillen J, Richardson D, Moore K. Angiopoietin-1 and angiopoietin-2 inhibitors: clinical development. Curr Oncol Rep. 2019;21(3):22.","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"1634_CR807","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/S1470-2045(19)30178-0","volume":"20","author":"I Vergote","year":"2019","unstructured":"Vergote I, Scambia G, O\u2019Malley DM, Van Calster B, Park SY, Del Campo JM, et al. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3\/ENGOT-ov2\/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(6):862\u201376.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1634_CR808","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1634\/theoncologist.2019-0119","volume":"24","author":"W Li","year":"2019","unstructured":"Li W, Chen P, Zhang N, Song T, Wu S. Endostatin and Oxaliplatin-based chemoradiotherapy for inoperable esophageal squamous cell carcinoma: results of a phase II study. Oncologist. 2019;24(4):461-e136.","journal-title":"Oncologist"},{"issue":"12","key":"1634_CR809","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1158\/1535-7163.MCT-08-0715","volume":"7","author":"J Ma","year":"2008","unstructured":"Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther. 2008;7(12):3670\u201384.","journal-title":"Mol Cancer Ther"},{"key":"1634_CR810","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-physiol-020518-114700","volume":"81","author":"JD Martin","year":"2019","unstructured":"Martin JD, Seano G, Jain RK. Normalizing function of tumor vessels: progress, opportunities, and challenges. Annu Rev Physiol. 2019;81:505\u201334.","journal-title":"Annu Rev Physiol"},{"issue":"1","key":"1634_CR811","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","volume":"11","author":"TT Batchelor","year":"2007","unstructured":"Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11(1):83\u201395.","journal-title":"Cancer Cell"},{"issue":"2","key":"1634_CR812","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1158\/0008-5472.CAN-11-2464","volume":"72","author":"AG Sorensen","year":"2012","unstructured":"Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2012;72(2):402\u20137.","journal-title":"Cancer Res"},{"issue":"2","key":"1634_CR813","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nm988","volume":"10","author":"CG Willett","year":"2004","unstructured":"Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10(2):145\u20137.","journal-title":"Nat Med"},{"key":"1634_CR814","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3389\/fbioe.2019.00324","volume":"7","author":"P Tharkar","year":"2019","unstructured":"Tharkar P, Varanasi R, Wong WSF, Jin CT, Chrzanowski W. Nano-enhanced drug delivery and therapeutic ultrasound for cancer treatment and beyond. Front Bioeng Biotechnol. 2019;7:324.","journal-title":"Front Bioeng Biotechnol"},{"issue":"4","key":"1634_CR815","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","volume":"17","author":"JD Martin","year":"2020","unstructured":"Martin JD, Cabral H, Stylianopoulos T, Jain RK. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat Rev Clin Oncol. 2020;17(4):251\u201366.","journal-title":"Nat Rev Clin Oncol"},{"issue":"46","key":"1634_CR816","doi-asserted-by":"publisher","first-page":"14325","DOI":"10.1073\/pnas.1518808112","volume":"112","author":"SM Tolaney","year":"2015","unstructured":"Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, et al. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc Natl Acad Sci U S A. 2015;112(46):14325\u201330.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"385","key":"1634_CR817","doi-asserted-by":"publisher","first-page":"eaak9670","DOI":"10.1126\/scitranslmed.aak9670","volume":"9","author":"M Schmittnaegel","year":"2017","unstructured":"Schmittnaegel M, Rigamonti N, Kadioglu E, Cassar\u00e1 A, Wyser Rmili C, Kiialainen A, et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med. 2017;9(385):eaak9670.","journal-title":"Sci Transl Med."},{"issue":"7","key":"1634_CR818","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1158\/1078-0432.CCR-17-1588","volume":"24","author":"M Hidalgo","year":"2018","unstructured":"Hidalgo M, Martinez-Garcia M, Le Tourneau C, Massard C, Garralda E, Boni V, et al. First-in-human phase I study of single-agent vanucizumab, a first-in-class bispecific anti-angiopoietin-2\/Anti-VEGF-A antibody, in adult patients with advanced solid tumors. Clin Cancer Res. 2018;24(7):1536\u201345.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"1634_CR819","doi-asserted-by":"publisher","first-page":"19634","DOI":"10.18632\/oncotarget.3839","volume":"6","author":"YW Paulis","year":"2015","unstructured":"Paulis YW, Huijbers EJ, van der Schaft DW, Soetekouw PM, Pauwels P, \nTjan-Heijnen VC, et al. CD44 enhances tumor aggressiveness by promoting tumor cell plasticity. Oncotarget. 2015;6(23):19634\u201346.","journal-title":"Oncotarget"},{"issue":"48","key":"1634_CR820","doi-asserted-by":"publisher","first-page":"80046","DOI":"10.18632\/oncotarget.11098","volume":"7","author":"M-V der Houven","year":"2016","unstructured":"der Houven M-V, van Oordt CW, Gomez-Roca C, van Herpen C, Coveler AL, Mahalingam D, Verheul HM, et al. First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. Oncotarget. 2016;7(48):80046\u201358.","journal-title":"Oncotarget"},{"issue":"3","key":"1634_CR821","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1055\/s-0030-1253454","volume":"36","author":"JA Nagy","year":"2010","unstructured":"Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. Heterogeneity of the tumor vasculature. Semin Thromb Hemost. 2010;36(3):321\u201331.","journal-title":"Semin Thromb Hemost"},{"key":"1634_CR822","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.591901","volume":"11","author":"JR Fleischer","year":"2020","unstructured":"Fleischer JR, Jodszuweit CA, Ghadimi M, De Oliveira T, Conradi LC. Vascular heterogeneity with a special focus on the hepatic microenvironment. Front Physiol. 2020;11: 591901.","journal-title":"Front Physiol"},{"issue":"27","key":"1634_CR823","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.2217\/nnm-2022-0176","volume":"17","author":"JV de Oliveira","year":"2022","unstructured":"de Oliveira JV, Oliveira da Rocha MC, de Sousa-Junior AA, Rodrigues MC, Farias GR, da Silva PB, et al. Tumor vascular heterogeneity and the impact of subtumoral nanoemulsion biodistribution. Nanomedicine (Lond). 2022;17(27):2073\u201388.","journal-title":"Nanomedicine (Lond)"},{"issue":"3","key":"1634_CR824","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccell.2020.03.002","volume":"37","author":"J Goveia","year":"2020","unstructured":"Goveia J, Rohlenova K, Taverna F, Treps L, Conradi LC, Pircher A, et al. An integrated gene expression landscape profiling approach to identify lung tumor endothelial cell heterogeneity and angiogenic candidates. Cancer Cell. 2020;37(3):421.","journal-title":"Cancer Cell"},{"key":"1634_CR825","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2015.01.011","volume":"33","author":"E Lanitis","year":"2015","unstructured":"Lanitis E, Irving M, Coukos G. Targeting the tumor vasculature to enhance T cell activity. Curr Opin Immunol. 2015;33:55\u201363.","journal-title":"Curr Opin Immunol"},{"issue":"12","key":"1634_CR826","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1158\/0008-5472.CAN-22-2838","volume":"83","author":"HR Park","year":"2023","unstructured":"Park HR, Shiva A, Cummings P, Kim S, Lee E, Leong A, et al. Angiopoietin-2-dependent spatial vascular destabilization promotes T-cell exclusion and limits immunotherapy in melanoma. Cancer Res. 2023;83(12):1968\u201383.","journal-title":"Cancer Res"},{"issue":"11","key":"1634_CR827","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/ni.3836","volume":"18","author":"A Johansson-Percival","year":"2017","unstructured":"Johansson-Percival A, He B, Li ZJ, Kjell\u00e9n A, Russell K, Li J, et al. De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. Nat Immunol. 2017;18(11):1207\u201317.","journal-title":"Nat Immunol"},{"issue":"3","key":"1634_CR828","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.celrep.2019.12.013","volume":"30","author":"B He","year":"2020","unstructured":"He B, Johansson-Percival A, Backhouse J, Li J, Lee GYF, Hamzah J, et al. Remodeling of metastatic vasculature reduces lung colonization and sensitizes overt metastases to immunotherapy. Cell Rep. 2020;30(3):714-24.e5.","journal-title":"Cell Rep"},{"issue":"5","key":"1634_CR829","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"1634_CR830","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116\u201327.","journal-title":"N Engl J Med"},{"key":"1634_CR831","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40425-015-0055-3","volume":"3","author":"A Amin","year":"2015","unstructured":"Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ, et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. J Immunother Cancer. 2015;3:14.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"1634_CR832","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.cell.2020.06.039","volume":"182","author":"G Oliver","year":"2020","unstructured":"Oliver G, Kipnis J, Randolph GJ, Harvey NL. The lymphatic vasculature in the 21st century: novel functional roles in homeostasis and disease. Cell. 2020;182(2):270\u201396.","journal-title":"Cell"},{"issue":"6500","key":"1634_CR833","doi-asserted-by":"publisher","first-page":"eaax4063","DOI":"10.1126\/science.aax4063","volume":"369","author":"TV Petrova","year":"2020","unstructured":"Petrova TV, Koh GY. Biological functions of lymphatic vessels. Science. 2020;369(6500):eaax4063.","journal-title":"Science"},{"issue":"407","key":"1634_CR834","doi-asserted-by":"publisher","first-page":"eaal712","DOI":"10.1126\/scitranslmed.aal4712","volume":"9","author":"M Fankhauser","year":"2017","unstructured":"Fankhauser M, Broggi MAS, Potin L, Bordry N, Jeanbart L, Lund AW, et al. Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma. Sci Transl Med. 2017;9(407):eaal712.","journal-title":"Sci Transl Med."},{"key":"1634_CR835","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3389\/fimmu.2019.00720","volume":"10","author":"L Garnier","year":"2019","unstructured":"Garnier L, Gkountidi AO, Hugues S. Tumor-associated lymphatic vessel features and immunomodulatory functions. Front Immunol. 2019;10:720.","journal-title":"Front Immunol"},{"key":"1634_CR836","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fonc.2013.00211","volume":"3","author":"S Azzi","year":"2013","unstructured":"Azzi S, Hebda JK, Gavard J. Vascular permeability and drug delivery in cancers. Front Oncol. 2013;3:211.","journal-title":"Front Oncol"},{"issue":"46","key":"1634_CR837","doi-asserted-by":"publisher","first-page":"18632","DOI":"10.1073\/pnas.1318415110","volume":"110","author":"T Stylianopoulos","year":"2013","unstructured":"Stylianopoulos T, Jain RK. Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A. 2013;110(46):18632\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1634_CR838","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.addr.2020.06.013","volume":"157","author":"PM Glassman","year":"2020","unstructured":"Glassman PM, Myerson JW, Ferguson LT, Kiseleva RY, Shuvaev VV, Brenner JS, et al. Targeting drug delivery in the vascular system: focus on endothelium. Adv Drug Deliv Rev. 2020;157:96\u2013117.","journal-title":"Adv Drug Deliv Rev"},{"key":"1634_CR839","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jconrel.2023.09.017","volume":"362","author":"C Wang","year":"2023","unstructured":"Wang C, Xu J, Zhang Y, Nie G. Emerging nanotechnological approaches to regulating tumor vasculature for cancer therapy. J Control Release. 2023;362:647\u201366.","journal-title":"J Control Release"},{"issue":"1","key":"1634_CR840","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1038\/s41467-023-40015-4","volume":"14","author":"MI Setyawati","year":"2023","unstructured":"Setyawati MI, Wang Q, Ni N, Tee JK, Ariga K, Ke PC, et al. Engineering tumoral vascular leakiness with gold nanoparticles. Nat Commun. 2023;14(1):4269.","journal-title":"Nat Commun"},{"issue":"10","key":"1634_CR841","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.3390\/cancers16101902","volume":"16","author":"PW Janes","year":"2024","unstructured":"Janes PW, Parslow AC, Cao D, Rigopoulos A, Lee FT, Gong SJ, et al. An anti-VEGF-B antibody reduces abnormal tumor vasculature and enhances the effects of chemotherapy. Cancers (Basel). 2024;16(10):1902.","journal-title":"Cancers (Basel)."},{"key":"1634_CR842","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1007\/s13346-024-01580-3","volume":"14","author":"E Lopez-Vince","year":"2024","unstructured":"Lopez-Vince E, Wilhelm C, Simon-Yarza T. Vascularized tumor models for the evaluation of drug delivery systems: a paradigm shift. Drug Deliv Transl Res. 2024;14:2216\u201341.","journal-title":"Drug Deliv Transl Res"},{"issue":"5","key":"1634_CR843","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.ccell.2024.03.013","volume":"42","author":"W Wang","year":"2024","unstructured":"Wang W, Li T, Cheng Y, Li F, Qi S, Mao M, et al. Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization. Cancer Cell. 2024;42(5):815-32.e12.","journal-title":"Cancer Cell"},{"issue":"12","key":"1634_CR844","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/14728222.2019.1702974","volume":"23","author":"LC B\u00f6ckelmann","year":"2019","unstructured":"B\u00f6ckelmann LC, Schumacher U. Targeting tumor interstitial fluid pressure: will it yield novel successful therapies for solid tumors? Expert Opin Ther Targets. 2019;23(12):1005\u201314.","journal-title":"Expert Opin Ther Targets"},{"key":"1634_CR845","doi-asserted-by":"publisher","first-page":"36641","DOI":"10.1038\/srep36641","volume":"6","author":"Q Chang","year":"2016","unstructured":"Chang Q, Ornatsky OI, Siddiqui I, Straus R, Baranov VI, Hedley DW. Biodistribution of cisplatin revealed by imaging mass cytometry identifies extensive collagen binding in tumor and normal tissues. Sci Rep. 2016;6:36641.","journal-title":"Sci Rep"},{"key":"1634_CR846","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216593","volume":"582","author":"M Wang","year":"2024","unstructured":"Wang M, Xia D, Xu D, Yin Y, Xu F, Zhang B, et al. Neovascularization directed by CAVIN1\/CCBE1\/VEGFC confers TMZ-resistance in glioblastoma. Cancer Lett. 2024;582: 216593.","journal-title":"Cancer Lett"},{"key":"1634_CR847","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.116117","volume":"171","author":"Y Wendong","year":"2024","unstructured":"Wendong Y, Jiali J, Qiaomei F, Yayun W, Xianze X, Zheng S, et al. Biomechanical forces and force-triggered drug delivery in tumor neovascularization. Biomed Pharmacother. 2024;171: 116117.","journal-title":"Biomed Pharmacother"},{"key":"1634_CR848","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.689132","volume":"12","author":"S Ren","year":"2021","unstructured":"Ren S, Xiong X, You H, Shen J, Zhou P. The combination of immune checkpoint blockade and angiogenesis inhibitors in the treatment of advanced non-small cell lung cancer. Front Immunol. 2021;12: 689132.","journal-title":"Front Immunol"},{"key":"1634_CR849","doi-asserted-by":"publisher","first-page":"1226360","DOI":"10.3389\/fimmu.2023.1226360","volume":"14","author":"H Dianat-Moghadam","year":"2023","unstructured":"Dianat-Moghadam H, Nedaeinia R, Keshavarz M, Azizi M, Kazemi M, Salehi R. Immunotherapies targeting tumor vasculature: challenges and opportunities. Front Immunol. \n2023;14:1226360.","journal-title":"Front Immunol"},{"issue":"11","key":"1634_CR850","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1038\/s12276-023-01114-w","volume":"55","author":"Y Choi","year":"2023","unstructured":"Choi Y, Jung K. Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy. Exp Mol Med. 2023;55(11):2308\u201319.","journal-title":"Exp Mol Med"},{"key":"1634_CR851","doi-asserted-by":"publisher","first-page":"1291530","DOI":"10.3389\/fimmu.2023.1291530","volume":"14","author":"C Qian","year":"2023","unstructured":"Qian C, Liu C, Liu W, Zhou R, Zhao L. Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy. Front Immunol. 2023;14:1291530.","journal-title":"Front Immunol"},{"issue":"37","key":"1634_CR852","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1038\/onc.2016.261","volume":"36","author":"D Kesanakurti","year":"2017","unstructured":"Kesanakurti D, Maddirela D, Banasavadi-Siddegowda YK, Lai TH, Qamri Z, Jacob NK, et al. A novel interaction of PAK4 with PPAR\u03b3 to regulate Nox1 and radiation-induced epithelial-to-mesenchymal transition in glioma. Oncogene. 2017;36(37):5309\u201320.","journal-title":"Oncogene"},{"issue":"10","key":"1634_CR853","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"issue":"5","key":"1634_CR854","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrc2818","volume":"10","author":"JT Huse","year":"2010","unstructured":"Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer. 2010;10(5):319\u201331.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1634_CR855","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019;25(3):462\u20139.","journal-title":"Nat Med"},{"issue":"16","key":"1634_CR856","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1073\/pnas.1817147116","volume":"116","author":"YJ Xie","year":"2019","unstructured":"Xie YJ, Dougan M, Jailkhani N, Ingram J, Fang T, Kummer L, et al. Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proc Natl Acad Sci U S A. 2019;116(16):7624\u201331.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1634_CR857","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1200\/EDBK_237987","volume":"39","author":"M Datta","year":"2019","unstructured":"Datta M, Coussens LM, Nishikawa H, Hodi FS, Jain RK. Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies. Am Soc Clin Oncol Educ Book. 2019;39:165\u201374.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"1634_CR858","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s43018-020-00147-8","volume":"2","author":"W Ma","year":"2021","unstructured":"Ma W, Wang Y, Zhang R, Yang F, Zhang D, Huang M, et al. Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma. Nat Cancer. 2021;2(1):83\u201397.","journal-title":"Nat Cancer"},{"issue":"3","key":"1634_CR859","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0002-9440(10)65173-5","volume":"155","author":"AJ Maniotis","year":"1999","unstructured":"Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe\u2019er J, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999;155(3):739\u201352.","journal-title":"Am J Pathol"},{"issue":"4","key":"1634_CR860","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/j.1349-7006.2011.02199.x","volume":"103","author":"Z Liu","year":"2012","unstructured":"Liu Z, Sun B, Qi L, Li H, Gao J, Leng X. Zinc finger E-box binding homeobox 1 promotes vasculogenic mimicry in colorectal cancer through induction of epithelial-to-mesenchymal transition. Cancer Sci. 2012;103(4):813\u201320.","journal-title":"Cancer Sci"},{"issue":"2","key":"1634_CR861","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/hep.23311","volume":"51","author":"T Sun","year":"2010","unstructured":"Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW, Che N, et al. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology. 2010;51(2):545\u201356.","journal-title":"Hepatology"},{"issue":"11","key":"1634_CR862","doi-asserted-by":"publisher","first-page":"978","DOI":"10.4161\/cbt.12.11.18155","volume":"12","author":"G Ling","year":"2011","unstructured":"Ling G, Wang S, Song Z, Sun X, Liu Y, Jiang X, et al. Transforming growth factor-\u03b2 is required for vasculogenic mimicry formation in glioma cell line U251MG. Cancer Biol Ther. 2011;12(11):978\u201388.","journal-title":"Cancer Biol Ther"},{"key":"1634_CR863","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fmolb.2019.00160","volume":"6","author":"E Henke","year":"2019","unstructured":"Henke E, Nandigama R, Erg\u00fcn S. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci. 2019;6:160.","journal-title":"Front Mol Biosci"},{"key":"1634_CR864","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3389\/fonc.2020.00397","volume":"10","author":"S Brassart-Pasco","year":"2020","unstructured":"Brassart-Pasco S, Br\u00e9zillon S, Brassart B, Ramont L, Oudart JB, Monboisse JC. Tumor microenvironment: extracellular matrix alterations influence tumor progression. Front Oncol. 2020;10:397.","journal-title":"Front Oncol"},{"issue":"1","key":"1634_CR865","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020;11(1):5120.","journal-title":"Nat Commun"},{"key":"1634_CR866","doi-asserted-by":"publisher","first-page":"1340634","DOI":"10.3389\/fimmu.2023.1340634","volume":"14","author":"W Du","year":"2023","unstructured":"Du W, Xia X, Hu F, Yu J. Extracellular matrix remodeling in the tumor immunity. Front Immunol. 2023;14:1340634.","journal-title":"Front Immunol"},{"issue":"4","key":"1634_CR867","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3390\/cancers15041221","volume":"15","author":"M Cortini","year":"2023","unstructured":"Cortini M, Macchi F, Reggiani F, Vitale E, Lipreri MV, Perut F, et al. Endogenous extracellular matrix regulates the response of osteosarcoma 3d spheroids to doxorubicin. Cancers (Basel). 2023;15(4):1221.","journal-title":"Cancers (Basel)."},{"issue":"5","key":"1634_CR868","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41419-024-06697-4","volume":"15","author":"Z Mai","year":"2024","unstructured":"Mai Z, Lin Y, Lin P, Zhao X, Cui L. Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy. Cell Death Dis. 2024;15(5):307.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1634_CR869","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3002406","volume":"22","author":"M Nazemi","year":"2024","unstructured":"Nazemi M, Yanes B, Martinez ML, Walker HJ, Pham K, Collins MO, et al. The extracellular matrix supports breast cancer cell growth under amino acid starvation by promoting tyrosine catabolism. PLoS Biol. 2024;22(1): e3002406.","journal-title":"PLoS Biol"},{"issue":"1","key":"1634_CR870","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/cells13010096","volume":"13","author":"CT Mierke","year":"2024","unstructured":"Mierke CT. Extracellular matrix cues regulate mechanosensing and mechanotransduction of cancer cells. Cells. 2024;13(1):96.","journal-title":"Cells"},{"key":"1634_CR871","doi-asserted-by":"publisher","first-page":"1340702","DOI":"10.3389\/fimmu.2024.1340702","volume":"15","author":"D Lv","year":"2024","unstructured":"Lv D, Fei Y, Chen H, Wang J, Han W, Cui B, et al. Crosstalk between T lymphocyte and extracellular matrix in tumor microenvironment. Front Immunol. 2024;15:1340702.","journal-title":"Front Immunol"},{"issue":"7","key":"1634_CR872","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/0008-5472.CAN-24-0394","volume":"84","author":"A Yui","year":"2024","unstructured":"Yui A, Oudin MJ. The rigidity connection: matrix stiffness and its impact on cancer progression. Cancer Res. 2024;84(7):958\u201360.","journal-title":"Cancer Res"},{"key":"1634_CR873","doi-asserted-by":"publisher","first-page":"1335636","DOI":"10.3389\/fcell.2024.1335636","volume":"12","author":"SA Lee","year":"2024","unstructured":"Lee SA, Cho GJ, Kim D, Kim DH. Biophysical interplay between extracellular matrix remodeling and hypoxia signaling in regulating cancer metastasis. Front Cell Dev Biol. 2024;12:1335636.","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"1634_CR874","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.devcel.2019.03.026","volume":"49","author":"F Kai","year":"2019","unstructured":"Kai F, Drain AP, Weaver VM. The extracellular matrix modulates the metastatic journey. Dev Cell. 2019;49(3):332\u201346.","journal-title":"Dev Cell"},{"issue":"5","key":"1634_CR875","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1158\/0008-5472.CAN-04-2463","volume":"65","author":"MB Mintz","year":"2005","unstructured":"Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 2005;65(5):1748\u201354.","journal-title":"Cancer Res"},{"issue":"5","key":"1634_CR876","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nm1764","volume":"14","author":"G Finak","year":"2008","unstructured":"Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14(5):518\u201327.","journal-title":"Nat Med"},{"issue":"5","key":"1634_CR877","doi-asserted-by":"publisher","first-page":"R123","DOI":"10.1186\/bcr3317","volume":"14","author":"M Riaz","year":"2012","unstructured":"Riaz M, Sieuwerts AM, Look MP, Timmermans MA, Smid M, Foekens JA, et al. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes. Breast Cancer Res. 2012;14(5):R123.","journal-title":"Breast Cancer Res"},{"issue":"8","key":"1634_CR878","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/sj.cdd.4401658","volume":"12","author":"DG Stupack","year":"2005","unstructured":"Stupack DG. Integrins as a distinct subtype of dependence receptors. Cell Death Differ. 2005;12(8):1021\u201330.","journal-title":"Cell Death Differ"},{"issue":"3","key":"1634_CR879","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10911-011-9226-0","volume":"16","author":"PJ Keely","year":"2011","unstructured":"Keely PJ. Mechanisms by which the extracellular matrix and integrin signaling act to regulate the switch between tumor suppression and tumor promotion. J Mammary Gland Biol Neoplasia. 2011;16(3):205\u201319.","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"1","key":"1634_CR880","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","volume":"8","author":"X Pang","year":"2023","unstructured":"Pang X, He X, Qiu Z, Zhang H, Xie R, Liu Z, et al. Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduct Target Ther. 2023;8(1):1.","journal-title":"Signal Transduct Target Ther"},{"key":"1634_CR881","doi-asserted-by":"publisher","first-page":"1274209","DOI":"10.3389\/fphar.2024.1274209","volume":"15","author":"HH Hu","year":"2024","unstructured":"Hu HH, Wang SQ, Shang HL, Lv HF, Chen BB, Gao SG, et al. Roles and inhibitors of FAK in cancer: current advances and future directions. Front Pharmacol. 2024;15:1274209.","journal-title":"Front Pharmacol"},{"key":"1634_CR882","doi-asserted-by":"publisher","first-page":"e47327","DOI":"10.7554\/eLife.47327","volume":"8","author":"CJ Diaz Osterman","year":"2019","unstructured":"Diaz Osterman CJ, Ozmadenci D, Kleinschmidt EG, Taylor KN, Barrie AM, Jiang S, et al. FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy. Elife. 2019;8:e47327.","journal-title":"Elife"},{"issue":"1","key":"1634_CR883","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bjc.2012.569","volume":"108","author":"PP Provenzano","year":"2013","unstructured":"Provenzano PP, Hingorani SR. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br J Cancer. 2013;108(1):1\u20138.","journal-title":"Br J Cancer"},{"issue":"4","key":"1634_CR884","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1200\/JCO.2017.74.9564","volume":"36","author":"SR Hingorani","year":"2018","unstructured":"Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, et al. HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel\/gemcitabine versus nab-paclitaxel\/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J Clin Oncol. 2018;36(4):359\u201366.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1634_CR885","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2217\/fon-2017-0338","volume":"14","author":"GJ Doherty","year":"2018","unstructured":"Doherty GJ, Tempero M, Corrie PG. HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. Future Oncol. 2018;14(1):13\u201322.","journal-title":"Future Oncol"},{"issue":"13","key":"1634_CR886","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1200\/JCO.18.01295","volume":"37","author":"RK Ramanathan","year":"2019","unstructured":"Ramanathan RK, McDonough SL, Philip PA, Hingorani SR, Lacy J, Kortmansky JS, et al. Phase IB\/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. J Clin Oncol. 2019;37(13):1062\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1634_CR887","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1634\/theoncologist.2017-0024","volume":"22","author":"AB Benson","year":"2017","unstructured":"Benson AB, Wainberg ZA, Hecht JR, Vyushkov D, Dong H, Bendell J, et al. A phase II randomized, double-blind, placebo-controlled study of simtuzumab or placebo in combination with gemcitabine for the first-line treatment of pancreatic adenocarcinoma. Oncologist. 2017;22(3):241-e15.","journal-title":"Oncologist"},{"issue":"3","key":"1634_CR888","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1634\/theoncologist.2016-0479","volume":"22","author":"JR Hecht","year":"2017","unstructured":"Hecht JR, Benson AB, Vyushkov D, Yang Y, Bendell J, Verma U. A phase II, randomized, double-blind, placebo-controlled study of simtuzumab in combination with FOLFIRI for the second-line treatment of metastatic KRAS mutant colorectal adenocarcinoma. Oncologist. 2017;22(3):243-e23.","journal-title":"Oncologist"},{"issue":"16","key":"1634_CR889","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.3390\/cancers13163946","volume":"13","author":"L De Lellis","year":"2021","unstructured":"De Lellis L, Veschi S, Tinari N, Mokini Z, Carradori S, Brocco D, et al. Drug repurposing, an attractive strategy in pancreatic cancer treatment: preclinical and clinical updates. Cancers (Basel). 2021;13(16):3946.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1634_CR890","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","volume":"9","author":"Y Xia","year":"2024","unstructured":"Xia Y, Sun M, Huang H, Jin WL. Drug repurposing for cancer therapy. Signal Transduct Target Ther. 2024;9(1):92.","journal-title":"Signal Transduct Target Ther"},{"key":"1634_CR891","doi-asserted-by":"publisher","first-page":"1329244","DOI":"10.3389\/fphar.2023.1329244","volume":"14","author":"N Fatemi","year":"2023","unstructured":"Fatemi N, Karimpour M, Bahrami H, Zali MR, Chaleshi V, Riccio A, et al. Current trends and future prospects of drug repositioning in gastrointestinal oncology. Front Pharmacol. 2023;14:1329244.","journal-title":"Front Pharmacol"},{"key":"1634_CR892","doi-asserted-by":"crossref","unstructured":"Xavier CPR, Palmeira A. (2024) Special Issue Drug Repurposing for Cancer Therapies. Int J Mol Sci. 25(2):10-92","DOI":"10.3390\/ijms25021092"},{"issue":"3","key":"1634_CR893","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/ph14030280","volume":"14","author":"R Rebelo","year":"2021","unstructured":"Rebelo R, Pol\u00f3nia B, Santos LL, Vasconcelos MH, Xavier CPR. Drug repurposing opportunities in pancreatic ductal adenocarcinoma. Pharmaceuticals (Basel). 2021;14(3):280.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"1634_CR894","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","volume":"5","author":"JE Murphy","year":"2019","unstructured":"Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol. 2019;5(7):1020\u20137.","journal-title":"JAMA Oncol"},{"issue":"20","key":"1634_CR895","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1001\/jama.2022.6147","volume":"327","author":"PJ Goodwin","year":"2022","unstructured":"Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, et al. Effect of t metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA32 randomized clinical trial. JAMA. 2022;327(20):1963\u201373.","journal-title":"JAMA"},{"issue":"422","key":"1634_CR896","doi-asserted-by":"publisher","first-page":"eaao0475","DOI":"10.1126\/scitranslmed.aao0475","volume":"10","author":"MC Lampi","year":"2018","unstructured":"Lampi MC, Reinhart-King CA. Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials. Sci Transl Med. 2018;10(422):eaao0475.","journal-title":"Sci Transl Med."},{"issue":"5","key":"1634_CR897","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41568-021-00340-6","volume":"21","author":"JC Dawson","year":"2021","unstructured":"Dawson JC, Serrels A, Stupack DG, Schlaepfer DD, Frame MC. Targeting FAK in anticancer combination therapies. Nat Rev Cancer. 2021;21(5):313\u201324.","journal-title":"Nat Rev Cancer"},{"key":"1634_CR898","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113116","volume":"151","author":"X Wu","year":"2022","unstructured":"Wu X, Wang J, Liang Q, Tong R, Huang J, Yang X, et al. Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment. Biomed Pharmacother. 2022;151: 113116.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"1634_CR899","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.3390\/ijms23041998","volume":"23","author":"S Pomella","year":"2022","unstructured":"Pomella S, Cassandri M, Braghini MR, Marampon F, Alisi A, Rota R. New insights on the nuclear functions and targeting of FAK in cancer. Int J Mol Sci. 2022;23(4):1998.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1634_CR900","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/mco2.381","volume":"4","author":"J Chen","year":"2023","unstructured":"Chen J, Zhu Y, \nZhao D, Zhang L, Zhang J, Xiao Y, et al. Co-targeting FAK and Gli inhibits the tumor-associated macrophages-released CCL22-mediated esophageal squamous cell carcinoma malignancy. MedComm. 2023;4(6):381.","journal-title":"MedComm."},{"issue":"9","key":"1634_CR901","doi-asserted-by":"publisher","first-page":"7058","DOI":"10.3390\/cimb45090446","volume":"45","author":"M Jeon","year":"2023","unstructured":"Jeon M, Hong S, Cho H, Park H, Lee SM, Ahn S. Targeting FAK\/PYK2 with SJP1602 for anti-tumor activity in triple-negative breast cancer. Curr Issues Mol Biol. 2023;45(9):7058\u201374.","journal-title":"Curr Issues Mol Biol"},{"key":"1634_CR902","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.863850","volume":"10","author":"C Bergonzini","year":"2022","unstructured":"Bergonzini C, Kroese K, Zweemer AJM, Danen EHJ. Targeting integrins for cancer therapy - disappointments and opportunities. Front Cell Dev Biol. 2022;10: 863850.","journal-title":"Front Cell Dev Biol"},{"key":"1634_CR903","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116246","volume":"224","author":"M Yang","year":"2024","unstructured":"Yang M, Xiang H, Luo G. Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders. Biochem Pharmacol. 2024;224: 116246.","journal-title":"Biochem Pharmacol"},{"key":"1634_CR904","doi-asserted-by":"publisher","first-page":"11675","DOI":"10.1038\/ncomms11675","volume":"7","author":"RC Turaga","year":"2016","unstructured":"Turaga RC, Yin L, Yang JJ, Lee H, Ivanov I, Yan C, et al. Rational design of a protein that binds integrin \u03b1v\u03b23 outside the ligand binding site. Nat Commun. 2016;7:11675.","journal-title":"Nat Commun"},{"key":"1634_CR905","doi-asserted-by":"crossref","unstructured":"Patnaik A, Calvo E, Piha-Paul SAA, Hollebecque A, Galvao V, Lopez JS. A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, Trial in Progress). Wolters Kluwer Health. 2021.","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS3144"},{"issue":"12","key":"1634_CR906","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/nm.4431","volume":"23","author":"N Hosen","year":"2017","unstructured":"Hosen N, Matsunaga Y, Hasegawa K, Matsuno H, Nakamura Y, Makita M, et al. The activated conformation of integrin \u03b27 is a novel multiple myeloma\u2013specific target for CAR T cell therapy. Nat Med. 2017;23(12):1436\u201343.","journal-title":"Nat Med"},{"issue":"2","key":"1634_CR907","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/mc.23273","volume":"60","author":"L Zhang","year":"2021","unstructured":"Zhang L, Zhao D, Wang Y, Zhang W, Zhang J, Fan J, et al. Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K\/AKT axis and downstream molecular network. Mol Carcinog. 2021;60(2):113\u201324.","journal-title":"Mol Carcinog"},{"issue":"3","key":"1634_CR908","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.3390\/ijms23031726","volume":"23","author":"HH Chuang","year":"2022","unstructured":"Chuang HH, Zhen YY, Tsai YC, Chuang CH, Hsiao M, Huang MS, et al. FAK in cancer: from mechanisms to therapeutic strategies. Int J Mol Sci. 2022;23(3):1726.","journal-title":"Int J Mol Sci"},{"issue":"24","key":"1634_CR909","doi-asserted-by":"publisher","first-page":"5254","DOI":"10.1158\/1078-0432.CCR-22-0308","volume":"28","author":"A Wang-Gillam","year":"2022","unstructured":"Wang-Gillam A, Lim KH, McWilliams R, Suresh R, Lockhart AC, Brown A, et al. Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: a phase i dose escalation and expansion study. Clin Cancer Res. 2022;28(24):5254\u201362.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1634_CR910","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","volume":"37","author":"DA Fennell","year":"2019","unstructured":"Fennell \nDA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, et al. Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND-a double-blind, randomized. Phase II Study J Clin Oncol. 2019;37(10):790\u20138.","journal-title":"Phase II Study J Clin Oncol"},{"issue":"6","key":"1634_CR911","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.21037\/jgo-22-86","volume":"13","author":"KL Aung","year":"2022","unstructured":"Aung KL, McWhirter E, Welch S, Wang L, Lovell S, Stayner LA, et al. A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. J Gastrointest Oncol. 2022;13(6):3216\u201326.","journal-title":"J Gastrointest Oncol"},{"issue":"13","key":"1634_CR912","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.19.00056","volume":"37","author":"A Wang-Gillam","year":"2019","unstructured":"Wang-Gillam A. Targeting stroma: a tale of caution. J Clin Oncol. 2019;37(13):1041\u20133.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1634_CR913","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s10555-022-10067-x","volume":"41","author":"E Andreucci","year":"2022","unstructured":"Andreucci E, Peppicelli S, Ruzzolini J, Bianchini F, Calorini L. Physicochemical aspects of the tumour microenvironment as drivers of vasculogenic mimicry. Cancer Metastasis Rev. 2022;41(4):935\u201351.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"1634_CR914","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/biomedicines11010210","volume":"11","author":"Y Hashimoto","year":"2023","unstructured":"Hashimoto Y, Tsuzuki-Nakao T, Kida N, Matsuo Y, Maruyama T, Okada H, et al. Inflammatory cytokine-induced HIF-1 activation promotes epithelial-mesenchymal transition in endometrial epithelial cells. Biomedicines. 2023;11(1):210.","journal-title":"Biomedicines."},{"issue":"1","key":"1634_CR915","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41392-022-01080-1","volume":"7","author":"Z Luo","year":"2022","unstructured":"Luo Z, Tian M, Yang G, Tan Q, Chen Y, Li G, et al. Hypoxia signaling in human health and diseases: implications and prospects for therapeutics. Signal Transduct Target Ther. 2022;7(1):218.","journal-title":"Signal Transduct Target Ther"},{"issue":"15","key":"1634_CR916","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1200\/jco.2010.28.15_suppl.3076","volume":"28","author":"R Tibes","year":"2010","unstructured":"Tibes R, Falchook GS, Von Hoff DD, Weiss GJ, Iyengar T, Kurzrock R, et al. Results from a phase, I dose-escalation study of PX-478, an orally available inhibitor of HIF-1\u03b1 (Abstract). J Clin Oncol. 2010;28(15):3076.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1634_CR917","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1158\/1535-7163.MCT-08-0510","volume":"7","author":"LM Greenberger","year":"2008","unstructured":"Greenberger LM, Horak ID, Filpula D, Sapra P, Westergaard M, Frydenlund HF, et al. A RNA antagonist of hypoxia-inducible factor-1\u03b1, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther. 2008;7(11):3598\u2013608.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1634_CR918","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3349\/ymj.2017.58.3.489","volume":"58","author":"T Yu","year":"2017","unstructured":"Yu T, Tang B, Sun X. Development of inhibitors targeting hypoxia-inducible factor 1 and 2 for cancer therapy. Yonsei Med J. 2017;58(3):489\u201396.","journal-title":"Yonsei Med J"},{"issue":"7","key":"1634_CR919","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1073\/pnas.0812801106","volume":"106","author":"K Lee","year":"2009","unstructured":"Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci. 2009;106(7):2353\u20138.","journal-title":"Proc Natl Acad Sci"},{"key":"1634_CR920","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3389\/fbioe.2020.00335","volume":"8","author":"YK Reshetnyak","year":"2020","unstructured":"Reshetnyak YK, Moshnikova A, Andreev OA, Engelman DM. Targeting acidic diseased tissues by pH-triggered membrane-associated peptide folding. Front Bioeng Biotechnol. 2020;8:335.","journal-title":"Front Bioeng Biotechnol"},{"issue":"10","key":"1634_CR921","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1021\/acs.bioconjchem.3c00401","volume":"34","author":"T Chu","year":"2023","unstructured":"Chu T, Cao B, Wang P, Li B, Ren J, Nie G, et al. Tumor-Targeted delivery of IL-2 by fusing with a pH Low insertion peptide for antitumor immunotherapy. Bioconjug Chem. 2023;34(10):1894\u2013901.","journal-title":"Bioconjug Chem"},{"issue":"15","key":"1634_CR922","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202207366","volume":"10","author":"Q Yang","year":"2023","unstructured":"Yang Q, Wang B, Zheng Q, Li H, Meng X, Zhou F, et al. A Review of gut microbiota-derived metabolites in tumor progression and cancer therapy. Adv Sci (Weinh). 2023;10(15): e2207366.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"1634_CR923","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-024-01541-w","volume":"17","author":"Z Li","year":"2024","unstructured":"Li Z, Xiong W, Liang Z, Wang J, Zeng Z, Ko\u0142at D, et al. Critical role of the gut microbiota in immune responses and cancer immunotherapy. J Hematol Oncol. 2024;17(1):33.","journal-title":"J Hematol Oncol"},{"key":"1634_CR924","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107321","volume":"207","author":"C Cao","year":"2024","unstructured":"Cao C, Yue S, Lu A, Liang C. Host-gut microbiota metabolic interactions and their role in precision diagnosis and treatment of gastrointestinal cancers. Pharmacol Res. 2024;207: 107321.","journal-title":"Pharmacol Res"},{"issue":"8027","key":"1634_CR925","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/s41586-024-07754-w","volume":"632","author":"B Roje","year":"2024","unstructured":"Roje B, Zhang B, Mastrorilli E, Kova\u010di\u0107 A, Su\u0161ak L, Ljubenkov I, et al. Gut microbiota carcinogen metabolism causes distal tissue tumours. Nature. 2024;632(8027):1137\u201344.","journal-title":"Nature"},{"issue":"15","key":"1634_CR926","doi-asserted-by":"publisher","first-page":"14429","DOI":"10.1007\/s00432-023-05244-6","volume":"149","author":"I Bene\u0161ov\u00e1","year":"2023","unstructured":"Bene\u0161ov\u00e1 I, K\u0159\u00ed\u017eov\u00e1 \u013d, Kverka M. Microbiota as the unifying factor behind the hallmarks of cancer. J Cancer Res Clin Oncol. 2023;149(15):14429\u201350.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"1634_CR927","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41568-022-00513-x","volume":"22","author":"MR Fernandes","year":"2022","unstructured":"Fernandes MR, Aggarwal P, Costa RGF, Cole AM, Trinchieri G. Targeting the gut microbiota for cancer therapy. Nat Rev Cancer. 2022;22(12):703\u201322.","journal-title":"Nat Rev Cancer"},{"key":"1634_CR928","doi-asserted-by":"publisher","first-page":"1287077","DOI":"10.3389\/fmicb.2024.1287077","volume":"15","author":"P Feng","year":"2024","unstructured":"Feng P, Xue X, Bukhari I, Qiu C, Li Y, Zheng P, et al. Gut microbiota and its therapeutic implications in tumor microenvironment interactions. Front Microbiol. 2024;15:1287077.","journal-title":"Front Microbiol"},{"issue":"1","key":"1634_CR929","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12866-023-03166-4","volume":"24","author":"G Pourali","year":"2024","unstructured":"Pourali G, Kazemi D, Chadeganipour AS, Arastonejad M, Kashani SN, Pourali R, et al. Microbiome as a biomarker and therapeutic target in pancreatic cancer. BMC Microbiol. 2024;24(1):16.","journal-title":"BMC Microbiol"},{"issue":"8","key":"1634_CR930","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/s41591-021-01406-6","volume":"27","author":"MC Andrews","year":"2021","unstructured":"Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021;27(8):1432\u201341.","journal-title":"Nat Med"},{"issue":"6529","key":"1634_CR931","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371(6529):595\u2013602.","journal-title":"Science"},{"issue":"6529","key":"1634_CR932","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","volume":"371","author":"EN Baruch","year":"2021","unstructured":"Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371(6529):602\u20139.","journal-title":"Science"},{"key":"1634_CR933","doi-asserted-by":"publisher","first-page":"1020583","DOI":"10.3389\/fcimb.2022.1020583","volume":"12","author":"S Ou","year":"2022","unstructured":"Ou S, Wang H, Tao Y, Luo K, Ye J, Ran S, et al. Fusobacterium nucleatum and colorectal cancer: from phenomenon to mechanism. Front Cell Infect Microbiol. 2022;12:1020583.","journal-title":"Front Cell Infect Microbiol"},{"issue":"9","key":"1634_CR934","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1093\/ibd\/izy182","volume":"24","author":"L Zhou","year":"2018","unstructured":"Zhou L, Zhang M, Wang Y, Dorfman RG, Liu H, Yu T, et al. Faecalibacterium prausnitzii produces butyrate to maintain Th17\/Treg balance and to ameliorate colorectal colitis by inhibiting histone deacetylase 1. Inflamm Bowel Dis. 2018;24(9):1926\u201340.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"1634_CR935","doi-asserted-by":"publisher","first-page":"14943","DOI":"10.1038\/s41598-021-94384-1","volume":"11","author":"W Shao","year":"2021","unstructured":"Shao W, Fujiwara N, Mouri Y, Kisoda S, Yoshida K, Yumoto H, et al. Conversion from epithelial to partial-EMT phenotype by Fusobacterium nucleatum infection promotes invasion of oral cancer cells. Sci Rep. 2021;11(1):14943.","journal-title":"Sci Rep"},{"key":"1634_CR936","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.759691","volume":"9","author":"J Deng","year":"2021","unstructured":"Deng J, Fleming JB. Inflammation and myeloid cells in cancer progression and metastasis. Front Cell Dev Biol. 2021;9: 759691.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"1634_CR937","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.3390\/nu14061152","volume":"14","author":"AS Gheorghe","year":"2022","unstructured":"Gheorghe AS, Negru \u0218, Preda M, Mih\u0103il\u0103 RI, Komporaly IA, Dumitrescu EA, et al. Biochemical and metabolical pathways associated with microbiota-derived butyrate in colorectal cancer and omega-3 fatty acids implications: a narrative review. Nutrients. 2022;14(6):1152.","journal-title":"Nutrients"},{"issue":"5","key":"1634_CR938","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3390\/biomedicines10051131","volume":"10","author":"B Garavaglia","year":"2022","unstructured":"Garavaglia B, Vallino L, Ferraresi A, Esposito A, Salwa A, Vidoni C, et al. Butyrate inhibits colorectal cancer cell proliferation through autophagy degradation of \u03b2-catenin regardless of. Biomedicines. 2022;10(5):1131.","journal-title":"Biomedicines."},{"issue":"12","key":"1634_CR939","doi-asserted-by":"publisher","first-page":"e2200028","DOI":"10.1002\/mnfr.202200028","volume":"66","author":"L Wang","year":"2022","unstructured":"Wang L, Shannar AAF, Wu R, Chou P, Sarwar MS, Kuo HC, et al. Butyrate drives metabolic rewiring and epigenetic reprogramming in human colon cancer cells. Mol Nutr Food Res. 2022;66(12):e2200028.","journal-title":"Mol Nutr Food Res"},{"issue":"4","key":"1634_CR940","first-page":"4439","volume":"16","author":"T Xiao","year":"2018","unstructured":"Xiao T, Wu S, Yan C, Zhao C, Jin H, Yan N, et al. Butyrate upregulates the TLR4 expression and the phosphorylation of MAPKs and NK-\u03baB in colon cancer cell. Oncol Lett. 2018;16(4):4439\u201347.","journal-title":"Oncol Lett"},{"issue":"7","key":"1634_CR941","doi-asserted-by":"publisher","first-page":"e28093","DOI":"10.1016\/j.heliyon.2024.e28093","volume":"10","author":"R Bi","year":"2024","unstructured":"Bi R, Jiang L, Hu R, Wen B, Jiang Z, Liu H, et al. Butyrate attenuates the stemness of lung cancer cells through lysosome Fe. Heliyon. 2024;10(7):e28093.","journal-title":"Heliyon"},{"issue":"5","key":"1634_CR942","doi-asserted-by":"publisher","first-page":"540","DOI":"10.2174\/187152008784533008","volume":"8","author":"A Zimber","year":"2008","unstructured":"Zimber A, Gespach C. Bile acids and derivatives, their nuclear receptors FXR, PXR and ligands: role in health and disease and their therapeutic potential. Anticancer Agents Med Chem. 2008;8(5):540\u201363.","journal-title":"Anticancer Agents Med Chem"},{"key":"1634_CR943","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jare.2023.11.027","volume":"64","author":"S Li","year":"2023","unstructured":"Li S, Zhu S, Yu J. The role of gut microbiota and metabolites in cancer chemotherapy. J Adv Res. 2023;64:223\u201335.","journal-title":"J Adv Res"},{"issue":"12","key":"1634_CR944","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1007\/s12094-022-02919-3","volume":"24","author":"L Liu","year":"2022","unstructured":"Liu L, Bai Y, Xiang L, Qi W, Gao L, Li X, et al. Interaction between gut microbiota and tumour chemotherapy. Clin Transl Oncol. 2022;24(12):2330\u201341.","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"1634_CR945","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41591-019-0377-7","volume":"25","author":"BA Helmink","year":"2019","unstructured":"Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V, Wargo JA. The microbiome, cancer, and cancer therapy. Nat Med. 2019;25(3):377\u201388.","journal-title":"Nat Med"},{"issue":"9","key":"1634_CR946","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41577-020-0374-6","volume":"20","author":"BB Finlay","year":"2020","unstructured":"Finlay BB, Goldszmid R, Honda K, Trinchieri G, Wargo J, Zitvogel L. Can we harness the microbiota to enhance the efficacy of cancer immunotherapy? Nat Rev Immunol. 2020;20(9):522\u20138.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"1634_CR947","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.neo.2017.08.004","volume":"19","author":"AE Frankel","year":"2017","unstructured":"Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, et al. Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia. 2017;19(10):848\u201355.","journal-title":"Neoplasia"},{"issue":"6371","key":"1634_CR948","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u20137.","journal-title":"Science"},{"issue":"6371","key":"1634_CR949","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. \nScience. 2018;359(6371):104\u20138.","journal-title":"Science"},{"issue":"6371","key":"1634_CR950","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97\u2013103.","journal-title":"Science"},{"issue":"4","key":"1634_CR951","doi-asserted-by":"publisher","first-page":"101478","DOI":"10.1016\/j.xcrm.2024.101478","volume":"5","author":"X Kang","year":"2024","unstructured":"Kang X, Lau HC, Yu J. Modulating gut microbiome in cancer immunotherapy: harnessing microbes to enhance treatment efficacy. Cell Rep Med. 2024;5(4):101478.","journal-title":"Cell Rep Med"},{"issue":"3","key":"1634_CR952","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.cell.2017.07.008","volume":"170","author":"T Yu","year":"2017","unstructured":"Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170(3):548-63.e16.","journal-title":"Cell"},{"issue":"18","key":"1634_CR953","doi-asserted-by":"publisher","first-page":"10525","DOI":"10.1111\/jcmm.15668","volume":"24","author":"QW Liu","year":"2020","unstructured":"Liu QW, Li JY, Zhang XC, Liu Y, Liu QY, Xiao L, et al. Human amniotic mesenchymal stem cells inhibit hepatocellular carcinoma in tumour-bearing mice. J Cell Mol Med. 2020;24(18):10525\u201341.","journal-title":"J Cell Mol Med"},{"issue":"45","key":"1634_CR954","doi-asserted-by":"publisher","first-page":"e2004529","DOI":"10.1002\/adma.202004529","volume":"32","author":"DW Zheng","year":"2020","unstructured":"Zheng DW, Li RQ, An JX, Xie TQ, Han ZY, Xu R, et al. Prebiotics-encapsulated probiotic spores regulate gut microbiota and suppress colon cancer. Adv Mater. 2020;32(45):e2004529.","journal-title":"Adv Mater"},{"issue":"17","key":"1634_CR955","doi-asserted-by":"publisher","first-page":"5135","DOI":"10.7150\/jca.47470","volume":"11","author":"Y Gao","year":"2020","unstructured":"Gao Y, Shang Q, Li W, Guo W, Stojadinovic A, Mannion C, et al. Antibiotics for cancer treatment: a double-edged sword. J Cancer. 2020;11(17):5135\u201349.","journal-title":"J Cancer"},{"issue":"5","key":"1634_CR956","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/cancers13050957","volume":"13","author":"Y Yoon","year":"2021","unstructured":"Yoon Y, Kim G, Jeon BN, Fang S, Park H. Strain-specific enhances the efficacy of cancer therapeutics in tumor-bearing mice. Cancers (Basel). 2021;13(5):957.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1634_CR957","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1038\/s41467-019-11738-0","volume":"10","author":"Z Xiao","year":"2019","unstructured":"Xiao Z, Dai Z, Locasale JW. Metabolic landscape of the tumor microenvironment at single cell resolution. Nat Commun. 2019;10(1):3763.","journal-title":"Nat Commun"},{"issue":"1","key":"1634_CR958","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s42255-020-00317-z","volume":"3","author":"I Elia","year":"2021","unstructured":"Elia I, Haigis MC. Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat Metab. 2021;3(1):21\u201332.","journal-title":"Nat Metab"},{"key":"1634_CR959","doi-asserted-by":"publisher","first-page":"1325360","DOI":"10.3389\/fimmu.2023.1325360","volume":"14","author":"T Katopodi","year":"2023","unstructured":"Katopodi T, Petanidis S, Anestakis D, Charalampidis C, Chatziprodromidou I, Floros G, et al. Tumor cell metabolic reprogramming and hypoxic immunosuppression: driving carcinogenesis to metastatic colonization. Front Immunol. 2023;14:1325360.","journal-title":"Front Immunol"},{"issue":"10","key":"1634_CR960","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.3390\/ijms25105288","volume":"25","author":"S Ucche","year":"2024","unstructured":"Ucche S, Hayakawa Y. Immunological aspects of cancer cell metabolism. Int J Mol Sci. 2024;25(10):5288.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1634_CR961","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41420-024-02006-2","volume":"10","author":"R Su","year":"2024","unstructured":"Su R, Shao Y, Huang M, Liu D, Yu H, Qiu Y. Immunometabolism in cancer: basic mechanisms and new targeting strategy. Cell Death Discov. 2024;10(1):236.","journal-title":"Cell Death Discov"},{"key":"1634_CR962","doi-asserted-by":"publisher","first-page":"1347181","DOI":"10.3389\/fimmu.2024.1347181","volume":"15","author":"L Xuekai","year":"2024","unstructured":"Xuekai L, Yan S, Jian C, Yifei S, Xinyue W, Wenyuan Z, et al. Advances in reprogramming of energy metabolism in tumor T cells. Front Immunol. 2024;15:1347181.","journal-title":"Front Immunol"},{"issue":"5","key":"1634_CR963","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cmet.2024.03.015","volume":"36","author":"J Liu","year":"2024","unstructured":"Liu J, He X, Deng S, Zhao S, Zhang S, Chen Z, et al. QDPR deficiency drives immune suppression in pancreatic cancer. Cell Metab. 2024;36(5):984-99.e8.","journal-title":"Cell Metab"},{"key":"1634_CR964","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ceb.2017.05.006","volume":"48","author":"M Reina-Campos","year":"2017","unstructured":"Reina-Campos M, Moscat J, Diaz-Meco M. Metabolism shapes the tumor microenvironment. Curr Opin Cell Biol. 2017;48:47\u201353.","journal-title":"Curr Opin Cell Biol"},{"issue":"11","key":"1634_CR965","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.tcb.2017.06.003","volume":"27","author":"CA Lyssiotis","year":"2017","unstructured":"Lyssiotis CA, Kimmelman AC. Metabolic interactions in the tumor microenvironment. Trends Cell Biol. 2017;27(11):863\u201375.","journal-title":"Trends Cell Biol"},{"issue":"1","key":"1634_CR966","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41416-018-0327-z","volume":"120","author":"NA Giraldo","year":"2019","unstructured":"Giraldo NA, Sanchez-Salas R, Peske JD, Vano Y, Becht E, Petitprez F, et al. The clinical role of the TME in solid cancer. Br J Cancer. 2019;120(1):45\u201353.","journal-title":"Br J Cancer"},{"issue":"9","key":"1634_CR967","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582\u201398.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"1634_CR968","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1158\/2326-6066.CIR-17-0190","volume":"5","author":"AN Woods","year":"2017","unstructured":"Woods AN, Wilson AL, Srivinisan N, Zeng J, Dutta AB, Peske JD, et al. Differential expression of homing receptor ligands on tumor-associated vasculature that control CD8 effector T-cell entry. Cancer Immunol Res. 2017;5(12):1062\u201373.","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"1634_CR969","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 2016;24(5):657\u201371.","journal-title":"Cell Metab"},{"issue":"3","key":"1634_CR970","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.4049\/jimmunol.0902584","volume":"184","author":"K Dietl","year":"2010","unstructured":"Dietl K, Renner K, Dettmer K, Timischl B, Eberhart K, Dorn C, et al. Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes. J Immunol. 2010;184(3):1200\u20139.","journal-title":"J Immunol"},{"issue":"1","key":"1634_CR971","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova \nNN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27\u201347.","journal-title":"Cell Metab"},{"issue":"6","key":"1634_CR972","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.trecan.2019.05.001","volume":"5","author":"UE H\u00f6pken","year":"2019","unstructured":"H\u00f6pken UE, Rehm A. Targeting the tumor microenvironment of leukemia and lymphoma. Trends Cancer. 2019;5(6):351\u201364.","journal-title":"Trends Cancer"},{"issue":"1","key":"1634_CR973","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1182\/asheducation-2017.1.610","volume":"2017","author":"K Tarte","year":"2017","unstructured":"Tarte K. Role of the microenvironment across histological subtypes of NHL. Hematology Am Soc Hematol Educ Program. 2017;2017(1):610\u20137.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"1634_CR974","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.3389\/fimmu.2018.01977","volume":"9","author":"RM Awad","year":"2018","unstructured":"Awad RM, De Vlaeminck Y, Maebe J, Goyvaerts C, Breckpot K. Turn back the time: targeting tumor infiltrating myeloid cells to revert cancer progression. Front Immunol. 2018;9:1977.","journal-title":"Front Immunol"},{"issue":"7","key":"1634_CR975","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.celrep.2016.01.042","volume":"14","author":"G Galletti","year":"2016","unstructured":"Galletti G, Scielzo C, Barbaglio F, Rodriguez TV, Riba M, Lazarevic D, et al. Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression. Cell Rep. 2016;14(7):1748\u201360.","journal-title":"Cell Rep"},{"issue":"11\u201312","key":"1634_CR976","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00335-018-9756-5","volume":"29","author":"K Gowrishankar","year":"2018","unstructured":"Gowrishankar K, Birtwistle L, Micklethwaite K. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells. Mamm Genome. 2018;29(11\u201312):739\u201356.","journal-title":"Mamm Genome"},{"issue":"4","key":"1634_CR977","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1093\/bib\/bby011","volume":"20","author":"SH Yip","year":"2019","unstructured":"Yip SH, Sham PC, Wang J. Evaluation of tools for highly variable gene discovery from single-cell RNA-seq data. Brief Bioinform. 2019;20(4):1583\u20139.","journal-title":"Brief Bioinform"},{"issue":"1","key":"1634_CR978","doi-asserted-by":"publisher","DOI":"10.1002\/cpmb.57","volume":"122","author":"TK Olsen","year":"2018","unstructured":"Olsen TK, Baryawno N. Introduction to single-cell RNA sequencing. Curr Protoc Mol Biol. 2018;122(1): e57.","journal-title":"Curr Protoc Mol Biol"},{"key":"1634_CR979","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3389\/fonc.2020.00447","volume":"10","author":"Y Wang","year":"2020","unstructured":"Wang Y, Mashock M, Tong Z, Mu X, Chen H, Zhou X, et al. Changing technologies of RNA sequencing and their applications in clinical oncology. Front Oncol. 2020;10:447.","journal-title":"Front Oncol"},{"issue":"6","key":"1634_CR980","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1038\/s41596-022-00692-9","volume":"17","author":"FC Grandi","year":"2022","unstructured":"Grandi FC, Modi H, Kampman L, Corces MR. Chromatin accessibility profiling by ATAC-seq. Nat Protoc. 2022;17(6):1518\u201352.","journal-title":"Nat Protoc"},{"issue":"14","key":"1634_CR981","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1182\/blood.2021013926","volume":"139","author":"N Purroy","year":"2022","unstructured":"Purroy N, Tong YE, Lemvigh CK, Cieri N, Li S, Parry EM, et al. Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. Blood. 2022;139(14):2252\u20136.","journal-title":"Blood"},{"key":"1634_CR982","doi-asserted-by":"publisher","first-page":"1143811","DOI":"10.3389\/fonc.2023.1143811","volume":"13","author":"B Oder","year":"2023","unstructured":"Oder B, Chatzidimitriou A, Langerak AW, Rosenquist R, \u00d6sterholm C. Recent revelations and future directions using single-cell technologies in chronic lymphocytic leukemia. Front Oncol. 2023;13:1143811.","journal-title":"Front Oncol"},{"issue":"1","key":"1634_CR983","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-020-00931-0","volume":"13","author":"M Zanoni","year":"2020","unstructured":"Zanoni M, Cortesi M, Zamagni A, Arienti C, Pignatta S, Tesei A. Modeling neoplastic disease with spheroids and organoids. J Hematol Oncol. 2020;13(1):97.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"1634_CR984","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/med.21765","volume":"41","author":"H Sadeghi Rad","year":"2021","unstructured":"Sadeghi Rad H, Monkman J, Warkiani ME, Ladwa R, O\u2019Byrne K, Rezaei N, et al. Understanding the tumor microenvironment for effective immunotherapy. Med Res Rev. 2021;41(3):1474\u201398.","journal-title":"Med Res Rev"},{"key":"1634_CR985","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.coi.2015.12.003","volume":"39","author":"AM Cook","year":"2016","unstructured":"Cook AM, Lesterhuis WJ, Nowak AK, Lake RA. Chemotherapy and immunotherapy: mapping the road ahead. Curr Opin Immunol. 2016;39:23\u20139.","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"1634_CR986","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541\u201350.","journal-title":"Nat Med"},{"issue":"2","key":"1634_CR987","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","volume":"12","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 Immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol. 2017;12(2):208\u201322.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"1634_CR988","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):e542\u201351.","journal-title":"Lancet Oncol"},{"issue":"25","key":"1634_CR989","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376(25):2415\u201326.","journal-title":"N Engl J Med"},{"issue":"5","key":"1634_CR990","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","volume":"33","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell. 2018;33(5):843-52.e4.","journal-title":"Cancer Cell"},{"key":"1634_CR991","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40425-017-0243-4","volume":"5","author":"S Gnjatic","year":"2017","unstructured":"Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, et al. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer. 2017;5:44.","journal-title":"J Immunother Cancer"},{"issue":"5795","key":"1634_CR992","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pag\u00e8s C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960\u20134.","journal-title":"Science"},{"issue":"6","key":"1634_CR993","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1200\/JCO.2010.30.5425","volume":"29","author":"B Mlecnik","year":"2011","unstructured":"Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6):610\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1634_CR994","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.4287","volume":"232","author":"J Galon","year":"2014","unstructured":"Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, et al. Towards the introduction of the \u201cImmunoscore\u201d in the classification of malignant tumours. J Pathol. 2014;232(2):199\u2013209.","journal-title":"J Pathol"},{"issue":"1","key":"1634_CR995","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/1078-0432.CCR-18-1984","volume":"25","author":"HH Yoon","year":"2019","unstructured":"Yoon HH, Shi Q, Heying EN, Muranyi A, Bredno J, Ough F, et al. Intertumoral heterogeneity of CD3+ and CD8+ T-cell densities in the microenvironment of DNA mismatch-repair-deficient colon cancers: implications for prognosis. Clin Cancer Res. 2019;25(1):125\u201333.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1634_CR996","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa0905680","volume":"362","author":"C Steidl","year":"2010","unstructured":"Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma. N Engl J Med. 2010;362(10):875\u201385.","journal-title":"N Engl J Med"},{"issue":"18","key":"1634_CR997","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1158\/1078-0432.CCR-10-0593","volume":"16","author":"DS Hsu","year":"2010","unstructured":"Hsu DS, Lan HY, Huang CH, Tai SK, Chang SY, Tsai TL, et al. Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. Clin Cancer Res. 2010;16(18):4561\u201371.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1634_CR998","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.lungcan.2008.02.007","volume":"62","author":"W Zhuo","year":"2008","unstructured":"Zhuo W, Wang Y, Zhuo X, Zhang Y, Ao X, Chen Z. Knockdown of Snail, a novel zinc finger transcription factor, via RNA interference increases A549 cell sensitivity to cisplatin via JNK\/mitochondrial pathway. Lung Cancer. 2008;62(1):8\u201314.","journal-title":"Lung Cancer"},{"issue":"2","key":"1634_CR999","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jss.2006.09.027","volume":"141","author":"T Yin","year":"2007","unstructured":"Yin T, Wang C, Liu T, Zhao G, Zha Y, Yang M. Expression of snail in pancreatic cancer promotes metastasis and chemoresistance. J Surg Res. 2007;141(2):196\u2013203.","journal-title":"J Surg Res"},{"issue":"3","key":"1634_CR1000","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3892\/ijo.2016.3342","volume":"48","author":"JJ Deng","year":"2016","unstructured":"Deng JJ, Zhang W, Xu XM, Zhang F, Tao WP, Ye JJ, et al. Twist mediates an aggressive phenotype in human colorectal cancer cells. Int J Oncol. 2016;48(3):1117\u201324.","journal-title":"Int J Oncol"},{"issue":"2","key":"1634_CR1001","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/cdd.2013.123","volume":"21","author":"E S\u00e1nchez-Till\u00f3","year":"2014","unstructured":"S\u00e1nchez-Till\u00f3 E, Fanlo L, Siles L, Montes-Moreno S, Moros A, Chiva-Blanch G, et al. The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma. Cell Death Differ. 2014;21(2):247\u201357.","journal-title":"Cell Death Differ"},{"issue":"8","key":"1634_CR1002","doi-asserted-by":"publisher","first-page":"e23108","DOI":"10.1371\/journal.pone.0023108","volume":"6","author":"J Benito","year":"2011","unstructured":"Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, et al. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS ONE. 2011;6(8):e23108.","journal-title":"PLoS ONE"},{"issue":"10","key":"1634_CR1003","doi-asserted-by":"publisher","first-page":"858","DOI":"10.4161\/cbt.20838","volume":"13","author":"O Frolova","year":"2012","unstructured":"Frolova O, Samudio I, Benito JM, Jacamo R, Kornblau SM, Markovic A, et al. Regulation of HIF-1\u03b1 signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther. 2012;13(10):858\u201370.","journal-title":"Cancer Biol Ther"},{"issue":"8","key":"1634_CR1004","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-09-0150","volume":"8","author":"Y Hu","year":"2009","unstructured":"Hu Y, Kirito K, Yoshida K, Mitsumori T, Nakajima K, Nozaki Y, et al. Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. Mol Cancer Ther. 2009;8(8):2329\u201338.","journal-title":"Mol Cancer Ther"},{"issue":"23","key":"1634_CR1005","doi-asserted-by":"publisher","first-page":"6851","DOI":"10.1158\/0008-5472.CAN-16-1201","volume":"76","author":"L Ireland","year":"2016","unstructured":"Ireland L, Santos A, Ahmed MS, Rainer C, Nielsen SR, Quaranta V, et al. Chemoresistance in pancreatic cancer is driven by stroma-derived insulin-like growth factors. Cancer Res. 2016;76(23):6851\u201363.","journal-title":"Cancer Res"},{"issue":"1","key":"1634_CR1006","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12943-021-01463-y","volume":"20","author":"C Li","year":"2021","unstructured":"Li C, Teixeira AF, Zhu HJ, Ten Dijke P. Cancer associated-fibroblast-derived exosomes in cancer progression. Mol Cancer. 2021;20(1):154.","journal-title":"Mol Cancer"},{"key":"1634_CR1007","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12935-019-1051-3","volume":"19","author":"H Guo","year":"2019","unstructured":"Guo H, Ha C, Dong H, Yang Z, Ma Y, Ding Y. Cancer-associated fibroblast-derived exosomal microRNA-98-5p promotes cisplatin resistance in ovarian cancer by targeting CDKN1A. Cancer Cell Int. 2019;19:347.","journal-title":"Cancer Cell Int"},{"issue":"21","key":"1634_CR1008","doi-asserted-by":"publisher","first-page":"2002518","DOI":"10.1002\/advs.202002518","volume":"7","author":"Y Gao","year":"2020","unstructured":"Gao Y, Li X, Zeng C, Liu C, Hao Q, Li W, et al. CD63(+) Cancer-associated fibroblasts confer tamoxifen resistance to breast cancer cells through exosomal miR-22. Adv Sci (Weinh). 2020;7(21):2002518.","journal-title":"Adv Sci (Weinh)"},{"issue":"7","key":"1634_CR1009","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/onc.2017.387","volume":"37","author":"Y Qiao","year":"2018","unstructured":"Qiao Y, Zhang C, Li A, Wang D, Luo Z, Ping Y, et al. IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma. Oncogene. 2018;37(7):873\u201383.","journal-title":"Oncogene"},{"issue":"10","key":"1634_CR1010","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.3390\/ijms19102861","volume":"19","author":"DA Senthebane","year":"2018","unstructured":"Senthebane DA, Jonker T, Rowe A, Thomford NE, Munro D, Dandara C, et al. The role of tumor microenvironment in chemoresistance: 3D extracellular matrices as accomplices. Int J Mol Sci. 2018;19(10):2861.","journal-title":"Int J Mol Sci"},{"key":"1634_CR1011","doi-asserted-by":"publisher","first-page":"1323914","DOI":"10.3389\/fonc.2024.1323914","volume":"14","author":"P Pophali","year":"2024","unstructured":"Pophali P, Varela JC, Rosenblatt J. Immune checkpoint blockade in hematological malignancies: current state and future potential. Front Oncol. 2024;14:1323914.","journal-title":"Front Oncol"},{"issue":"8","key":"1634_CR1012","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3390\/cancers16081599","volume":"16","author":"P Bl\u00fcm","year":"2024","unstructured":"Bl\u00fcm P, Kayser S. Chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies: clinical implications and limitations. Cancers (Basel). 2024;16(8):1599.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"1634_CR1013","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/annonc\/mdy551","volume":"30","author":"KM Heinhuis","year":"2019","unstructured":"Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol. 2019;30(2):219\u201335.","journal-title":"Ann Oncol"},{"issue":"17","key":"1634_CR1014","doi-asserted-by":"publisher","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","volume":"115","author":"E Peranzoni","year":"2018","unstructured":"Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci U S A. 2018;115(17):E4041\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"389","key":"1634_CR1015","doi-asserted-by":"publisher","first-page":"eaal3604","DOI":"10.1126\/scitranslmed.aal3604","volume":"9","author":"SP Arlauckas","year":"2017","unstructured":"Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, et al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med. 2017;9(389):eaal3604.","journal-title":"Sci Transl Med."},{"issue":"34","key":"1634_CR1016","doi-asserted-by":"publisher","first-page":"55804","DOI":"10.18632\/oncotarget.18437","volume":"8","author":"PE Clavijo","year":"2017","unstructured":"Clavijo PE, Moore EC, Chen J, Davis RJ, Friedman J, Kim Y, et al. Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells. Oncotarget. 2017;8(34):55804\u201320.","journal-title":"Oncotarget"},{"issue":"2","key":"1634_CR1017","doi-asserted-by":"publisher","first-page":"36","DOI":"10.14715\/cmb\/2020.66.2.5","volume":"66","author":"L Yu","year":"2020","unstructured":"Yu L, Liu Q, Huo J, Wei F, Guo W. Cancer-associated fibroblasts induce immunotherapy resistance in hepatocellular carcinoma animal model. Cell Mol Biol. 2020;66(2):36\u201340.","journal-title":"Cell Mol Biol"},{"issue":"9","key":"1634_CR1018","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1172\/JCI90499","volume":"127","author":"NA Taylor","year":"2017","unstructured":"Taylor NA, Vick SC, Iglesia MD, Brickey WJ, Midkiff BR, McKinnon KP, et al. Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. J Clin Invest. 2017;127(9):3472\u201383.","journal-title":"J Clin Invest"},{"issue":"23","key":"1634_CR1019","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.1158\/1078-0432.CCR-19-0101","volume":"25","author":"ZX Yan","year":"2019","unstructured":"Yan ZX, Li L, Wang W, OuYang BS, Cheng S, Wang L, et al. Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 Chimeric antigen receptor T cells in refractory B-cell non-hodgkin\u2019s lymphoma. Clin Cancer Res. 2019;25(23):6995\u20137003.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1634_CR1020","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/2326-6066.CIR-15-0097","volume":"3","author":"DS Thommen","year":"2015","unstructured":"Thommen DS, Schreiner J, M\u00fcller P, Herzig P, Roller A, Belousov A, et al. Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors. Cancer Immunol Res. 2015;3(12):1344\u201355.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"1634_CR1021","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","volume":"212","author":"T Voron","year":"2015","unstructured":"Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet AL, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212(2):139\u201348.","journal-title":"J Exp Med"},{"issue":"11","key":"1634_CR1022","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3390\/biom10111493","volume":"10","author":"H Tu","year":"2020","unstructured":"Tu H, Costa M. XIAP\u2019s profile in human cancer. Biomolecules. 2020;10(11):1493.","journal-title":"Biomolecules"},{"issue":"6","key":"1634_CR1023","first-page":"5286","volume":"18","author":"Y Sato","year":"2018","unstructured":"Sato Y, Yoshino H, Kazama Y, Kashiwakura I. Involvement of caspase-8 in apoptosis enhancement by cotreatment with retinoic acid-inducible gene-I-like receptor agonist and ionizing radiation in human non-small cell lung cancer. Mol Med Rep. 2018;18(6):5286\u201394.","journal-title":"Mol Med Rep"},{"issue":"8","key":"1634_CR1024","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1158\/0008-5472.CAN-03-3547","volume":"64","author":"B Lu","year":"2004","unstructured":"Lu B, Mu Y, Cao C, Zeng F, Schneider S, Tan J, et al. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res. 2004;64(8):2840\u20135.","journal-title":"Cancer Res"},{"issue":"13","key":"1634_CR1025","doi-asserted-by":"publisher","first-page":"6125","DOI":"10.1111\/jcmm.16526","volume":"25","author":"H Sun","year":"2021","unstructured":"Sun H, Du Y, Yao M, Wang Q, Ji K, Du L, et al. cIAP1\/2 are involved in the radiosensitizing effect of birinapant on NSCLC cell line in vitro. J Cell Mol Med. 2021;25(13):6125\u201336.","journal-title":"J Cell Mol Med"},{"issue":"7120","key":"1634_CR1026","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature05236","volume":"444","author":"S Bao","year":"2006","unstructured":"Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756\u201360.","journal-title":"Nature"},{"issue":"4","key":"1634_CR1027","first-page":"5627","volume":"15","author":"B Hu","year":"2018","unstructured":"Hu B, Ma Y, Yang Y, Zhang L, Han H, Chen J. CD44 promotes cell proliferation in non-small cell lung cancer. Oncol Lett. 2018;15(4):5627\u201333.","journal-title":"Oncol Lett"},{"issue":"3","key":"1634_CR1028","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/0008-5472.CAN-19-1108","volume":"80","author":"T Kong","year":"2020","unstructured":"Kong T, Ahn R, Yang K, Zhu X, Fu Z, Morin G, et al. CD44 Promotes PD-L1 expression and its tumor-intrinsic function in breast and lung cancers. Cancer Res. 2020;80(3):444\u201357.","journal-title":"Cancer Res"},{"key":"1634_CR1029","doi-asserted-by":"publisher","first-page":"1133899","DOI":"10.3389\/fimmu.2023.1133899","volume":"14","author":"T Zhou","year":"2023","unstructured":"Zhou T, Zhang LY, He JZ, Miao \nZM, Li YY, Zhang YM, et al. Review: Mechanisms and perspective treatment of radioresistance in non-small cell lung cancer. Front Immunol. 2023;14:1133899.","journal-title":"Front Immunol"},{"issue":"1","key":"1634_CR1030","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/mutage\/gen048","volume":"24","author":"A Glaviano","year":"2009","unstructured":"Glaviano A, Mothersill C, Case CP, Rubio MA, Newson R, Lyng F. Effects of hTERT on genomic instability caused by either metal or radiation or combined exposure. Mutagenesis. 2009;24(1):25\u201333.","journal-title":"Mutagenesis"},{"issue":"3","key":"1634_CR1031","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.cell.2014.09.051","volume":"159","author":"MC Boelens","year":"2014","unstructured":"Boelens MC, Wu TJ, Nabet BY, Xu B, Qiu Y, Yoon T, et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell. 2014;159(3):499\u2013513.","journal-title":"Cell"},{"issue":"3","key":"1634_CR1032","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1158\/0008-5472.CAN-07-5714","volume":"68","author":"RF Hwang","year":"2008","unstructured":"Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 2008;68(3):918\u201326.","journal-title":"Cancer Res"},{"key":"1634_CR1033","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ebiom.2017.02.019","volume":"17","author":"Y Wang","year":"2017","unstructured":"Wang Y, Gan G, Wang B, Wu J, Cao Y, Zhu D, et al. Cancer-associated fibroblasts promote irradiated cancer cell recovery through autophagy. EBioMedicine. 2017;17:45\u201356.","journal-title":"EBioMedicine"},{"issue":"5","key":"1634_CR1034","doi-asserted-by":"publisher","first-page":"e2790","DOI":"10.1038\/cddis.2017.180","volume":"8","author":"H Zhang","year":"2017","unstructured":"Zhang H, Yue J, Jiang Z, Zhou R, Xie R, Xu Y, et al. CAF-secreted CXCL1 conferred radioresistance by regulating DNA damage response in a ROS-dependent manner in esophageal squamous cell carcinoma. Cell Death Dis. 2017;8(5):e2790.","journal-title":"Cell Death Dis"},{"issue":"4","key":"1634_CR1035","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2011.02.049","volume":"80","author":"C Bayer","year":"2011","unstructured":"Bayer C, Shi K, Astner ST, Maftei CA, Vaupel P. Acute versus chronic hypoxia: why a simplified classification is simply not enough. Int J Radiat Oncol Biol Phys. 2011;80(4):965\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1634_CR1036","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0076-6879(04)81023-1","volume":"381","author":"P Vaupel","year":"2004","unstructured":"Vaupel P, Mayer A, H\u00f6ckel M. Tumor hypoxia and malignant progression. Methods Enzymol. 2004;381:335\u201354.","journal-title":"Methods Enzymol"},{"key":"1634_CR1037","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fphar.2011.00049","volume":"2","author":"PE Porporato","year":"2011","unstructured":"Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol. 2011;2:49.","journal-title":"Front Pharmacol"},{"issue":"22","key":"1634_CR1038","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.1158\/0008-5472.CAN-16-1730","volume":"76","author":"D Samanta","year":"2016","unstructured":"Samanta D, Semenza GL. Serine synthesis helps hypoxic cancer stem cells regulate redox. Cancer Res. 2016;76(22):6458\u201362.","journal-title":"Cancer Res"},{"issue":"1","key":"1634_CR1039","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1038\/oncsis.2015.50","volume":"5","author":"KL Eales","year":"2016","unstructured":"Eales KL, Hollinshead KE, Tennant DA. Hypoxia and metabolic adaptation of cancer cells. Oncogenesis. 2016;5(1):e190.","journal-title":"Oncogenesis"},{"issue":"4","key":"1634_CR1040","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.semradonc.2013.05.006","volume":"23","author":"M Koritzinsky","year":"2013","unstructured":"Koritzinsky M, Wouters BG. The roles of reactive oxygen species and autophagy in mediating the tolerance of tumor cells to cycling hypoxia. Semin Radiat Oncol. 2013;23(4):252\u201361.","journal-title":"Semin Radiat Oncol"},{"issue":"2","key":"1634_CR1041","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jbo.2016.03.001","volume":"5","author":"H Feng","year":"2016","unstructured":"Feng H, Wang J, Chen W, Shan B, Guo Y, Xu J, et al. Hypoxia-induced autophagy as an additional mechanism in human osteosarcoma radioresistance. J Bone Oncol. 2016;5(2):67\u201373.","journal-title":"J Bone Oncol"},{"issue":"2","key":"1634_CR1042","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.bbadis.2011.09.014","volume":"1822","author":"SB Wu","year":"2012","unstructured":"Wu SB, Wei YH. AMPK-mediated increase of glycolysis as an adaptive response to oxidative stress in human cells: implication of the cell survival in mitochondrial diseases. Biochim Biophys Acta. 2012;1822(2):233\u201347.","journal-title":"Biochim Biophys Acta"},{"key":"1634_CR1043","doi-asserted-by":"crossref","unstructured":"1046.Nakao K, Minato N, Uemoto S. Innovative Medicine: Basic Research and Development. 2015.","DOI":"10.1007\/978-4-431-55651-0"},{"key":"1634_CR1044","doi-asserted-by":"publisher","first-page":"6809105","DOI":"10.1155\/2016\/6809105","volume":"2016","author":"A Fidoamore","year":"2016","unstructured":"Fidoamore A, Cristiano L, Antonosante A, d\u2019Angelo M, Di Giacomo E, Astarita C, et al. Glioblastoma stem cells microenvironment: the paracrine roles of the niche in drug and radioresistance. Stem Cells Int. 2016;2016:6809105.","journal-title":"Stem Cells Int"},{"issue":"1","key":"1634_CR1045","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","volume":"7","author":"Y Yang","year":"2022","unstructured":"Yang Y, Li S, Wang Y, Zhao Y, Li Q. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduct Target Ther. 2022;7(1):329.","journal-title":"Signal Transduct Target Ther"},{"key":"1634_CR1046","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107522","volume":"210","author":"CB Meador","year":"2020","unstructured":"Meador CB, Hata AN. Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights. Pharmacol Ther. 2020;210: 107522.","journal-title":"Pharmacol Ther"},{"issue":"6","key":"1634_CR1047","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/nrc822","volume":"2","author":"JP Thiery","year":"2002","unstructured":"Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442\u201354.","journal-title":"Nat Rev Cancer"},{"issue":"75","key":"1634_CR1048","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.","journal-title":"Sci Transl Med."},{"issue":"7","key":"1634_CR1049","first-page":"2513","volume":"30","author":"H Uramoto","year":"2010","unstructured":"Uramoto H, Iwata T, Onitsuka T, Shimokawa H, Hanagiri T, Oyama T. Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res. 2010;30(7):2513\u20137.","journal-title":"Anticancer Res"},{"issue":"7408","key":"1634_CR1050","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nature11183","volume":"487","author":"R Straussman","year":"2012","unstructured":"Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500\u20134.","journal-title":"Nature"},{"issue":"5","key":"1634_CR1051","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/hep.31792","volume":"73","author":"M Song","year":"2021","unstructured":"Song M, He J, Pan QZ, Yang J, Zhao J, \nZhang YJ, et al. Cancer-associated fibroblast-mediated cellular crosstalk supports hepatocellular carcinoma progression. Hepatology. 2021;73(5):1717\u201335.","journal-title":"Hepatology"},{"issue":"3","key":"1634_CR1052","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2018.02.001","volume":"6","author":"SS Watson","year":"2018","unstructured":"Watson SS, Dane M, Chin K, Tatarova Z, Liu M, Liby T, et al. Microenvironment-mediated mechanisms of resistance to HER2 inhibitors differ between HER2+ breast cancer subtypes. Cell Syst. 2018;6(3):329-42.e6.","journal-title":"Cell Syst"},{"issue":"1","key":"1634_CR1053","first-page":"1","volume":"1855","author":"SC Joosten","year":"2015","unstructured":"Joosten SC, Hamming L, Soetekouw PM, Aarts MJ, Veeck J, van Engeland M, et al. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives. Biochim Biophys Acta. 2015;1855(1):1\u201316.","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"1634_CR1054","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/1535-7163.MCT-17-1299","volume":"17","author":"P Makhov","year":"2018","unstructured":"Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG, Kolenko VM. Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies. Mol Cancer Ther. 2018;17(7):1355\u201364.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"1634_CR1055","doi-asserted-by":"publisher","first-page":"858","DOI":"10.20517\/cdr.2023.89","volume":"6","author":"PL Sweeney","year":"2023","unstructured":"Sweeney PL, Suri Y, Basu A, Koshkin VS, Desai A. Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma. Cancer Drug Resist. 2023;6(4):858\u201373.","journal-title":"Cancer Drug Resist"},{"issue":"7","key":"1634_CR1056","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.intimp.2011.01.030","volume":"11","author":"J Finke","year":"2011","unstructured":"Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol. 2011;11(7):856\u201361.","journal-title":"Int Immunopharmacol"},{"key":"1634_CR1057","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3389\/fimmu.2018.02159","volume":"9","author":"KH Susek","year":"2018","unstructured":"Susek KH, Karvouni M, Alici E, Lundqvist A. The role of CXC chemokine receptors 1\u20134 on immune cells in the tumor microenvironment. Front Immunol. 2018;9:2159.","journal-title":"Front Immunol"},{"issue":"12","key":"1634_CR1058","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1002\/eji.201041037","volume":"40","author":"M Elkabets","year":"2010","unstructured":"Elkabets M, Ribeiro VS, Dinarello CA, Ostrand-Rosenberg S, Di Santo JP, Apte RN, et al. IL-1\u03b2 regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol. 2010;40(12):3347\u201357.","journal-title":"Eur J Immunol"},{"issue":"6","key":"1634_CR1059","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1158\/0008-5472.CAN-08-4323","volume":"69","author":"H Xin","year":"2009","unstructured":"Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 2009;69(6):2506\u201313.","journal-title":"Cancer Res"},{"issue":"4","key":"1634_CR1060","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s13402-019-00446-y","volume":"42","author":"X Yin","year":"2019","unstructured":"Yin X, Han S, Song C, Zou H, Wei Z, Xu W, et al. Metformin enhances gefitinib efficacy by interfering with interactions between tumor-associated macrophages and head and neck squamous cell carcinoma cells. Cell Oncol (Dordr). 2019;42(4):459\u201375.","journal-title":"Cell Oncol (Dordr)"},{"issue":"14","key":"1634_CR1061","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1038\/s41388-021-01734-4","volume":"40","author":"S Ma","year":"2021","unstructured":"Ma S, Zhang L, Ren Y, Dai W, Chen T, Luo L, et al. Epiregulin confers EGFR-TKI resistance via EGFR\/ErbB2 heterodimer in non-small cell lung cancer. Oncogene. 2021;40(14):2596\u2013609.","journal-title":"Oncogene"},{"issue":"1","key":"1634_CR1062","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41416-019-0482-x","volume":"121","author":"N Dong","year":"2019","unstructured":"Dong N, Shi X, Wang S, Gao Y, Kuang Z, Xie Q, et al. M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma. Br J Cancer. 2019;121(1):22\u201333.","journal-title":"Br J Cancer"},{"issue":"4","key":"1634_CR1063","doi-asserted-by":"publisher","first-page":"e20221007","DOI":"10.1084\/jem.20221007","volume":"220","author":"XF Li","year":"2023","unstructured":"Li XF, Selli C, Zhou HL, Cao J, Wu S, Ma RY, et al. Macrophages promote anti-androgen resistance in prostate cancer bone disease. J Exp Med. 2023;220(4):e20221007.","journal-title":"J Exp Med"},{"issue":"9","key":"1634_CR1064","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.jtho.2018.05.015","volume":"13","author":"S Gettinger","year":"2018","unstructured":"Gettinger S, Hellmann MD, Chow LQM, Borghaei H, Antonia S, Brahmer JR, et al. Nivolumab plus erlotinib in patients with EGFR-mutant advanced NSCLC. J Thorac Oncol. 2018;13(9):1363\u201372.","journal-title":"J Thorac Oncol"},{"key":"1634_CR1065","doi-asserted-by":"publisher","first-page":"746707","DOI":"10.3389\/fphar.2021.746707","volume":"12","author":"Q Cui","year":"2021","unstructured":"Cui Q, Hu Y, Wu D, Mao Y, Ma D, Liu H. Osimertinib rechallenge with bevacizumab versus chemotherapy plus bevacizumab in EGFR-mutant NSCLC patients with osimertinib resistance. Front Pharmacol. 2021;12:746707.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1634_CR1066","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0640","volume":"7","author":"S Zhao","year":"2019","unstructured":"Zhao S, Ren S, Jiang T, Zhu B, Li X, Zhao C, et al. Low-Dose Apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1\/PD-L1 blockade in lung cancer. Cancer Immunol Res. 2019;7(4):630\u201343.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1634_CR1067","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3892\/mmr.2015.3356","volume":"12","author":"J Li","year":"2015","unstructured":"Li J, Liu H, Yu J, Yu H. Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor \u03b2 signaling in HCT116 colon cancer cells. Mol Med Rep. 2015;12(1):192\u20138.","journal-title":"Mol Med Rep"},{"issue":"4","key":"1634_CR1068","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/onc.2011.263","volume":"31","author":"L Sun","year":"2012","unstructured":"Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M, et al. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene. 2012;31(4):432\u201345.","journal-title":"Oncogene"},{"issue":"8","key":"1634_CR1069","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1158\/1078-0432.CCR-08-2372","volume":"15","author":"QQ Li","year":"2009","unstructured":"Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F, et al. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res. 2009;15(8):2657\u201365.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1634_CR1070","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1002\/stem.154","volume":"27","author":"NK Kurrey","year":"2009","unstructured":"Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY, et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells. 2009;27(9):2059\u201368.","journal-title":"Stem Cells"},{"issue":"1","key":"1634_CR1071","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8274.CD-10-0028","volume":"1","author":"DG DeNardo","year":"2011","unstructured":"DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1(1):54\u201367.","journal-title":"Cancer Discov"},{"issue":"23","key":"1634_CR1072","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1101\/gad.180331.111","volume":"25","author":"T Shree","year":"2011","unstructured":"Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 2011;25(23):2465\u201379.","journal-title":"Genes Dev"},{"issue":"17","key":"1634_CR1073","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-14-3587","volume":"75","author":"R Hughes","year":"2015","unstructured":"Hughes R, Qian BZ, Rowan C, Muthana M, Keklikoglou I, Olson OC, et al. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res. 2015;75(17):3479\u201391.","journal-title":"Cancer Res"},{"issue":"7","key":"1634_CR1074","doi-asserted-by":"publisher","first-page":"djv135","DOI":"10.1093\/jnci\/djv135","volume":"107","author":"KB Challagundla","year":"2015","unstructured":"Challagundla KB, Wise PM, Neviani P, Chava H, Murtadha M, Xu T, et al. Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. J Natl Cancer Inst. 2015;107(7):djv135.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"1634_CR1075","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.ccr.2012.02.017","volume":"21","author":"ES Nakasone","year":"2012","unstructured":"Nakasone ES, Askautrud HA, Kees T, Park JH, Plaks V, Ewald AJ, et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell. 2012;21(4):488\u2013503.","journal-title":"Cancer Cell"},{"issue":"9","key":"1634_CR1076","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm.2890","volume":"18","author":"Y Sun","year":"2012","unstructured":"Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 2012;18(9):1359\u201368.","journal-title":"Nat Med"},{"issue":"13","key":"1634_CR1077","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1084\/jem.20131195","volume":"210","author":"F Lotti","year":"2013","unstructured":"Lotti F, Jarrar AM, Pai RK, Hitomi M, Lathia J, Mace A, et al. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med. 2013;210(13):2851\u201372.","journal-title":"J Exp Med"},{"key":"1634_CR1078","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","volume":"7","author":"S Koyama","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, et al. Adaptive \nresistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501.","journal-title":"Nat Commun"},{"issue":"5","key":"1634_CR1079","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nm.4308","volume":"23","author":"J Gao","year":"2017","unstructured":"Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017;23(5):551\u20135.","journal-title":"Nat Med"},{"issue":"12","key":"1634_CR1080","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1038\/modpathol.2017.89","volume":"30","author":"H Kakavand","year":"2017","unstructured":"Kakavand H, Jackett LA, Menzies AM, Gide TN, Carlino MS, Saw RPM, et al. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Mod Pathol. 2017;30(12):1666\u201376.","journal-title":"Mod Pathol"},{"issue":"7","key":"1634_CR1081","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1158\/0008-5472.CAN-13-1506","volume":"74","author":"I Le Mercier","year":"2014","unstructured":"Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P, et al. VISTA Regulates the development of protective antitumor immunity. Cancer Res. 2014;74(7):1933\u201344.","journal-title":"Cancer Res"},{"issue":"1","key":"1634_CR1082","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","volume":"1","author":"MV Maus","year":"2013","unstructured":"Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013;1(1):26\u201331.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"1634_CR1083","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123\u201338.","journal-title":"J Clin Invest"},{"issue":"24","key":"1634_CR1084","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","volume":"24","author":"KT Mueller","year":"2018","unstructured":"Mueller KT, Waldron E, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2018;24(24):6175\u201384.","journal-title":"Clin Cancer Res"},{"key":"1634_CR1085","doi-asserted-by":"publisher","first-page":"1148692","DOI":"10.3389\/fimmu.2023.1148692","volume":"14","author":"C Iliadi","year":"2023","unstructured":"Iliadi C, Verset L, Bouchart C, Martinive P, Van Gestel D, Krayem M. The current understanding of the immune landscape relative to radiotherapy across tumor types. Front Immunol. 2023;14:1148692.","journal-title":"Front Immunol"},{"key":"1634_CR1086","doi-asserted-by":"publisher","first-page":"648652","DOI":"10.3389\/fimmu.2021.648652","volume":"12","author":"Q Wang","year":"2021","unstructured":"Wang Q, Li S, Qiao S, Zheng Z, Duan X, Zhu X. Changes in T lymphocyte subsets in different tumors before and after radiotherapy: a meta-analysis. Front Immunol. 2021;12:648652.","journal-title":"Front Immunol"},{"issue":"4","key":"1634_CR1087","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/ijc.28418","volume":"134","author":"O Draghiciu","year":"2014","unstructured":"Draghiciu O, Walczak M, Hoogeboom BN, Franken KL, Melief KJ, Nijman HW, et al. Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination. Int J Cancer. \n2014;134(4):859\u201372.","journal-title":"Int J Cancer"},{"issue":"3","key":"1634_CR1088","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1158\/2326-6066.CIR-18-0633","volume":"7","author":"M Mondini","year":"2019","unstructured":"Mondini M, Loyher PL, Hamon P, Gerb\u00e9 de Thor\u00e9 M, Laviron M, Berthelot K, et al. CCR2-dependent recruitment of tregs and monocytes following radiotherapy is associated with TNF\u03b1-mediated resistance. Cancer Immunol Res. 2019;7(3):376\u201387.","journal-title":"Cancer Immunol Res"},{"issue":"13","key":"1634_CR1089","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.3390\/ijms20133212","volume":"20","author":"M Jarosz-Biej","year":"2019","unstructured":"Jarosz-Biej M, Smolarczyk R, Cicho\u0144 T, Ku\u0142ach N. Tumor microenvironment as a \u201cgame changer\u201d in cancer radiotherapy. Int J Mol Sci. 2019;20(13):3212.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1634_CR1090","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1080\/0284186X.2017.1348623","volume":"56","author":"A Schernberg","year":"2017","unstructured":"Schernberg A, Blanchard P, Chargari C, Deutsch E. Neutrophils, a candidate biomarker and target for radiation therapy? Acta Oncol. 2017;56(11):1522\u201330.","journal-title":"Acta Oncol"},{"issue":"1","key":"1634_CR1091","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s12967-021-03112-w","volume":"19","author":"T Hellevik","year":"2021","unstructured":"Hellevik T, Berzaghi R, Lode K, Islam A, Martinez-Zubiaurre I. Immunobiology of cancer-associated fibroblasts in the context of radiotherapy. J Transl Med. 2021;19(1):437.","journal-title":"J Transl Med"},{"issue":"1","key":"1634_CR1092","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.clcc.2021.10.001","volume":"21","author":"H Bando","year":"2022","unstructured":"Bando H, Tsukada Y, Ito M, Yoshino T. Novel immunological approaches in the treatment of locally advanced rectal cancer. Clin Colorectal Cancer. 2022;21(1):3\u20139.","journal-title":"Clin Colorectal Cancer"},{"key":"1634_CR1093","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3389\/fonc.2012.00089","volume":"2","author":"CS Chiang","year":"2012","unstructured":"Chiang CS, Fu SY, Wang SC, Yu CF, Chen FH, Lin CM, et al. Irradiation promotes an m2 macrophage phenotype in tumor hypoxia. Front Oncol. 2012;2:89.","journal-title":"Front Oncol"},{"key":"1634_CR1094","doi-asserted-by":"publisher","first-page":"670464","DOI":"10.3389\/fonc.2021.670464","volume":"11","author":"C Zhang","year":"2021","unstructured":"Zhang C, Liang Z, Ma S, Liu X. Radiotherapy and cytokine storm: risk and mechanism. Front Oncol. 2021;11:670464.","journal-title":"Front Oncol"},{"issue":"7","key":"1634_CR1095","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","volume":"71","author":"BC Burnette","year":"2011","unstructured":"Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res. 2011;71(7):2488\u201396.","journal-title":"Cancer Res"},{"issue":"1","key":"1634_CR1096","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/s41467-017-01566-5","volume":"8","author":"H Liang","year":"2017","unstructured":"Liang H, Deng L, Hou Y, Meng X, Huang X, Rao E, et al. Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. Nat Commun. 2017;8(1):1736.","journal-title":"Nat Commun"},{"key":"1634_CR1097","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.3389\/fimmu.2018.03154","volume":"9","author":"LB Darragh","year":"2018","unstructured":"Darragh LB, Oweida AJ, Karam SD. Overcoming resistance to combination radiation-immunotherapy: a focus on contributing pathways within the tumor microenvironment. Front Immunol. 2018;9:3154.","journal-title":"Front Immunol"},{"issue":"9","key":"1634_CR1098","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942\u20139.","journal-title":"Nat Med"},{"issue":"4","key":"1634_CR1099","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3892\/ijo.2014.2259","volume":"44","author":"SW Wang","year":"2014","unstructured":"Wang SW, Sun YM. The IL-6\/JAK\/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review). Int J Oncol. 2014;44(4):1032\u201340.","journal-title":"Int J Oncol"},{"issue":"2","key":"1634_CR1100","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.18632\/aging.203833","volume":"14","author":"X Chen","year":"2022","unstructured":"Chen X, Zhang W, Yang W, Zhou M, Liu F. Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects. Aging (Albany NY). 2022;14(2):1048\u201364.","journal-title":"Aging (Albany NY)"},{"issue":"5","key":"1634_CR1101","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S1535-6108(04)00115-1","volume":"5","author":"BJ Moeller","year":"2004","unstructured":"Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell. 2004;5(5):429\u201341.","journal-title":"Cancer Cell"},{"issue":"8","key":"1634_CR1102","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.1074\/jbc.M806653200","volume":"284","author":"H Harada","year":"2009","unstructured":"Harada H, Itasaka S, Kizaka-Kondoh S, Shibuya K, Morinibu A, Shinomiya K, et al. The Akt\/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. J Biol Chem. 2009;284(8):5332\u201342.","journal-title":"J Biol Chem"},{"key":"1634_CR1103","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/1748-717X-7-154","volume":"7","author":"C Brooks","year":"2012","unstructured":"Brooks C, Sheu T, Bridges K, Mason K, Kuban D, Mathew P, et al. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer. Radiat Oncol. 2012;7:154.","journal-title":"Radiat Oncol"},{"issue":"6","key":"1634_CR1104","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.3892\/ol.2016.5247","volume":"12","author":"YQ Ding","year":"2016","unstructured":"Ding YQ, Qin Q, Yang Y, Sun XC, Yang X, Zhu HC, et al. Improved sensitization effect of sunitinib in cancer cells of the esophagus under hypoxic microenviroment. Oncol Lett. 2016;12(6):4671\u20136.","journal-title":"Oncol Lett"},{"issue":"22","key":"1634_CR1105","doi-asserted-by":"publisher","first-page":"7069","DOI":"10.1158\/1078-0432.CCR-09-0688","volume":"15","author":"MI Koukourakis","year":"2009","unstructured":"Koukourakis MI, Giatromanolaki A, Sheldon H, Buffa FM, Kouklakis G, Ragoussis I, et al. Phase I\/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab. Clin Cancer Res. 2009;15(22):7069\u201376.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1634_CR1106","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.drup.2012.04.002","volume":"15","author":"EA Kleibeuker","year":"2012","unstructured":"Kleibeuker EA, Griffioen AW, Verheul HM, Slotman BJ, Thijssen VL. Combining angiogenesis inhibition and radiotherapy: a double-edged sword. Drug Resist Updat. 2012;15(3):173\u201382.","journal-title":"Drug Resist Updat"},{"issue":"2","key":"1634_CR1107","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10456-017-9546-9","volume":"20","author":"LC Hamming","year":"2017","unstructured":"Hamming LC, Slotman BJ, Verheul HMW, Thijssen VL. The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future. Angiogenesis. 2017;20(2):217\u201332.","journal-title":"Angiogenesis"},{"issue":"5","key":"1634_CR1108","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0092-8674(03)00154-5","volume":"112","author":"T Cramer","year":"2003","unstructured":"Cramer T, Yamanishi Y, Clausen BE, F\u00f6rster I, Pawlinski R, Mackman N, et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell. 2003;112(5):645\u201357.","journal-title":"Cell"},{"issue":"1","key":"1634_CR1109","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.canlet.2014.07.048","volume":"354","author":"YH Kim","year":"2014","unstructured":"Kim YH, Yoo KC, Cui YH, Uddin N, Lim EJ, Kim MJ, et al. Radiation promotes malignant progression of glioma cells through HIF-1alpha stabilization. Cancer Lett. 2014;354(1):132\u201341.","journal-title":"Cancer Lett"},{"issue":"2","key":"1634_CR1110","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ijrobp.2004.03.025","volume":"60","author":"H Ishikawa","year":"2004","unstructured":"Ishikawa H, Sakurai H, Hasegawa M, Mitsuhashi N, Takahashi M, Masuda N, et al. Expression of hypoxic-inducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2004;60(2):513\u201321.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"1634_CR1111","first-page":"2911","volume":"61","author":"DM Aebersold","year":"2001","unstructured":"Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001;61(7):2911\u20136.","journal-title":"Cancer Res"},{"issue":"2","key":"1634_CR1112","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood-2007-01-065714","volume":"110","author":"Y Huang","year":"2007","unstructured":"Huang Y, Chen X, Dikov MM, Novitskiy SV, Mosse CA, Yang L, et al. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood. 2007;110(2):624\u201331.","journal-title":"Blood"},{"issue":"11","key":"1634_CR1113","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1182\/blood.V92.11.4150","volume":"92","author":"D Gabrilovich","year":"1998","unstructured":"Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92(11):4150\u201366.","journal-title":"Blood"},{"issue":"7","key":"1634_CR1114","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1245\/s10434-020-09371-z","volume":"28","author":"F Tang","year":"2021","unstructured":"Tang F, Tie Y, Hong W, Wei Y, Tu C, Wei X. Targeting myeloid-derived suppressor cells for premetastatic niche disruption after tumor resection. Ann Surg Oncol. 2021;28(7):4030\u201348.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1634_CR1115","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","volume":"15","author":"Y Tie","year":"2022","unstructured":"Tie Y, Tang F, Wei YQ, Wei XW. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol. 2022;15(1):61.","journal-title":"J Hematol Oncol"},{"key":"1634_CR1116","doi-asserted-by":"publisher","first-page":"1164985","DOI":"10.3389\/fonc.2023.1164985","volume":"13","author":"H Zhang","year":"2023","unstructured":"Zhang H, Wang X, Ma Y, Zhang Q, Liu R, Luo H, et al. Review of possible mechanisms of radiotherapy resistance in cervical cancer. Front Oncol. 2023;13:1164985.","journal-title":"Front Oncol"},{"issue":"4","key":"1634_CR1117","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","volume":"168","author":"AW Lambert","year":"2017","unstructured":"Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168(4):670\u201391.","journal-title":"Cell"},{"issue":"2","key":"1634_CR1118","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrc3447","volume":"13","author":"B De Craene","year":"2013","unstructured":"De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13(2):97\u2013110.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1634_CR1119","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.molonc.2015.11.007","volume":"10","author":"A Gower","year":"2016","unstructured":"Gower A, Hsu WH, Hsu ST, Wang Y, Giaccone G. EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer. Mol Oncol. 2016;10(4):601\u20139.","journal-title":"Mol Oncol"},{"issue":"22","key":"1634_CR1120","doi-asserted-by":"publisher","first-page":"33316","DOI":"10.18632\/oncotarget.8955","volume":"7","author":"C Voena","year":"2016","unstructured":"Voena C, Varesio LM, Zhang L, Menotti M, Poggio T, Panizza E, et al. Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1. Oncotarget. 2016;7(22):33316\u201330.","journal-title":"Oncotarget"},{"issue":"6","key":"1634_CR1121","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.molonc.2013.08.001","volume":"7","author":"HR Kim","year":"2013","unstructured":"Kim HR, Kim WS, Choi YJ, Choi CM, Rho JK, Lee JC. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. Mol Oncol. 2013;7(6):1093\u2013102.","journal-title":"Mol Oncol"},{"issue":"1","key":"1634_CR1122","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/cancers10010010","volume":"10","author":"J Wei","year":"2018","unstructured":"Wei J, van der Wekken AJ, Saber A, Terpstra MM, Schuuring E, Timens W, et al. Mutations in EMT-related genes in ALK positive crizotinib resistant non-small cell lung cancers. Cancers (Basel). 2018;10(1):10.","journal-title":"Cancers (Basel)."},{"issue":"5","key":"1634_CR1123","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.3892\/mmr.2016.5770","volume":"14","author":"HX Gao","year":"2016","unstructured":"Gao HX, Yan L, Li C, Zhao LM, Liu W. miR-200c regulates crizotinib-resistant ALK-positive lung cancer cells by reversing epithelial-mesenchymal transition via targeting ZEB1. Mol Med Rep. 2016;14(5):4135\u201343.","journal-title":"Mol Med Rep"},{"issue":"2","key":"1634_CR1124","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","volume":"7","author":"JJ Lin","year":"2017","unstructured":"Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov. 2017;7(2):137\u201355.","journal-title":"Cancer Discov"},{"issue":"1","key":"1634_CR1125","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","volume":"19","author":"LA Byers","year":"2013","unstructured":"Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013;19(1):279\u201390.","journal-title":"Clin Cancer Res"},{"issue":"24 Pt 1","key":"1634_CR1126","doi-asserted-by":"publisher","first-page":"8686","DOI":"10.1158\/1078-0432.CCR-05-1492","volume":"11","author":"RL Yauch","year":"2005","unstructured":"Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res. 2005;11(24 Pt 1):8686\u201398.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"1634_CR1127","doi-asserted-by":"publisher","first-page":"9455","DOI":"10.1158\/0008-5472.CAN-05-1058","volume":"65","author":"S Thomson","year":"2005","unstructured":"Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005;65(20):9455\u201362.","journal-title":"Cancer Res"},{"issue":"17","key":"1634_CR1128","doi-asserted-by":"publisher","first-page":"7328","DOI":"10.18632\/oncotarget.2397","volume":"5","author":"C Wilson","year":"2014","unstructured":"Wilson C, Nicholes K, Bustos D, Lin E, Song Q, Stephan JP, et al. Overcoming EMT-associated resistance to anti-cancer drugs via Src\/FAK pathway inhibition. Oncotarget. 2014;5(17):7328\u201341.","journal-title":"Oncotarget"},{"issue":"42","key":"1634_CR1129","doi-asserted-by":"publisher","first-page":"44332","DOI":"10.18632\/oncotarget.6293","volume":"6","author":"J Zhou","year":"2015","unstructured":"Zhou J, Wang J, Zeng Y, Zhang X, Hu Q, Zheng J, et al. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer. Oncotarget. 2015;6(42):44332\u201345.","journal-title":"Oncotarget"},{"issue":"20","key":"1634_CR1130","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1158\/0008-5472.CAN-15-0377","volume":"75","author":"M Soucheray","year":"2015","unstructured":"Soucheray M, Capelletti M, Pulido I, Kuang Y, Paweletz CP, Becker JH, et al. Intratumoral heterogeneity in EGFR-mutant NSCLC results in divergent resistance mechanisms in response to EGFR tyrosine kinase inhibition. Cancer Res. 2015;75(20):4372\u201383.","journal-title":"Cancer Res"},{"issue":"7456","key":"1634_CR1131","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","volume":"499","author":"CGAR Network","year":"2013","unstructured":"Network CGAR. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43\u20139.","journal-title":"Nature"},{"issue":"6","key":"1634_CR1132","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1158\/1535-7163.MCT-09-1106","volume":"9","author":"HJ Hammers","year":"2010","unstructured":"Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther. 2010;9(6):1525\u201335.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"1634_CR1133","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.ccell.2021.07.006","volume":"39","author":"K Tanaka","year":"2021","unstructured":"Tanaka K, Yu HA, Yang S, Han S, Selcuklu SD, Kim K, et al. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell. 2021;39(9):1245-61.e6.","journal-title":"Cancer Cell"},{"issue":"1","key":"1634_CR1134","doi-asserted-by":"publisher","first-page":"e0147344","DOI":"10.1371\/journal.pone.0147344","volume":"11","author":"T Yoshida","year":"2016","unstructured":"Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam KC, et al. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS ONE. 2016;11(1):e0147344.","journal-title":"PLoS ONE"},{"issue":"12","key":"1634_CR1135","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1111\/iju.15042","volume":"29","author":"Y Sekino","year":"2022","unstructured":"Sekino Y, Teishima J, Liang G, Hinata N. Molecular \nmechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma. Int J Urol. 2022;29(12):1419\u201328.","journal-title":"Int J Urol"},{"issue":"5","key":"1634_CR1136","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1158\/0008-5472.CAN-20-1895","volume":"81","author":"JM Konen","year":"2021","unstructured":"Konen JM, Rodriguez BL, Padhye A, Ochieng JK, Gibson L, Diao L, et al. Dual inhibition of MEK and AXL targets tumor cell heterogeneity and prevents resistant outgrowth mediated by the epithelial-to-mesenchymal transition in NSCLC. Cancer Res. 2021;81(5):1398\u2013412.","journal-title":"Cancer Res"},{"issue":"6","key":"1634_CR1137","doi-asserted-by":"publisher","first-page":"119016","DOI":"10.1016\/j.bbamcr.2021.119016","volume":"1868","author":"CY Wang","year":"2021","unstructured":"Wang CY, Lee MH, Kao YR, Hsiao SH, Hong SY, Wu CW. Alisertib inhibits migration and invasion of EGFR-TKI resistant cells by partially reversing the epithelial-mesenchymal transition. Biochim Biophys Acta Mol Cell Res. 2021;1868(6):119016.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"1634_CR1138","doi-asserted-by":"publisher","first-page":"1072651","DOI":"10.3389\/fphar.2022.1072651","volume":"13","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Wang G, Li Y, Lei D, Xiang J, Ouyang L, et al. Recent progress in DNA methyltransferase inhibitors as anticancer agents. Front Pharmacol. 2022;13:1072651.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1634_CR1139","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s13046-018-0988-8","volume":"37","author":"Y Su","year":"2018","unstructured":"Su Y, Hopfinger NR, Nguyen TD, Pogash TJ, Santucci-Pereira J, Russo J. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors. J Exp Clin Cancer Res. 2018;37(1):314.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1634_CR1140","doi-asserted-by":"publisher","first-page":"17412","DOI":"10.1038\/s41598-024-68109-z","volume":"14","author":"E Li","year":"2024","unstructured":"Li E, Cheung HCZ, Ma S. CTHRC1+ fibroblasts and SPP1+ macrophages synergistically contribute to pro-tumorigenic tumor microenvironment in pancreatic ductal adenocarcinoma. Sci Rep. 2024;14(1):17412.","journal-title":"Sci Rep"},{"issue":"9","key":"1634_CR1141","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1158\/0008-5472.CAN-23-1183","volume":"84","author":"H Xiang","year":"2024","unstructured":"Xiang H, Pan Y, Sze MA, Wlodarska M, Li L, van de Mark KA, et al. Single-cell analysis identifies NOTCH3-mediated interactions between stromal cells that promote microenvironment remodeling and invasion in lung adenocarcinoma. Cancer Res. 2024;84(9):1410\u201325.","journal-title":"Cancer Res"},{"issue":"20","key":"1634_CR1142","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1158\/1078-0432.CCR-23-4097","volume":"30","author":"C Massaro","year":"2024","unstructured":"Massaro C, Sensoy HN, Mulders M, De Schrijver C, Gomez-Martin C, Simon-Nieto J, et al. Tumor-secreted extracellular vesicles counteract therapy response by triggering inflammatory mesenchymal stem cell development. Clin Cancer Res. 2024;30(20):4714\u201328.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1634_CR1143","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/neuonc\/noae085","volume":"26","author":"JD Hendriksen","year":"2024","unstructured":"Hendriksen JD, Locallo A, Maarup S, Debnath O, Ishaque N, Hasselbach B, et al. Immunotherapy drives mesenchymal tumor cell state shift and TME immune response in glioblastoma patients. Neuro Oncol. 2024;26(8):1453\u201366.","journal-title":"Neuro Oncol"},{"key":"1634_CR1144","doi-asserted-by":"publisher","DOI":"10.1172\/JCI161913","author":"D Cui","year":"2023","unstructured":"Cui D, Li J, Zhu Z, Berk M, Hardaway A, McManus J, et al. Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI161913.","journal-title":"J Clin Invest"},{"issue":"1","key":"1634_CR1145","doi-asserted-by":"publisher","first-page":"113575","DOI":"10.1016\/j.celrep.2023.113575","volume":"43","author":"L Qin","year":"2024","unstructured":"Qin L, Berk M, Chung YM, Cui D, Zhu Z, Chakraborty AA, et al. Chronic hypoxia stabilizes 3\u03b2HSD1 via autophagy suppression. Cell Rep. 2024;43(1):113575.","journal-title":"Cell Rep"},{"issue":"7","key":"1634_CR1146","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ccell.2023.05.016","volume":"41","author":"H Wang","year":"2023","unstructured":"Wang H, Li N, Liu Q, Guo J, Pan Q, Cheng B, et al. Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. Cancer Cell. 2023;41(7):1345-62.e9.","journal-title":"Cancer Cell"},{"issue":"8","key":"1634_CR1147","doi-asserted-by":"publisher","first-page":"e20240045","DOI":"10.1084\/jem.20240045","volume":"221","author":"MA Tran","year":"2024","unstructured":"Tran MA, Youssef D, Shroff S, Chowhan D, Beaumont KG, Sebra R, et al. Urine scRNAseq reveals new insights into the bladder tumor immune microenvironment. J Exp Med. 2024;221(8):e20240045.","journal-title":"J Exp Med"},{"issue":"4","key":"1634_CR1148","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3390\/ijms20040840","volume":"20","author":"C Roma-Rodrigues","year":"2019","unstructured":"Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20(4):840.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1634_CR1149","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.7150\/ijbs.72534","volume":"18","author":"A Zhang","year":"2022","unstructured":"Zhang A, Miao K, Sun H, Deng CX. Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. Int J Biol Sci. 2022;18(7):3019\u201333.","journal-title":"Int J Biol Sci"},{"issue":"6","key":"1634_CR1150","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s13770-020-00258-4","volume":"17","author":"M Devarasetty","year":"2020","unstructured":"Devarasetty M, Forsythe SD, Shelkey E, Soker S. In vitro modeling of the tumor microenvironment in tumor organoids. Tissue Eng Regen Med. 2020;17(6):759\u201371.","journal-title":"Tissue Eng Regen Med"},{"key":"1634_CR1151","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115586","volume":"213","author":"S Hockney","year":"2023","unstructured":"Hockney S, Parker J, Turner JE, Todd X, Todryk S, Gieling RG, et al. Next generation organoid engineering to replace animals in cancer drug testing. Biochem Pharmacol. 2023;213: 115586.","journal-title":"Biochem Pharmacol"},{"key":"1634_CR1152","doi-asserted-by":"publisher","first-page":"1146738","DOI":"10.3389\/fimmu.2023.1146738","volume":"14","author":"J Su","year":"2023","unstructured":"Su J, Zhou L, Zhang Z, Xiao X, Qin Y, Zhou X, et al. The components of tumor microenvironment as biomarker for immunotherapy in metastatic renal cell carcinoma. Front Immunol. 2023;14:1146738.","journal-title":"Front Immunol"},{"issue":"12","key":"1634_CR1153","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3390\/cancers11121822","volume":"11","author":"M Garc\u00eda-Aranda","year":"2019","unstructured":"Garc\u00eda-Aranda M, Redondo M. Immunotherapy: a challenge of breast cancer treatment. Cancers (Basel). 2019;11(12):1822.","journal-title":"Cancers (Basel)."},{"key":"1634_CR1154","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.641469","volume":"9","author":"P Wu","year":"2021","unstructured":"Wu P, Gao W, Su M, Nice EC, Zhang W, Lin J, et al. Adaptive mechanisms of tumor therapy resistance driven by tumor microenvironment. Front Cell Dev Biol. 2021;9: \n641469.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1634_CR1155","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13046-021-01893-y","volume":"40","author":"H Li","year":"2021","unstructured":"Li H, Zhou L, Zhou J, Li Q, Ji Q. Underlying mechanisms and drug intervention strategies for the tumour microenvironment. J Exp Clin Cancer Res. 2021;40(1):97.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1634_CR1156","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/15384047.2017.1394538","volume":"19","author":"H Patel","year":"2018","unstructured":"Patel H, Nilendu P, Jahagirdar D, Pal JK, Sharma NK. Modulating secreted components of tumor microenvironment: a masterstroke in tumor therapeutics. Cancer Biol Ther. 2018;19(1):3\u201312.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"1634_CR1157","doi-asserted-by":"publisher","first-page":"e21043","DOI":"10.1002\/cso2.1043","volume":"2","author":"A Biswas","year":"2022","unstructured":"Biswas A, Ghaddar B, Riedlinger G, De S. Inference on spatial heterogeneity in tumor microenvironment using spatial transcriptomics data. Comput Syst Oncol. 2022;2(3):e21043.","journal-title":"Comput Syst Oncol."},{"issue":"1","key":"1634_CR1158","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3390\/ijms25010142","volume":"25","author":"Y Su","year":"2023","unstructured":"Su Y, Wang F, Lei Z, Li J, Ma M, Yan Y, et al. An integrated multi-omics analysis identifying immune subtypes of pancreatic cancer. Int J Mol Sci. 2023;25(1):142.","journal-title":"Int J Mol Sci"},{"issue":"22","key":"1634_CR1159","doi-asserted-by":"publisher","first-page":"13345","DOI":"10.18632\/aging.205246","volume":"15","author":"Y Yang","year":"2023","unstructured":"Yang Y, Li H, Zheng D, Li X, Liu H. Immune microenvironment heterogeneity reveals distinct subtypes in neuroblastoma: insights into prognosis and therapeutic targets. Aging (Albany NY). 2023;15(22):13345\u201367.","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"1634_CR1160","doi-asserted-by":"publisher","first-page":"122","DOI":"10.5937\/jomb0-39234","volume":"42","author":"Z Xiao","year":"2023","unstructured":"Xiao Z, Liu X, Mo Y, Chen W, Zhang S, Yu Y, et al. Prognosis and clinical features analysis of EMT-related signature and tumor Immune microenvironment in glioma. J Med Biochem. 2023;42(1):122\u201337.","journal-title":"J Med Biochem"},{"key":"1634_CR1161","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.942966","volume":"9","author":"N Wang","year":"2022","unstructured":"Wang N, Gao X, Ji H, Ma S, Wu J, Dong J, et al. Machine learning-based screening of an epithelial-mesenchymal transition-related long non-coding RNA signature reveals lower-grade glioma prognosis and the tumor microenvironment and predicts antitumor therapy response. Front Mol Biosci. 2022;9: 942966.","journal-title":"Front Mol Biosci"},{"issue":"2","key":"1634_CR1162","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1124\/pr.109.001289","volume":"61","author":"H J\u00e4rvel\u00e4inen","year":"2009","unstructured":"J\u00e4rvel\u00e4inen H, Sainio A, Koulu M, Wight TN, Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev. 2009;61(2):198\u2013223.","journal-title":"Pharmacol Rev"},{"key":"1634_CR1163","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.117049","volume":"239","author":"M Najafi","year":"2019","unstructured":"Najafi M, Mortezaee K, Majidpoor J. Stromal reprogramming: a target for tumor therapy. Life Sci. 2019;239: 117049.","journal-title":"Life Sci"},{"issue":"12","key":"1634_CR1164","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.3390\/cancers12123650","volume":"12","author":"P Ghahremanifard","year":"2020","unstructured":"Ghahremanifard P, Chanda A, Bonni S, Bose P. TGF-\u03b2 mediated immune evasion in cancer-spotlight on cancer-associated fibroblasts. Cancers (Basel). 2020;12(12):3650.","journal-title":"Cancers (Basel)."},{"issue":"16","key":"1634_CR1165","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.4161\/cc.21384","volume":"11","author":"C Guido","year":"2012","unstructured":"Guido C, Whitaker-Menezes D, Capparelli C, Balliet R, Lin Z, Pestell RG, et al. Metabolic reprogramming of cancer-associated fibroblasts by TGF-\u03b2 drives tumor growth: connecting TGF-\u03b2 signaling with \u201cWarburg-like\u201d cancer metabolism and L-lactate production. Cell Cycle. 2012;11(16):3019\u201335.","journal-title":"Cell Cycle"},{"key":"1634_CR1166","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.semcancer.2024.05.002","volume":"101","author":"B Jiang","year":"2024","unstructured":"Jiang B, Zhang W, Zhang X, Sun Y. Targeting senescent cells to reshape the tumor microenvironment and improve anticancer efficacy. Semin Cancer Biol. 2024;101:58\u201373.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"1634_CR1167","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1080\/15384047.2022.2035629","volume":"23","author":"G Wang","year":"2022","unstructured":"Wang G, Zhou X, Guo Z, Huang N, Li J, Lv Y, et al. The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-\u03b2. Cancer Biol Ther. 2022;23(1):150\u201362.","journal-title":"Cancer Biol Ther"},{"issue":"12","key":"1634_CR1168","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1659096","volume":"8","author":"K Kapp","year":"2019","unstructured":"Kapp K, Volz B, Oswald D, Wittig B, Baumann M, Schmidt M. Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors. Oncoimmunology. 2019;8(12): e1659096.","journal-title":"Oncoimmunology"},{"issue":"3","key":"1634_CR1169","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1053\/j.seminoncol.2012.02.002","volume":"39","author":"JA Berzofsky","year":"2012","unstructured":"Berzofsky JA, Terabe M, Wood LV. Strategies to use immune modulators in therapeutic vaccines against cancer. Semin Oncol. 2012;39(3):348\u201357.","journal-title":"Semin Oncol"},{"issue":"11","key":"1634_CR1170","doi-asserted-by":"publisher","first-page":"10165","DOI":"10.18632\/aging.205858","volume":"16","author":"S Li","year":"2024","unstructured":"Li S, Sheng J, Zhang D, Qin H. Targeting tumor-associated macrophages to reverse antitumor drug resistance. Aging (Albany NY). 2024;16(11):10165\u201396.","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"1634_CR1171","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1615\/CritRevOncog.2024053667","volume":"29","author":"R McWhorter","year":"2024","unstructured":"McWhorter R, Bonavida B. The role of TAMs in the regulation of tumor cell resistance to chemotherapy. Crit Rev Oncog. 2024;29(4):97\u2013125.","journal-title":"Crit Rev Oncog"},{"issue":"4","key":"1634_CR1172","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.adro.2018.08.018","volume":"3","author":"GW Tormoen","year":"2018","unstructured":"Tormoen GW, Crittenden MR, Gough MJ. Role of the immunosuppressive microenvironment in immunotherapy. Adv Radiat Oncol. 2018;3(4):520\u20136.","journal-title":"Adv Radiat Oncol"},{"key":"1634_CR1173","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.canlet.2021.10.027","volume":"525","author":"C Wang","year":"2022","unstructured":"Wang C, Zhang Y, Gao WQ. The evolving role of immune cells in prostate cancer. Cancer Lett. 2022;525:9\u201321.","journal-title":"Cancer Lett"},{"key":"1634_CR1174","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3959342\/v1","author":"H Korkaya","year":"2024","unstructured":"Korkaya H, Koksalar Alkan F, Caglayan A, Alkan H, Benson E, Gunduz Y, et al. Dual activity of Minnelide chemosensitize basal\/triple negative breast cancer stem cells and reprograms immunosuppressive tumor microenvironment. Res Sq. 2024. https:\/\/doi.org\/10.21203\/rs.3.rs-3959342\/v1.","journal-title":"Res Sq."},{"issue":"1","key":"1634_CR1175","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40364-024-00646-1","volume":"12","author":"H Zhang","year":"2024","unstructured":"Zhang H, Li S, Wang D, Liu S, Xiao T, Gu W, et al. Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment. Biomark Res. 2024;12(1):96.","journal-title":"Biomark Res"},{"issue":"1","key":"1634_CR1176","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1186\/s12885-018-4806-7","volume":"18","author":"L Zhong","year":"2018","unstructured":"Zhong L, Liu Y, Wang K, He Z, Gong Z, Zhao Z, et al. Biomarkers: paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma. BMC Cancer. 2018;18(1):911.","journal-title":"BMC Cancer"},{"key":"1634_CR1177","doi-asserted-by":"publisher","first-page":"1190637","DOI":"10.3389\/fbioe.2023.1190637","volume":"11","author":"X He","year":"2023","unstructured":"He X, Jiang Y, Zhang L, Li Y, Hu X, Hua G, et al. Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer. Front Bioeng Biotechnol. 2023;11:1190637.","journal-title":"Front Bioeng Biotechnol"},{"issue":"3\u20134","key":"1634_CR1178","first-page":"79","volume":"6","author":"P Krzyszczyk","year":"2018","unstructured":"Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, et al. The growing role of precision and personalized medicine for cancer treatment. Technology (Singap World Sci). 2018;6(3\u20134):79\u2013100.","journal-title":"Technology (Singap World Sci)"},{"issue":"8","key":"1634_CR1179","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","volume":"19","author":"L Bodei","year":"2022","unstructured":"Bodei L, Herrmann K, Sch\u00f6der H, Scott AM, Lewis JS. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol. 2022;19(8):534\u201350.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1634_CR1180","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2967\/jnumed.123.265670","volume":"64","author":"WA Weber","year":"2023","unstructured":"Weber WA, Barthel H, Bengel F, Eiber M, Herrmann K, Sch\u00e4fers M. What Is theranostics? J Nucl Med. 2023;64(5):669\u201370.","journal-title":"J Nucl Med"},{"issue":"55","key":"1634_CR1181","doi-asserted-by":"publisher","first-page":"94969","DOI":"10.18632\/oncotarget.21662","volume":"8","author":"Z Xu","year":"2017","unstructured":"Xu Z, Li XF, Zou H, Sun X, Shen B. F-Fluoromisonidazole in tumor hypoxia imaging. Oncotarget. 2017;8(55):94969\u201379.","journal-title":"Oncotarget"},{"issue":"8","key":"1634_CR1182","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1200\/JCO.23.01308","volume":"42","author":"NY Lee","year":"2024","unstructured":"Lee NY, Sherman EJ, Sch\u00f6der H, Wray R, Boyle JO, Singh B, et al. Hypoxia-directed treatment of human papillomavirus-related oropharyngeal carcinoma. J Clin Oncol. 2024;42(8):940\u201350.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1634_CR1183","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1007\/s00259-021-05307-1","volume":"48","author":"FL Giesel","year":"2021","unstructured":"Giesel FL, Kratochwil C, Schlittenhardt J, Dendl K, Eiber M, Staudinger F, et al. Head-to-head intra-individual comparison of biodistribution and tumor uptake of. Eur J Nucl Med Mol Imaging. 2021;48(13):4377\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"1634_CR1184","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1007\/s00259-022-05849-y","volume":"49","author":"AK Buck","year":"2022","unstructured":"Buck AK, Serfling SE, Lindner T, H\u00e4nscheid H, Schirbel A, Hahner S, et al. CXCR4-targeted theranostics in oncology. Eur J Nucl Med Mol Imaging. 2022;49(12):4133\u201344.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1634_CR1185","doi-asserted-by":"publisher","first-page":"374","DOI":"10.2174\/1874471013666201224114148","volume":"14","author":"ZF Theranostic","year":"2021","unstructured":"Theranostic ZF, Fibroblasts R-A. Curr Radiopharm. 2021;14(4):374\u201393.","journal-title":"Curr Radiopharm"},{"issue":"5","key":"1634_CR1186","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1021\/ml300410d","volume":"4","author":"K Jansen","year":"2013","unstructured":"Jansen K, Heirbaut L, Cheng JD, Joossens J, Ryabtsova O, Cos P, et al. Selective inhibitors of fibroblast activation protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold. ACS Med Chem Lett. 2013;4(5):491\u20136.","journal-title":"ACS Med Chem Lett"},{"issue":"2","key":"1634_CR1187","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2967\/jnumed.119.241232","volume":"61","author":"J Calais","year":"2020","unstructured":"Calais J. FAP: The next billion dollar nuclear theranostics target? J Nucl Med. 2020;61(2):163\u20135.","journal-title":"J Nucl Med"},{"issue":"9","key":"1634_CR1188","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","volume":"19","author":"G Sgouros","year":"2020","unstructured":"Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19(9):589\u2013608.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"1634_CR1189","doi-asserted-by":"publisher","first-page":"488","DOI":"10.2967\/jnumed.118.222893","volume":"61","author":"ME Mayerhoefer","year":"2020","unstructured":"Mayerhoefer ME, Materka A, Langs G, H\u00e4ggstr\u00f6m I, Szczypi\u0144ski P, Gibbs P, et al. Introduction to radiomics. J Nucl Med. 2020;61(4):488\u201395.","journal-title":"J Nucl Med"},{"key":"1634_CR1190","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1007\/s00330-024-10637-3","volume":"34","author":"JP McGale","year":"2024","unstructured":"McGale JP, Chen DL, Trebeschi S, Farwell MD, Wu AM, Cutler CS, et al. Artificial intelligence in immunotherapy PET\/SPECT imaging. Eur Radiol. 2024;34:5829\u201341.","journal-title":"Eur Radiol"},{"issue":"3","key":"1634_CR1191","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.239003","volume":"306","author":"L Dercle","year":"2023","unstructured":"Dercle L, Sun S, Seban RD, Mekki A, Sun R, Tselikas L, et al. Emerging and evolving concepts in cancer immunotherapy imaging. Radiology. 2023;306(3): e239003.","journal-title":"Radiology"},{"issue":"1","key":"1634_CR1192","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.1038\/s41467-023-41820-7","volume":"14","author":"M Crispin-Ortuzar","year":"2023","unstructured":"Crispin-Ortuzar M, Woitek R, Reinius MAV, Moore E, Beer L, Bura V, et al. Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer. Nat Commun. 2023;14(1):6756.","journal-title":"Nat Commun"},{"issue":"1","key":"1634_CR1193","doi-asserted-by":"publisher","first-page":"9984","DOI":"10.1038\/s41598-021-88239-y","volume":"11","author":"B Yousefi","year":"2021","unstructured":"Yousefi B, LaRiviere MJ, Cohen EA, Buckingham TH, Yee SS, Black TA, et al. Combining radiomic phenotypes of non-small cell lung cancer with liquid biopsy data may improve prediction of response to EGFR inhibitors. Sci Rep. 2021;11(1):9984.","journal-title":"Sci Rep"},{"issue":"2","key":"1634_CR1194","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41571-021-00560-7","volume":"19","author":"K Bera","year":"2022","unstructured":"Bera K, Braman N, Gupta A, Velcheti V, Madabhushi A. Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nat Rev Clin Oncol. 2022;19(2):132\u201346.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01634-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-024-01634-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01634-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T16:57:59Z","timestamp":1736787479000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01634-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":1194,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1634"],"URL":"https:\/\/doi.org\/10.1186\/s13045-024-01634-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"20 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all the authors. All figures are original and were drawn using BioRender by the authors for this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work in this paper. M.H.A. is founder, shareholder and scientific advisor of IO Biotech ApS. LMC is a consultant for Evergreen Theragnostics. S.K. has consulted for Telix Pharmaceuticals Ltd., acknowledges support for investigator services from RayzeBio and holds the following patent: PCT\/US2021\/039418 (THOR cell (tumor homing radio-emitting cell).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}